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I. Abstract  
a. Background 
Cannabis use is the most used ‘illicit’ drug worldwide. Prevalence of use among 
adolescents in Mexico has increased significantly in the last decade (Villatoro et al., 
2012). Research has shown that cannabis use during adolescence may have worse 
adverse effects than using cannabis later in life, such as poor mental health and cannabis 
dependence (Gorey, Kuhns, Smaragdi, Kroon, & Cousijn, 2019). Furthermore, there has 
been an increased interest in the association between high potency cannabis use and its 
impact on psychotic-like experiences. Research has shown that highly potent cannabis 
use is associated with psychotic disorders (Di Forti et al., 2014). Furthermore, this 
association may be stronger when onset of use occurs earlier in life.  
 
b. Aim 
To identify if cannabis use predicts the appearance of psychotic-like experiences in an 
adolescent student sample and an adolescent substance misuse clinical sample of mainly 
cannabis users in Mexico City aged 15 to 19 years old. 
 
c. Hypotheses 
o Adolescent Student Sample (15 to 19 years old) 
1. Lifetime cannabis use predicts the presence of psychotic-like experiences 
in an adolescent student sample in Mexico City and Estado de Mexico. 
2. Frequent cannabis use predicts the presence of psychotic-like 
experiences in an adolescent student sample in Mexico City and Estado 
de Mexico. 
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3. Use of skunk-type cannabis vs. herbal-type cannabis predicts an 
increased presence of psychotic-like experiences in an adolescent student 
sample in Mexico City and Estado de Mexico.  
 
o Adolescent Substance Misuse Clinical Sample (13 to 21 years old) 
1. Increased frequency of cannabis use predicts the presence of psychotic-
like experiences in an adolescent substance misuse clinical sample in 
Mexico City and Estado de Mexico.  
2. An earlier age of first cannabis use predicts an earlier age of onset of 
psychotic-like experiences in an adolescent substance misuse clinical 
sample in Mexico City and Estado de Mexico. 
3. Skunk-type cannabis vs. herbal-type cannabis use predicts the presence 
of psychotic-like experiences in an adolescent substance misuse clinical 
sample in Mexico City and Estado de Mexico.  
 
d. Methods 
This is a cross-sectional study conducted to examine patterns of cannabis use and 
prevalence of psychotic-like experiences in two adolescent samples in Mexico City: an 
adolescent student sample, a total of 657 participants completed all the questionnaires 
(53% females, mean age 16.51) and an adolescent substance misuse clinical sample, a 
total of 121 participants completed all the questionnaires (14.8% females, mean age 
16.56). Quantitative data was collected through questionnaires regarding cannabis use, 
psychotic-like experiences, use of other drugs and sociodemographic characteristics in 
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both samples. Descriptive statistics, ANOVAS, chi-square, odds ratios, linear, logistic 
and multinomial logistic regression analyses were conducted.  
 
e. Results 
Results are summarised by sample to facilitate identification of specific outcomes. In 
the student sample, no statistically significant associations were found between different 
patterns of cannabis use and psychotic-like experiences. In the substance misuse clinical 
sample, initially, daily cannabis use and use of 2 or more joints, were significantly 
associated with higher mean scores in the total score of psychotic-like experiences 
questionnaire. However, associations were no longer statistically significant whilst 
controlling for demographics, tobacco and use of other illicit drugs. Lastly, a significant 
association was found between low potency herbal type-cannabis and psychotic-like 
experiences (OR=.24; 95%CI=.08--.73; p=0.011) in the adolescent substance misuse 
clinical sample.  
 
f. Conclusions 
Overall, results from the present study are unexpected, as emerging research has shown 
that high potency cannabis use is associated with psychotic experiences. Although a 
significant association was found between herbal-type cannabis and psychotic-like 
experiences in the substance misuse clinical sample, this is opposite to what previous 
research has shown. This study has important clinical, educational and policy 
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VI. Study Overview 
a. Introduction  
The potential association between cannabis use and psychotic-like experiences, and the 
origins of any association, have been an important field of research during the past two 
decades. Studies have shown that frequent cannabis use is an important contributor to 
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the development of psychotic-like experiences (PLE’s)  (Di Forti et al., 2015) and, 
research has shown that the earlier the age of first use, the higher the probability of 
developing psychotic-like experiences (Fergusson, Horwood, & Swain-Campbell, 
2003). Research has shown that adolescence is a crucial phase in human development, 
both physical and neurological (Wright & Kutcher, 2016) and substance use at this 
stage in life has more detrimental educational and cognitive repercussions than use later 
in life (Casadio, Fernandes, Murray, & Di Forti, 2011). However, most research has 
been conducted in Europe or the United States of America, and there is need for 
replication in different populations and different countries.  
 
In addition, surveys have shown that the prevalence of cannabis use among adolescent 
students has steadily increased since 2006 (Villatoro et al., 2015). Studies to identify the 
repercussions cannabis use has in adolescent populations are needed to support and 
assist in the development of public policies. Studies regarding cannabis use and 
psychotic-like experiences have been conducted in developed countries, for example the 
United Kingdom (Mackie et al., 2013) and United States of America (Bechtold, 
Hipwell, Lewis, Loeber, & Pardini, 2016). However, research in developing countries, 
including Mexico, is largely absent from the literature, and essential.  
 
Furthermore, since 2016, Mexico has undergone major debates about changing policy 
regarding cannabis (SEGOB, 2016) and recently, the Senate discussed changing 
legalization and proposed a reform of the current laws around possession, cultivation 




Cannabis use in adolescents has been shown to increase the risk of developing psychotic 
like experiences. Studies have been conducted in both, adolescent general population 
(Kuepper et al., 2011; Miettunen et al., 2008) and adolescent clinical settings (substance 
users) and in both, the risk of presenting these experiences increase with cannabis use 
(Hodgins, Larm, & Westerman, 2016). The present study aims to identify if cannabis 
use predicts the appearance of psychotic-like experiences in two adolescent samples in 
Mexico. Participants were recruited from a school and a substance misuse clinical 
sample of young people seeking treatment for cannabis related problems. To the best of 
my knowledge this is the first study examining cannabis use and psychotic-like 
experiences in adolescent population in Mexico City. Due to fundamental differences 
between samples, data will not be combined for analysis; instead each set of data will be 
analysed individually to identify and observe the outcomes of each individual sample.  
 
c. Research Questions 
o Adolescent Student Sample (15 to 19 years old) 
1. Does lifetime cannabis use predict the presence of psychotic-like 
experiences in an adolescent student sample in Mexico City? 
2. Does frequent cannabis use predict the presence of psychotic-like 
experiences in an adolescent student sample in Mexico City? 
3. Does the use of skunk-type cannabis vs. herbal-type cannabis predict an 
increased presence of psychotic-like experiences in an adolescent student 
sample in Mexico City? 
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o Adolescent Substance Misuse Clinical Sample (13 to 21 years old) 
1. Does increased frequency of cannabis use predict presence of psychotic-like 
experiences in an adolescent substance misuse clinical sample in Mexico 
City? 
2. Does an earlier age of first cannabis use predict an earlier age of onset of 
psychotic-like experiences in an adolescent substance misuse clinical sample 
in Mexico City? 
3. Does skunk-type cannabis vs. herbal-type cannabis use predict presence of 
psychotic-like experiences in an adolescent substance misuse clinical sample 
in Mexico City?  
 
d. Aim and Objective 
The aim of the present study is to identify if cannabis use predicts the appearance of 
psychotic-like experiences in an adolescent student sample 15 to 19-year olds and an 
adolescent substance misuse clinical sample of mainly cannabis users in Mexico City 
aged 13 to 21-year olds. 
 
VII. Chapter Overview 
Chapter 1. Introduction: Cannabis Use History, Prevalence, Pharmacology and 
Effects 
Chapter One portrays an introduction to history of cannabis use worldwide and 
particularly in Mexico. This is followed by comparisons between the United States of 
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America, the United Kingdom and Mexico regarding prevalence of use. Lastly, a review 
of the known effects of cannabis in adolescents and how cannabis has been associated 
with psychotic-like experiences, symptoms and disorders.  
 
Chapter 2. Cannabis Use and Psychotic-Like Experiences in Adolescents: A 
Systematic Review 
Chapter Two shows the results of a systematic review conducted in all available 
research on cannabis use and psychotic-like experiences in adolescents. Systematic 
reviews have been previously conducted in the subject among adult population, 
however, never for adolescents. Results are summarized by patterns of cannabis use and 
an extensive and in-depth table with all relevant information of each study can be found 
in the Appendix.  
 
Chapter 3. Methodology 
The third chapter comprises the full description of the methodology used throughout the 
study. It also contains a summary of the school system in Mexico, of the boroughs 
attended and of the organization that was contacted in order to conduct data collection. 
The recruitment and sampling strategies are described along with detail about the 
questionnaires used for data collection and their background. Lastly a small description 
of each sample is given.  
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Chapter 4. Patterns of Cannabis Use and Associated Factors in an Adolescent 
Student Sample in Mexico City 
Chapter Four provides a detailed description of the constructs assessed regarding 
cannabis use. Patterns of cannabis use are fully depicted (lifetime, frequency, quantity, 
type of cannabis mainly used, method of use and social vs. non-social use), alongside 
associated factors (age, gender, ethnicity, socioeconomic level and cannabis experience 
questionnaire). Psychometric properties of the cannabis experience questionnaire are 
presented. 
 
Chapter 5. Cannabis Use and Psychotic-Like Experiences in an Adolescent 
Student Sample in Mexico City 
Chapter Five describes the psychometric properties of the PRIME Screen 
Questionnaire. It also describes the prevalence of psychotic-like experiences in the 
student sample, the associations with sociodemographic characteristics, patterns of 
cannabis use and use of other drugs. 
 
Chapter 6. Cannabis Use and Psychotic-Like Experiences in an Adolescent 
Substance Misuse Clinical Sample in Mexico City 
Chapter Six provides the rationale behind the examination of cannabis use and 
psychotic-like experiences in an adolescent substance misuse clinical sample, the 
associations between cannabis use and use of other drugs, the associations between use 
of other drugs and psychotic-like experiences and the associations between patterns of 
cannabis use and psychotic-like experiences bivariate and full adjusted models.  
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Chapter 7. Discussion  
This final chapter will provide an overview of the results of the present study along with 
different hypotheses to explain those results. The chapter will conduct a thorough 
examination of similarities and differences between the present study and research 






1. Introduction: Cannabis Use: Prevalence, History, Pharmacology and 
Effects 
The focus of this chapter is an examination of cannabis; antecedents of use, its 
pharmacodynamics and pharmacokinetics, prevalence of use and adverse effects. 
Furthermore, a review of the literature available on adolescent cannabis use and adverse 
effects during this period of life is provided below. Lastly, a brief summary of research 
on cannabis use and how it may contribute and increase the risk to develop psychotic-
like experiences is provided as an introduction to Chapter 2, Cannabis Use and 
Psychotic-Like Experiences in Adolescents: A Systematic Review.  
 
1.1. Cannabis History 
It has been difficult to determine with complete certainty the origins of cannabis, 
however some of the first traces of cannabis sativa date back more than 4,000 years. 
These first traces were found in China and the surrounding area. It was mainly used 
with medicinal purposes and to manufacture textiles (Russo, 2007). The first 
documented records were found in north-eastern Asia around 2,700 B.C., when it was 
mainly used as an analgesic, muscle relaxant, antidepressant, hypnotic, anti-
inflammatory among others (Aggarwal, 2009; Zuardi, 2006). Cannabis comes from a 
complex family of cannabaceae, where different types of cannabis can be found; for 
example, cannabis sativa, cannabis indica and cannabis ruderalis (Russo, 2007). 
Furthermore, from these types of cannabis different preparations for its use can be 
found, depending of method of use. For smoked cannabis preparations are normally, 
herbal cannabis, also known as marijuana or grass, sinsemilla, also known as skunk, and 
hashish (Russo, 2007). However, other preparations can now be found, like vaporizers, 
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concentrates and edibles which, after cannabis legalisation in parts of the United States 
of America, have become more prevalent in some states (UN, 2019a). 
 
1.2. Cannabis Psychopharmacology 
A breakthrough in cannabis pharmacological research occurred in 1964 when Gaoni and 
Mecholuam identified delta-9-tetrahydrocannabinol (THC) as the main active ingredient 
in cannabis sativa (Meyer & Quenzer, 2013; Wright & Kutcher, 2016). This is only one 
of the at least 143 unique cannabinoid compounds that can be found in cannabis. 
Research has shown that THC is the principal component that provides the psychoactive 
effects or the feeling of “high”, for example euphoria and disinhibition (Bloomfield et 
al., 2019). The second most important compound, which has been subject to extensive 
research is cannabidiol (CBD), which is known for its non-psychoactive effects and, it 
has also been shown to counteract the effects produced by THC (Bloomfield et al., 
2019).  
 
Research has shown that each preparation has different characteristics and different 
levels of THC and CBD. Recently, a study that examined the changes in potency 
(concentration of delta-9-tetrahydrocannabinol) in cannabis resin and herbal cannabis 
across Europe found an increase in potency in resin from 8.14% in 2006 to 17.22% in 
2016; furthermore, potency observed in herbal cannabis increased from 5% in 2006 to 
10.22% in 2016 (Freeman et al., 2018).  
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Cultivation processes have been continuously changing, from outdoor cultivation to 
more recently, indoor cultivation, which usually involves the use of controlled growing 
conditions and selective breeding. These controlled conditions and selective breeding 
focus on altering the quantity of different compounds found in the plant and increase 
levels of THC to increase the desirable effects of users.  
 
Furthermore, a program at the University of Mississippi in the United States of America 
(USA), alongside the National Institute on Drug Abuse (NIDA) have been continuously 
monitoring the potency of USA cannabis preparations. Cannabis samples are obtained 
from confiscated samples and then classified in different categories, depending on its 
characteristics. Categories are as follows: cannabis, hashish and hash oil; cannabis is 
then categorised as marijuana or sinsemilla. Analyses over the last decade have shown a 
significant increase in delta-9-tetrahydrocannabinol concentrations from 8.9% in 2008 
to 17.1% in 2017 (Chandra et al., 2019). Examination of mean delta-9-THC:CBD ratio 
across time also showed a considerable increase, from 23 in 2008 to 104 in 2017. To the 
best of my knowledge, no research has been conducted in Mexico to identify different 
levels of concentrations of THC or CBD in cannabis. However, research worldwide in 
recent years has shown that CBD concentrations continue to decrease, whereas THC 
concentration levels continue to increase.  
 
Burning of cannabis, which is the most prevalent method of use, causes THC to 
vaporise and enter the user’s lungs in small particles. The amount of THC absorbed is 
affected by the amount used and by the pattern of smoking, which means that the effects 
are influenced by puff volume, frequency, inhalation depth and breath-hold duration 
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(Onaivi, 2006). THC is rapidly absorbed through the lungs, resulting in increasing 
levels of THC in blood plasma, once peak levels have been reached, THC levels in 
plasma start to decline fairly rapidly as a result of metabolism in the liver and 
accumulation of cannabis in fat cells in the body. However, complete elimination is 
much slower because of the persistence of the drug in fat tissue. Overall, elimination 
rate is from 20 to 30 hours, nevertheless due to its storage in fat cells, urine screening 
for THC can result positive even after 2 weeks after a single use of cannabis. Even 
when there are other methods of use, the most prevalent one is by smoking.   
 
1.3. Endogenous Cannabinoid System  
The pharmacological characterization of a central nervous system cannabinoid receptor 
was announced in 1988 by a group of researchers at the Pfizer pharmaceutical company 
(Meyer & Quenzer, 2013). Research followed and showed that the cannabinoid receptor 
was significantly expressed in many brain regions including the basal ganglia, 
hippocampus, cerebellum and cerebral cortex, which is consistent with the visible 
effects cannabis has on coordination, memory and locomotor activity (Glass, 
Dragunow, & Faull, 1997). Cannabinoid receptor named as CB1R, can be found at high 
concentrations in specific brain regions linked with cognitive and emotional processing 
and rewards (Bloomfield et al., 2019). Later, another cannabinoid receptor was 
identified and named as CB2, which can be found in bones, gastrointestinal tract, fat 
cells and in the immune system (Meyer & Quenzer, 2013).   
 
Cannabinoid receptors belong to the family of metabotropic receptors, second 
messengers, they exert their effects by coupling to G-proteins. Effects involve inhibition 
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of cAMP (cyclic adenosine monophosphate), voltage sensitive Ca2+ (calcium) channels 
and activation of K+ (potassium) channel opening. Cannabinoid receptors can also 
influence gene expression through a complex system of protein kinases known as the 
mitogen-activated protein kinase (MAPK) system. CB1 receptors have been found on 
the axon terminal instead of the postsynaptic cell, and by activating presynaptic 
receptors cannabinoids can inhibit the release of different neurotransmitters, for 
example serotonin, glutamate, dopamine, norepinephrine, acetylcholine and GABA 
(gamma aminobutyric acid) (Iversen, 2003). Research has shown that THC acts as a 
partial agonist rather than a full CB1 and CB2 receptor agonist. In addition to THC, 
cannabis’ leaves usually contain more than 143 other types of cannabinoids (Hanus, 
Meyer, Munoz, Taglialatela-Scafati, & Appendino, 2016). Cannabidiol has been shown 
to have therapeutic effects on the treatment for epilepsy, anxiety, psychosis and 
addictions (Bloomfield et al., 2019).   
 
1.4. Cannabis Use in Mexico 
Records show that hemp (one of the strains belonging to the cannabis sativa family) was 
first introduced in Mexico in the fifteenth century, during the Spanish conquest, by 
mandate of the Spanish Crown who ordered its cultivation in the country (Campos, 
2012). Hemp was widely used by the Spanish as a source of fabric to produce various 
goods, for example ropes and sails used in the navy, therefore the interest of the crown 
to produce and manufacture it. Although its use was firstly meant for textile production, 
it was not long before people working in the fields realised the potential medicinal use 
of hemp (Campos, 2012). Cultivation started in different parts of Mexico; however, as 
people were not familiar with the process of growing hemp, instructions had to be 
provided and it took time for people to learn. For two hundred years hemp was seen 
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only as a fibre from which textiles could be produced, however in the 1760’s 
approximately, locals around Mexico City started using different preparations of hemp 
for different purposes and, as a result, people started viewing it as an indigenous drug. 
This marks the start of the prohibitionist view in Mexico and the reason cannabis started 
to be seen as something that could provoke disorder and madness. All of this provides 
an overview of how cannabis was firstly introduced in Mexico and the relationship 
people in the country developed with it. Cannabis was then banned in 1920 in Mexico 
by sanitary authorities. Seventeen years later the United States of America passed the 
first legislation to control cannabis sales.  
 
1.5. Prevalence of Cannabis Use: Comparison between the United Kingdom, 
United States of America and Mexico 
Cannabis is the illegal drug most commonly used worldwide, with approximately 188 
million lifetime users (UN, 2019a). From 1998 to 2007, global prevalence of lifetime 
cannabis use increased from 3.4% to 3.9%. During the last decade it has remained 
relatively stable. On the other hand, past year cannabis use has shown an estimated 
increase of roughly 30% from 1998 to 2017 (UN, 2019a). Furthermore, past year 
cannabis use has been seen to increase in Canada and in the United States of America; 
with 7% of the population aged from 15 to 64 in 2007 reporting past year use to 8.4% in 
2017, with the highest increase observed in the United States (UN, 2019a). 
Epidemiological research in the United States on substance use show that lifetime 
cannabis use among adults increased 10% from 2002 to 2017; furthermore, past year 
use increased 50% and monthly cannabis use increased 65%. Lastly, data show that 
daily or nearly daily use has doubled particularly over the past decade (CBHSQ, 2017). 
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Regarding adolescent cannabis use in the United States of America, data from the most 
recent publication of the report Monitoring the Future conducted among 8th, 10th and 
12th graders showed that lifetime cannabis use has remained relatively stable among 
adolescents in the past decade with 27.9% reporting ever use in 2008 to 29.7% in 2018. 
Moreover, past year cannabis use has shown a slight increase from 21.5% of 
adolescents reporting use in the last 12 months in 2008 to 24.3% in 2018; lastly, 
prevalence of past month cannabis use went form 12.5% of adolescents reporting use in 
the past 30 days in 2008 to 14.6% in 2018 (Johnston et al., 2019).  
 
In the United Kingdom, prevalence of lifetime cannabis use was 30% among 16 to 59-
year olds. Furthermore, it was found that 7.2% of adults (16 to 59 years old) reported 
past year use of cannabis, and among 16 to 24-year olds 16.7% reported past year 
cannabis use. Overall, data have shown that cannabis use has decreased among both 
groups in the past 20 years (Flatley, 2018).  
 
1.5.1. Prevalence of Cannabis Use in Mexico 
The most recent national report on drug use in Mexico was published in 2017, results 
showed that cannabis is the illegal drug most widely used in the country, with a 
prevalence of lifetime use of 8.6% in the general population. Overall, research has 
shown that cannabis use has increased in Mexico, particularly in the past few years 
(Villatoro, 2017). Prevalence of use at least once (lifetime use) in 2016 was 8.6% 
among general population (age range of 12 to 65 years old), which has more than 
doubled since the year 2002 when prevalence of ever use among the general population 
was of 3.5%. Furthermore, when examining prevalence of lifetime cannabis use by 
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gender it can be observed that the increase among females has been greater, with an 
increase of more than five times, showing 0.7% in 2002 of women reporting ever use of 
cannabis compared to 3.7% in 2016 (Villatoro, 2017); whereas in men, prevalence of 
use doubled from 6.9% in 2002 to 14% in 2016 (Figure 1.1). Research has shown that 
prevalence of cannabis use in the past year in Mexico has increased, with 0.6% 
reporting past year use in 2002 to 2.1% in 2016. Furthermore, past month cannabis use 
has also been shown to increase, with 0.8% reporting use in the last month in 2011 to 
1.4% in 2016 (Villatoro, 2017). 
 
Figure 1.1 Lifetime Cannabis Use in General Population in Mexico  
(12 to 65 Year Olds) 
 
 
Even when cannabis continues to be the most prevalent illegal drug used worldwide, 
when comparing its prevalence of use among similar populations in different countries, 
for example Mexico and the United Kingdom; it can be observed that prevalence of use 



























prevalence of use does not seem to be increasing (Flatley, 2018). This is not the case in 
Mexico, as stated above; prevalence of cannabis use among the general population and 
particularly among females continues to increase  
 
To date, there has been limited published research on patterns of cannabis use and 
potential harmful effects in Mexico. Nonetheless, available epidemiological evidence 
suggests that a substantial number of adolescents in Mexico use cannabis and that the 
prevalence of use is increasing. In the report previously mentioned from Villatoro et al., 
data collected from adolescents from 12 to 17 years old in Mexico indicates that lifetime 
cannabis use is rapidly increasing. In 2002 only 1.1% of adolescents in the country 
reported lifetime cannabis use, whereas in 2016 this number increased to 5.3% (Figure 
1.2). Furthermore, female cannabis use in this age range had a major increase going 
from 0.2% of lifetime users in 2002 to 4.8% in 2016 (Villatoro, 2017). 
 
Figure 1.2 Lifetime Cannabis Use in Adolescents in Mexico (12 to 17 Year Olds) 
 
Past year cannabis use has also shown a significant increase in the past decade among 




























Prevalence of past year use in 2002 was 0.5% among adolescents, however, recent data 
show a significant increase, with 2.6% of adolescents reporting cannabis use in the past 
year (Villatoro, 2017). According to gender, and as observed in lifetime cannabis use, 
females show a higher increase in prevalence of use, with only 0.1% of participants 
reporting past year cannabis use in 2002 compared to 2.1% in 2016 (Figure 1.3). 
 
Figure 1.3 Past Year Cannabis Use in Adolescents in Mexico (12 to 17 Year Olds) 
 
 
1.5.2. Cannabis Use in Adolescents in Mexico City 
Mexico City is the largest city in Mexico, with a total population of 8,918,653 (INEGI, 
2017a). Prevalence of lifetime cannabis use in Mexico City among the general 
population in 2016 was 9.1%, and past year cannabis use was 2.5% (Villatoro, 2017). A 
survey among adolescent students from 13 to 19 years old in Mexico City found that the 
prevalence of use of any illegal drug in 2014 was 26.6% and the average age of 



























adolescent-students (13 to 19-year olds) in the city reported using cannabis at least once 
in their lifetime in 2014 (Villatoro et al., 2012; Villatoro et al., 2015). 
 
As shown in  
Figure 1.4 an increasing trend has been observed in the prevalence of cannabis use in 
the adolescent population in Mexico City. From 5.8% of adolescents reporting ever use 
of cannabis in 2000 to 19.6% in 2014. With the most pronounced increase shown from 
2006 with 8.8% of adolescents reporting lifetime use to 19.6% in 2014. When 
examining ever use of cannabis by school grade (secondary school and high school) in 
2014, results showed that 9.8% of adolescents in secondary school reported lifetime 
cannabis use, compared to 30.1% of adolescents in high school. Results indicate that 
adolescents in high school are more likely to have used cannabis at least once in their 
lifetime than adolescents in secondary school, probably due to age and easier 
availability.  
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Figure 1.4 Lifetime Cannabis Use in Adolescents in Mexico City  
(13 to 19 Year Olds) 
 
When examining differences in lifetime cannabis use by gender, results showed that 
males are more likely to use cannabis, results indicate an average of 5 points higher 
prevalence of cannabis use in males than in females. Nevertheless, a significant increase 
in cannabis use among females was seen from 2012 to 2014, with a prevalence of use of 
12.9% to 17.2% respectively, which indicate that adolescent females are being more 
prone to experiment with cannabis in recent years than previously. Similar trends have 
been identified in other reports such as the World Drug Report, where data show 
significantly higher prevalence of use among males in Canada than females  (UN, 
2019b).  
 
Apart from lifetime cannabis use, students from 13 to 19 years old had to report 
cannabis use in the past year. Results showed a significant increase from data in 2009 to 
2014, with 8.2% of students reporting past year use of cannabis compared to 14.2% 
respectively. Overall, results show significant difference in prevalence of past year 

































previously observed in lifetime prevalence of cannabis use among females, a significant 
increase in past year prevalence of female cannabis use was reported with 6.2% in 2009 
to more than double in 2014 with 12.7% (Villatoro et al., 2015). 
Figure 1.5 Past Year Cannabis Use in Adolescents in Mexico City  
(13 to 19 Year Olds) 
 
 
Figure 1.6 Cannabis Use in Adolescents in Mexico City According to Gender in 2014  





















































Furthermore, results by gender on lifetime, last year and last month cannabis use are 
shown in Figure 1.6. Throughout, it can be observed that prevalence of use is higher 
among males than females, particularly in ever use, however, monthly use show a minor 
difference in comparison with the other types of measurements, with 8.7% of males 
reporting monthly use compared to 6.4% of females.  
Figure 1.7 Cannabis Use According to Age in Adolescents in Mexico City in 2014 
 
It can be observed that cannabis use was more common among adolescents from 16 to 
19 years old; ranging from 27.2% lifetime use in 16-year olds to almost half of 19-year 
olds having used cannabis at least once in their life (Figure 1.7). The following data on 
prevalence of use will focus on adolescents aged from 16 to 19 years old.  
 
1.5.3. Cannabis Use in Adolescents from 16 to 19 Years Old in Mexico City  
The main interest of the present study and the age range of the population recruited and 
analysed were adolescents from 15 to 19 years old. As shown in Figure 1.7, previous 
reports have shown that prevalence of use in Mexico City among adolescents aged 16 to 
































Figure 1.8 Cannabis Use in Adolescents from 16 to 19 Years Old in Mexico City 
 
Prevalence of lifetime cannabis use has tripled since 2000, with 30.1% of adolescents 
reporting ever use of cannabis in 2014, compared to 10.2% in 2000 (Figure 1.8). 
Furthermore, adolescents reporting use of cannabis in the last year increased from 5.7% 
in 2000 to 21.2% in 2014, showing a significant increase recent use of cannabis than 
previously. Similarly, monthly cannabis use has increased significantly, with 2.8% of 
adolescents in 2000 reporting frequent use compared to 11.1% in 2014. These results 
indicate that cannabis use among adolescents in Mexico City continues to increase, and 
with this increase of prevalence of use, health and mental risk factors may do as well. 
Moreover, debates in Mexico regarding plausible legalisation started to emerge in 
Mexico (SEGOB, 2016), therefore, evidence about cannabis use and its adverse effects 
is paramount. In the following sections I will discuss research conducted in other 
























1.5.4. Cannabis Use During Adolescence  
Adolescence is a significant period of human development. During adolescent years 
physical, emotional, social and neurocognitive changes take place, influenced by 
genetic and environmental factors, which interact and impact on the development and 
behaviour of the individual (Wright & Kutcher, 2016). The World Health Organisation 
defines adolescents as people between the ages of 10 to 19 years old; youth is defined 
by the United Nations as 15 to 24-year olds; and young people as 10 to 24 years old 
(UN, 1989). Substance use during these years could have potential long-term 
consequences; therefore, the importance of the present study. For the purpose of the 
present study, the age range used for the term adolescence is 10 to 24 years old.  
 
Research has shown that the endocannabinoid system is involved in brain development 
during adolescence. Continued use of cannabis may alter the normal development  
process (Lubman, Cheetham, & Yücel, 2015) and have short- and long-term 
consequences, for example disturbance in prefrontal development and disinhibition of 
prefrontal function (lack of impulse control) (Miller & Cohen, 2001) . Furthermore, 
frequent and heavy cannabis use has been associated with different cognitive 
impairments, for example memory and learning (Medina et al., 2007) response 
perseveration (recurrence of a response without the appropriate stimuli) (Allison, 1966; 
Lane, Cherek, Tcheremissine, Steinberg, & Sharon, 2007) and attention (Harvey, 
Sellman, Porter, & Frampton, 2007). 
 
A longitudinal study following 1,037 participants from birth to adult life, assessing 
neuropsychological performance found that participants using cannabis weekly or that 
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were diagnosed with cannabis dependence prior to 18 years old showed higher 
deterioration in full scale of IQ than participants without weekly use or that were 
diagnosed later in adulthood. Among adolescent onset, heavy user’s impairment 
remained even after one or more years of abstinence (Meier et al., 2012). A systematic 
review found that executive functions are generally more impaired in regular cannabis 
users, compared to adults and that age dependent effects may be more pronounced in 
dependent and heavy users (Gorey et al., 2019). Research has found that during 
adolescence some risk behaviours are correlated with cannabis use, abuse and 
sometimes problematic use to the point of dependence, for example, smoking and some 
antisocial behaviours (Coffey & Patton, 2016).  
 
1.5.5. Adverse Effects of Cannabis Use  
Cannabis effects can be divided into acute or chronic. Acute effects are those 
experienced immediately after use, that is while intoxicated, and can include anxiety, 
paranoia and dysphoria as well as psychomotor impairment particularly when driving  
(Silverman et al., 2015). Moreover, a review of the existing literature found that when 
used daily or almost daily, cannabis may have worse adverse long-term consequences in 
health and social life. Some of these adverse consequences include attention and 
memory deficits, and risks of mental health problems including depression and 
psychotic-like experiences (Hall, 2014). 
 
A longitudinal birth cohort study examined the relationship between adolescent 
cannabis use and tobacco use by age 15 and later educational outcomes. Results showed 
that tobacco and cannabis use at age 15 were significantly associated with later negative 
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educational outcomes at 16; effects remained after adjusting for various covariates 
(Stiby et al., 2015). Furthermore, a study that examined data from three cohort studies 
in three Australasian samples found that participants that did not use cannabis before 18 
years old were up to four times more likely to complete high school (OR=3.6; 95%CI= 
1.6-2.2), up to three times more likely to be enrolled in an university (OR=2.3; 95%CI= 
1.8-3.1) and almost five times more likely to have complete an university degree 
(OR=3.7; 95%CI= 2.8-4.9) (Horwood et al., 2010). These results, alongside a previous 
review conducted on adolescent cannabis use and educational attainment (Lynskey & 
Hall, 2000) show that cannabis use during adolescence may have detrimental effects in 
attaining good educational outcomes. However, studies have also shown that the 
strength of the association between cannabis use and detrimental effects on cognition is 
weak (Gorey et al., 2019).  
 
Moreover, cannabis use has been shown to impact mental health. A longitudinal study 
examined if adolescent cannabis use and tobacco at age 16 increased the risk of 
depression at age 18 and found that after adjustment for pre-birth and childhood 
confounders the effect of the relationship was attenuated but persisted for cannabis use 
(OR= 1.38; 95%CI= 1.09-1.75; p=.007) (Gage et al., 2015). Furthermore, a systematic 
review conducted in 2007 which examined cannabis use and the risk of psychosis or 
other type of mental health problems, e.g. affective symptoms, found that ever use of 
cannabis increased the risk of presenting any type of psychotic symptom or disorder 
(OR=1.41; 95%CI= 1.20-1.65). The risk increased when frequency of cannabis use was 
higher (OR=2.09; 95%CI= 1.54-2.84) showing a dose-response effect, where the more 
frequent cannabis use, the higher the risk of psychotic outcomes (Moore et al., 2007).  
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Occasionally, cannabis may not be perceived as a harmful drug, as users claim it is –
natural- and that given the absence of “harmful chemicals” in it the risk of using is 
small or non-existent (McGinty, Niederdeppe, Heley, & Barry, 2017). Nevertheless, 
research has shown that cannabis can have harmful effects in users (Hall, 2014). 
Furthermore, modifications in concentrations made in cannabis are a matter of concern 
as this increases its potency and in consequence increases the risk of developing short- 
and long-term harms, for example psychotic-like experiences. 
 
1.6. Psychotic-Like Experiences 
1.6.1. History of Psychosis 
The term “psychosis” was first created in 1845, and initially it encompassed a number 
of different mental disorders. Firstly used in Germany by Feuchtersleben who coined 
the term “psychosis” and “psychopathy”, believed that these disorders were “diseases of 
the personality” and that these were caused by a different combination of factors, both 
physical and “psychic”, and that these affected the person as a whole (Beer, 1996). 
Furthermore, both terms were a different form to call “insanity”. The term ´psychosis´ 
when viewed from the Greek structure translates as follows: psyche translates as soul or 
life, and in a more modern terminology it means “mind”. The suffix “-osis” means “any 
illness of” which in conjunction, psychosis means “any illness of the mind” (Beer, 
1996). Initially it can be observed by the way authors used the term that psychosis and 
psychopathy, both referred to any type of mental disorder. It was only later, that 
distinctions had to be made in order to distinguish between the different types of mental 
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disorders. In the early nineteenth century, even the psychiatrist Alzheimer used 
psychosis interchangeably with other types of mental disorders (Beer, 1996).  
1.6.2. Psychotic-Spectrum Disorders 
To understand further the interest in the development of psychotic-like experiences, it is 
important to know what these experiences are and the repercussions they have in daily 
life functioning. Currently, psychosis is identified as only one end of the psychotic-
spectrum disorders, which can occur due to different medical, psychiatric or 
neurological conditions and, schizoid personality disorder to be in the other end 
(Arciniegas, 2015). It is important to remember that these are disorders, both in the 
extreme end of the psychosis continuum, which is addressed below. Prodromal 
symptoms are described as tenuous, subclinical symptomatology that does not meet 
criteria for a full psychotic diagnosis and these symptoms have been found to appear 
prior to the formal clinical diagnosis of a psychotic disorder (Bagot, Milin, & Kaminer, 
2015).  
 
Difficulties arise from trying to differentiate terms that frequently have been used 
interchangeably to explain psychotic symptoms or psychotic-like experiences. A 
systematic review conducted in 2016 on definitions and assessments of psychotic-like 
experiences found that the following terms have been used to refer to “psychotic-like 
experiences”: schizotypy traits, magical ideation, unusual experiences, anomalous 
experiences, hallucinatory experiences, delusional-like experiences, psychotic or 
psychosis-like experiences and subclinical psychotic symptoms (Lee et al., 2016). These 
findings show the lack of agreement and the variability which researchers and clinicians 
face when assessing these symptoms or experiences.  
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Psychotic-like experiences are symptoms observed in psychotic disorders, for example 
in schizophrenia or brief psychotic disorder. These symptoms or experiences can be 
distortions of thought and perception, including hallucinations (visual, auditory or 
tactile), delusions and thought disorders (WHO, 2016). Someone experiencing a 
psychotic episode might find it difficult to distinguish what is real from what is not. 
Other symptoms that may appear during a psychotic episode are anxiety, depression, 
social inadequacy, lack of motivation and problems functioning in day to day life 
(CBHSQ, 2017).  
 
1.6.3. Subclinical Psychotic-Experiences in the General Population 
Recently, it has been found that these experiences or symptoms are not only found in 
patients with diagnosed psychotic disorders, but also in the general population (Kelleher 
et al., 2012). A systematic review and meta-analysis conducted in 2009 examining 
psychotic experiences as a continuum showed prevalence rates from 5% to 8% in 
general population (van Os, Linscott, Myin-Germeys, Delespaul, & Krabbendam, 
2009). Results indicate that the clinically diagnosed psychoses represent only a small 
proportion of the continuum and that non-clinical psychotic-like experiences are more 
common than previously thought. Furthermore, providing that people in this proportion 
of the continuum are also using cannabis, which by its own has shown to increase the 
risk of developing psychotic-like experiences, they could be at risk of an increased 
presence of psychotic-like experiences or worsening of symptoms (Griffith-Lendering 
et al., 2013). Another example of this type of continuum is blood pressure and glucose, 
these are continuously present in the general population however, medical terms like 
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hypertension and diabetes exist to explain the extreme of the continuous, that is the 
clinical cases of the continuum; which in this case, would be a diagnosis of a psychotic 
disorder (Van Os, 2001).  
 
1.6.4. Cannabis Use and Psychosis or Psychotic-Like Experiences 
One of the first epidemiological studies showing evidence of an association between 
cannabis use and psychosis, more specifically, in-patient admission for schizophrenia, 
was conducted in 1987 by Andréasson et al. in a Swedish cohort of 45,570 male 
conscripts (age range 18 to 21-year olds). Results from extracted data showed that 
conscripts that had used cannabis over fifty times, had six times higher risk of 
developing schizophrenia than non-users (CI 95%, 4.0 – 8.9) (Andreasson, 1987). Since 
then, the association between cannabis use and psychotic-like experiences has been a 
matter of continuing scientific interest; a longitudinal study of a New Zealand birth 
cohort examined the risk for developing schizophreniform disorder and schizophrenia 
symptoms in adolescent cannabis users studied from age 11 to 26-years (Arseneault et 
al., 2002). Whilst controlling for psychotic symptoms at 11, logistic regressions showed 
that cannabis users at 15 were four times more likely to develop a schizophreniform 
disorder at age 26 than individuals who had never used cannabis.  
 
Fergusson et al. in 2003, reported the results of a longitudinal study that examined the 
links between cannabis dependence (DSM-IV criteria) at ages 18 and 21 and rates of 
psychotic symptoms, assessed by using items from the Symptom Checklist 90 (SCL-
90). Results showed that cannabis dependent users at age 18 had 3 to 7 times higher 
rates of psychotic symptoms than non-cannabis dependent users. At age 21 cannabis 
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dependent (DSM-IV criteria) participants showed 2 to 3 times higher rates of psychotic-
symptoms than non-dependent participants. The association remained significant 
(RR=1.8; 95%CI= 1.2-2.6) after the adjustment of confounding factors such as other 
substance use, anxiety and depression (Fergusson et al., 2003). Substance use, apart 
from cannabis, has been continuously and persistently associated with psychotic-like 
experiences and it has been shown to be a significant risk factor for the later 
development of psychotic disorders (Fonseca-Pedrero, Lucas-Molina, Perez-Albeniz, 
Inchausti, & Ortuno-Sierra, 2019; Levy & Weitzman, 2019; Mackie et al., 2013). 
 
Furthermore, in 2016, Marconi et al. conducted a meta-analysis exploring levels of 
cannabis use and risk of psychosis, of all published data including general population 
and first episode psychosis patients, reporting a consistent and strong association 
between the amount of cannabis used and the risk for psychosis. The studies included in 
the meta-analysis assessed use of cannabis exploring frequency, amount and severity 
prior to the onset of psychosis and psychotic related data established with validated 
measures. They found a four-fold increased  (OR = 3.9, CI 95%, 2.8 – 5.34; unadjusted) 
risk in participants with more severe cannabis use (daily use/cannabis dependence) and 
a two-fold increase for the average (year/monthly use) cannabis user in comparison to 
non-cannabis users (Marconi, Di Forti, Lewis, Murray, & Vassos, 2016). Furthermore, a 
recent case-control study conducted in different countries across Europe and Brazil 
found that patients presenting to psychiatric services with a first episode psychosis and 
controls who reported daily cannabis use had up to 3 times increased odds of psychotic 
disorders and up to 5 times increased odds when the type of cannabis was high-potency 
cannabis (Di Forti et al., 2019). The association between cannabis use and psychosis has 
been studied extensively, and debates continue. Nevertheless, a potential limitation of 
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much of the research in this area is that it has paid insufficient attention to potential 
variations in the potency in the types of cannabis being used.  
 
1.6.5. Different Types of Cannabis and the Risk for Developing Psychotic-Like 
Experiences 
Evidence has emerged that different types of cannabis might confer more risk than other 
types in developing psychotic-like experiences or psychotic disorders (Di Forti et al., 
2015). Cannabis sativa is the plant from which different cannabis preparations are 
derived; the most common preparations are herbal cannabis or grass, hash and skunk or 
sinsemilla (Casadio et al., 2011)  
 
Different strains of cannabis contain different concentrations of THC and CBD. 
Recently, a study conducted in the United Kingdom in 2018, reported the average 
concentrations among different cannabis samples seized from the same areas from 
which samples were collected in a study previously conducted in 2008 (Hardwick, 
2008). Findings showed an average of 14.2% THC in cannabis type sinsemilla or skunk 
(Potter, Hammond, Tuffnell, Walker, & Di Forti, 2018). A study in South London, 
conducted amongst first episode psychosis patients, showed that individuals using 
skunk-like cannabis were three times more likely to have a psychotic disorder compared 
to those individuals that have never used cannabis. However, people using hash type 
cannabis did not have an increased risk compared to those who have never used 
cannabis, notwithstanding frequency of use (Di Forti et al., 2015).  
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Additionally, a study conducted in the United Kingdom, analysed hair samples of 140 
individuals to examine levels of THC and CBD and identify if the presence of 
schizophrenia like symptoms differed, depending on THC / CBD levels found (Morgan 
& Curran, 2008). Three groups were identified, hair samples containing THC only, hair 
samples containing THC and CBD and hair samples with no cannabinoid. Researchers 
found that participants with only THC found in hair sample, exhibited higher levels of 
unusual experiences (the equivalent to positive symptoms in schizophrenia) than 
participants with both THC and CBD present in hair samples and those with no 
cannabinoids. These findings show that presence of CBD in the type of cannabis being 
used might decrease the risk of psychotic-like experiences induced by THC only 
(Morgan & Curran, 2008). Furthermore, a randomised double-blind crossover study was 
conducted to estimate the effects of both CBD and THC on psychotic-like experiences. 
Researchers found that THC increased psychotic-like experiences in laboratory-
controlled conditions (Morgan et al., 2018). When examining the CBD / THC 2:1 ratio, 
results indicated no changes in psychotic-like symptoms in frequent cannabis users, 
indicating that frequent users may have a slow or weak reaction to the anti-psychotic 
effects of CBD.  
 
The before mentioned studies demonstrate the importance of identifying the different 
types of cannabis available, potency in each type, which one is being more prevalently 
used and to identify the possible consequences in user’s mental health according to type 
of cannabis. To the best of my knowledge, there is non-existent information regarding 
the types of cannabis being used in Mexico, and no research has been conducted 
previously regarding cannabis use and psychotic-like experiences. Most available 
research examining the association between cannabis use and psychotic-like 
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experiences has been conducted in either English speaking countries or European 
countries, therefore, the importance of conducting the present study in Mexico.  
1.6.6. Conclusion  
Cannabis is widely used by adolescents in Mexico City and research shows that the 
prevalence of use continues to increase. International research has demonstrated 
possible associations between cannabis use during adolescent years and an increased 
risk of developing psychotic-like experiences. Moreover, these associations may vary 
depending on the type of cannabis used, as strains with higher THC and low CBD 
concentrations have been found to increase the association. Although little is known 
about the different types of cannabis being used in Mexico, it is important to consider 
whether these associations vary by type of cannabis used. Moreover, it is relevant to 




2. Cannabis Use and Psychotic Like Experiences in Adolescents: A 
Systematic Review 
2.1. Introduction 
Research has shown that cannabis use might be a risk factor in the development of 
psychotic disorders in adults, more specifically schizophrenia. The first study to 
examine the association between cannabis use and the later development of 
schizophrenia was conducted in an 18-year-old cohort of conscripts in Sweden. Results 
showed that participants reporting cannabis use on more than 50 occasions had up to six 
times higher risk (RR=6.0; 95CI=4.0-8.9) to be diagnosed with schizophrenia than non-
users (Andreasson, 1987). Sixteen years later research in the field continued in New 
Zealand, where data was obtained from a multidisciplinary study of a general 
population birth cohort (Arseneault et al., 2002). The study examined if adolescent use 
of cannabis was a risk factor for the development of any type of schizophreniform 
disorder later in life. Results showed that participants reporting cannabis use at 15 
presented more psychotic symptoms than controls (B=7.2; SE=1.07; p=0.001) after 
controlling for use of other drugs; furthermore, logistic regression analyses showed that 
participants reporting cannabis use by age 15 were up to eleven times more likely to 
have a diagnosis of schizophreniform disorder (OR=11.38, 95%CI=1.84-70.45; 
p=0.009) while controlling for use of other drugs.  
 
A systematic review conducted to identify whether cannabis use could cause psychotic 
symptoms that persisted after intoxication was first conducted in 2007 (Moore et al., 
2007). Results indicated an increased risk of presenting any type of psychotic-symptom 
in participants that reported lifetime use of cannabis (OR=1.41; 95%CI=1.20-1.65). 
Furthermore, higher frequency in cannabis use conferred greater risk of presenting any 
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psychotic-symptom (OR-2.09; 95%CI=1.54-2.84). Psychosis outcomes included any 
psychotic type disorder and delusion, hallucinations or thought disorder were 
requirements for psychotic-outcomes.  
   
Large et al., in 2011 conducted a systematic meta-analysis to examine the extent to 
which cannabis use and use of other drugs impacts the age of onset of psychosis. 
Researchers separated cohorts by drug and examined age at onset of patients reporting 
substance use compared to age at onset of non-using patients. Results indicated that age 
of onset of psychotic illness was 2.70 (standardized mean difference=-0.414) years 
earlier for participants reporting specifically cannabis use than for non-users (Large, 
Sharma, Compton, Slade, & Nielssen, 2011).  
 
Recently, a meta-analysis was conducted to identify if higher levels of cannabis use 
were significantly associated with an increased risk for psychosis (Marconi et al., 2016). 
Results indicate that participants using cannabis more heavily (daily, weekly, regular, 
60+) were almost four times more likely to be diagnosed with schizophrenia or other 
psychotic-related disorders than non-users (OR=3.90; 95%CI=2.84-5.34; unadjusted).   
 
Previous systematic reviews and meta-analyses have considered mainly the -present or 
absent- approach when examining the association between cannabis use and psychotic 
symptoms. However, research has shown that the psychotic-spectrum might be more 
complex and to categorise it as a dichotomous phenomenon might be a reductionist 
approach (Van Os, 2001). From the epidemiological perspective, psychosis could be 
considered as a continuum rather than as a dichotomous entity, therefore the importance 
of exploring experiences or symptoms rather than presence or absence of a disorder.  
 55 
 
Systematic reviews and meta-analyses have been shown to be paramount to condense 
evidence regarding a specific area of interest. However, it is important to follow a 
methodological approach in order to cover and report all important and relevant aspects 
of each study (Liberati et al., 2009). To the best of my knowledge, a systematic review 
examining the plausible effects the use of cannabis may have in adolescents, has not 
been conducted until now. The present systematic review follows the PRISMA 
Statement methodology and examines the association between cannabis use and the 
occurrence of psychotic-like experiences in adolescents from the general population. 
Details of the methodology used are stated below. 
 
2.2. Objectives  
To conduct a systematic review of available literature to identify if adolescent cannabis 
use is associated with the development of psychotic-like experiences in the general 
population. To formulate a specific and structured research question, the PICOS 
(Population, Intervention, Comparison, Outcome) approach was followed.  
 
2.3. Research Questions 
o Is adolescent cannabis use associated with psychotic-like experiences in the 
general population? 
o Is frequent and heavy adolescent cannabis use associated with psychotic-like 
experiences in the general population? 
o Is age of onset of adolescent cannabis use associated with psychotic-like 
experiences in the general population? 
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2.4. Methods 
2.4.1. Protocol and Registration 
A protocol was structured in 2016 and was submitted for revision and approval for the 
upgrade from MPhil to PhD process in 2017.  
2.4.2. Eligibility Criteria  
a) Type of Participants: Participants from 9 to 26 years old, sample was restricted 
to general population, therefore, studies including participants with prior 
diagnosis of schizophrenia or another psychotic-spectrum disorder were 
excluded. 
b) Types of Intervention: Observational studies examining cannabis use and the 
risk of presenting psychotic-like experiences later in life.  
c) Comparator Group: Participants from 9 to 26 years old from the general 
population without history of cannabis use.  
d) Types of Outcome Measures: Mean scores of continuous measures of psychotic-
like experiences and dichotomous outcomes defined as presence or absence of 
psychotic-like experiences. 
e) Types of Studies: Observational studies examining the risk between psychotic-
like experiences and cannabis use in adolescents. Including longitudinal, 
retrospective, case-control and cohort studies. Restrictions regarding language 
were applied, and studies were only included if they were published in English 
or Spanish. Exclusively peered reviewed publications were included. No 
publication date or publication status were imposed.  
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2.4.3. Information Sources 
Studies were identified by searching electronic databases and additional resources. 
Databases and resources were selected after consulting a specialist librarian at King’s 
College London for her advice on which resource would be the most helpful to identify 
studies to include in the present study. The main electronic databases searched included: 
Applied Social Sciences Index and Abstracts (ASSIA), Cumulative Index to Nursing 
and Allied Health Literature (CINHAL), Cochrane Library, Excerpta Medica Database 
(EMBASE), Health Management Information Consortium (HMIC), International 




Search strategies were developed by exploring each database’s subject headings and 
MESH terms related to the main interest of the review (‘cannabis’ + ‘adolescence’ + 
‘psychotic-like experiences’ including synonyms); every database had a unique search 
strategy as search terms for each one was different. Once all the search strategies were 
structured and reviewed, searches were run, the results were saved and exported to 
EndNote for screening. The search strategy conducted for EMBASE is presented below 
and unique strategies for each database can be found in the Appendix. 
 
2.4.5. Search Strategy 








4. Cannabis use 
Tetrahydrocannabinol 
5. Adolescent 
6. Psychotic symptom* / Psychotic ADJ5 Symptom*     
7. Psychosis 
Cannabis-induced psychosis 
8.  Prodrom* symptom* / Prodrom* ADJ5 Symptom* 
9.  Vulnerability for psychosis / Vulnerability ADJ5 Psychosis 
Disease predisposition  
10. Early onset psychosis / Early ADJ5 Psychosis 
11. First episode psychosis / First ADJ5 Psychosis  
12. Psychotic like experiences / Psychotic ADJ5 Experiences 
  
((“substance abuse”) OR (“substance related disorders”) OR (cannabis) OR (marijuana) 
OR (“cannabis use”) OR (“marijuana abuse”) OR (“marijuana smoking”)) AND 
((adolescent) OR (“adolescent psychiatry”)) AND ((“psychotic symptom*”) OR 
(psychotic adj5 symptom*) OR (psychosis) OR (“prodrom* symptom*”) OR (prodrom* 
adj5 symptom*) OR (“vulnerability for psychosis”) OR (vulnerability adj5 psychosis) 
OR (“substance-induced psychoses”) OR (“early onset psychosis”) OR (early adj5 
psychosis) OR (“first episode psychosis”) OR (first adj5 psychosis) OR (“psychotic like 
experiences”) OR (psychotic adj5 experiences)) 
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2.4.6. Study Selection 
Eligibility assessment for the inclusion of studies was conducted individually by two 
different reviewers. Once the screening process was completed, disagreements were 
resolved after discussion and consensus by both reviewers.  
 
2.4.7. Data Collection Process  
A data extraction sheet was developed in line with the Cochrane Consumers and 
Communications Review Group’s data extraction template, modified for the specific 
aims of the present review. Data extraction was conducted by one author.   
 
2.4.8. Data Items  
The following data were extracted from each individual study: authors, country were the 
study was conducted, study design, number of participants included in analyses, 
cannabis use assessment, psychotic-like experiences assessment, prevalence of cannabis 
use, prevalence of psychotic-like experiences, covariates, types of analyses, estimated 
effect size, odds ratios and/or unstandardized beta depending on the type of analysis 
conducted.  
 
2.4.9. Risk of Bias within Individual Studies 
The Newcastle-Ottawa Scale was employed for assessing the quality of individual 
studies. It helps with the assessment of non-randomized study designs by evaluating 
selection of the study group, comparability of study groups, and the ascertainment of the 
outcome (Wells, 2014). Results are shown in Table 2.4, Table 2.5 and Table 2.6. 
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2.4.10. Summary Measures 
Depending of the type of analysis conducted in each study data were identified 
accordingly. For logistic regression analyses, odds ratios of both adjusted and 
unadjusted models alongside their respective confidence intervals were extracted and 
for linear regression analysis unstandardized beta, standard deviation and p-values. 
 
2.4.11. Synthesis of Results 
Studies included varied in the type of analyses conducted. Two main type of analyses 
were identified, linear regression analyses and logistic regression analyses. Twelve of 
the included studies analysed their data using linear regression, sixteen employed 
logistic regression and, of those studies, four were included in both groups as they 
conducted both type of analyses. Three studies included in the systematic review were 
not included in either group as the type of analysis employed differed from the before 
mentioned analyses. Data can be observed in Table 2.3. 
 
2.4.12. Risk of Bias across Studies 
No risk of bias assessment across studies was conducted.  
 
2.4.13. Additional Analyses 




2.5.1. Study Selection 
A final search was conducted on the 3rd of July 2019. No date limit was imposed, 
therefore all available papers in the databases searched were included in the screening 
process. Searches were conducted in eleven electronic databases which provided 15,837 
references. After duplicate removal, from the eleven databases, 12,493 references were 
screened by title and/or abstract and 195 of these were selected for full-text screening. A 
total of 168 references were excluded and 27 were included in the systematic review as 
they met the inclusion criteria.  
 
2.5.2. Reasons for Exclusion  
After full text screening was conducted on the 195 eligible studies, 168 papers were 
excluded. Reasons for exclusion are the following: study identified was a review, letter 
to editor, opinion article, systematic review, meta-analysis or conference abstract; 
participants did not meet the inclusion criteria, there was no age range provided, 
predictor or outcome variable was not of interest for the present review and publication 
was not in English or Spanish language. 
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through database search  
15,837 
Records after duplicates removed 
 12,493 
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12,493 Records excluded 
12,299 
Additional records 




excluded with reasons 
168* 
 
Full-text articles assessed 
for eligibility  
195 
 
Studies included in 
qualitative synthesis  
27 
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2.5.3. Study Characteristics 
Twenty-seven papers were found that met the inclusion criteria. Of the 27 studies 
included in the systematic review, nineteen had a longitudinal design, nine cross-
sectional and one identified as retrospective. Overall, the included studies comprised 
75,081 participants, with an age range of 9 to 26 years old. Sixteen studies ran logistic 
regression analyses to identify risk. Eight conducted linear regression analysis to 
examine associations between cannabis use and psychotic-like experiences. Three 
studies conducted different analyses to the ones mentioned above. One conducted Cox 
Regression Analysis Survival Time and Hazard Ratios, the second study conducted 
Spearman Correlation Test, Multivariate Econometric Linear Regression Model and 
Mann-Whitney U Test and, lastly, the third study conducted Multivariate Analysis of 
Variance (MANOVA), Chi-Square Analysis, Partial eta Squared for Effect Size, 
Mediation Analysis and Sobel Test to verify the significance of the possible indirect 
effect.  
 
Studies were conducted in New Zealand (2), Germany (2), Finland (2), Netherlands (3), 
Switzerland, United Kingdom (3), United States of America (4), Canada, Denmark, 
Greece, Australia (2), Trinidad y Tobago, Brussels and Spain. The first study included 
in the present review was published in 2002 and the last one was conducted in 2019. 
Specific data regarding types of assessment by individual studies can be observed in 
Table 2.1, Table 2.2 and Table 2.3. Three tables were structured according to type of 





2.5.4. Results of Individual Studies  
Table 2.1 Study Characteristics: Logistic Regression Analyses 
# Author, Year & Country 
Study Design & 
Participants 
Assessments 
Cannabis Use Psychotic-Like Experiences 
1* 







Controls Never or once: 
Cannabis users at age 15: 
three times or more 
Cannabis users at age 18: 












Diagnostic and Statistical 
Manual of Mental 
Disorders (DSM-IV) 
Items from the Symptom 
Checklist 90 (SCL-90) 
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17,698 Euros spent on cannabis 
Community Assessment of 
Psychic Experiences (CAPE) 
7 







Interview and Rating of 

























1,756 Self-report questionnaire 
Semi-structured interview 
(PLIKSi: Zammit et al. 2013) 
10* 


















Detection of Alcohol and 






# Author, Year & Country 
Study Design & 
Participants 
Assessments 
Cannabis Use Psychotic-Like Experiences 
12 





Abbreviated and locally 
computerized version of 
the Minnesota Centre for 
Twin and Family 
Research self-report 
substance use measure 
GOASSSESS, a 
computerized, structured 
interview adapted from the 
Kiddie Schedule for 
Affective Disorders and 
Schizophrenia 
13 






“Have you ever tried…” ICD-10 
14 






No use of cannabis or 
cigarettes 
Cigarette only 
Cannabis with or without 
Semi-structured psychosis-
like symptom interview 
(PLIKSi) 
15 






Lifetime use and 
frequency of use (never, 
once, 2-4 times, 5 times or 
more or regularly 











about symptoms of 
cannabis use disorder 
based on the modified 
World Mental Health 
Composite International 
Diagnostic Interview 
“In the past 12 months, how 
often have you felt anxious or 
paranoid during or after using 
marijuana?” 
“In the past 12 months, how 
often have you seen, felt, or 
heard things that were not 
really there (i.e., 
hallucinations) during or after 
using marijuana?” 
 
Table 2.2 Study Characteristics: Linear Regression Analyses 




Cannabis Use Psychotic-Like Experiences 
1* 







Controls: Never or once 
Cannabis users at age 15: 
three times or more 
Cannabis users at age 18: 




















frequency use (never, 
once, 2-4 times, 5 times 
or more) 
Systematic Use: Daily or 
Almost Daily 









Youth Risk Behaviour 
Survey (YRBS) 








Cannabis Use Psychotic-Like Experiences 
5 
Konings, M. et al. 
(2008) 
Trinidad y Tobago 
Cross-Sectional 
472 
Questionnaire on past 
and current cannabis use 
Community Assessment of 
Psychic Experiences 
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once or twice 
Users: At least monthly 
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Early CU: before 14 
years old 
Children in the Community 
Self Report Schizotypal 
Personality Disorder Scale 
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Frequency of cannabis 
use (never, ever but not 
past year, once or twice 
during past year, 
between 3 and 39 times) 










regarding frequency in 
the last year 
Youth Self-report subscales 
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Youth Self Report: 
Subclinical psychotic 
symptoms 




Detection of Alcohol and 












Past 6 months use 
Frequency of use past six 
months 
Frequency of use past 
month 
Adapted version of the short 
form of the Oxford-
Liverpool Inventory of 
Feeling and Experiences 
12 
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Table 2.3 Study Characteristics: Other Analyses 
# Author, Year & Country 




Cannabis Use Psychotic-Like Experiences 
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Diagnostic Interview (CIDI) 
Lifetime symptoms 
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Lifetime and current 
cannabis use 
 
Aberrant Salience Inventory 
(ASI) 
















2.5.5. Risk of Bias within Studies 
Risk of bias within studies was assessed using the Newcastle-Ottawa Scale. The aim of 
the scale is to assess the quality of non-randomized studies to be used in systematic 
reviews (Wells, 2014). The maximum score a study can have is nine, indicating that the 
quality of said study is high. The pointing rate score depends on selection process, 
comparability and outcome. The selection process assesses the selection of the cohorts, 
ascertainment of exposure and demonstration that outcome of interest was not present at 
the start of the study. Comparability assesses that both cohorts are matched and that 
confounders are or not adjusted in the analyses and, lastly, outcome assesses how 
exposure is measured if acquired.  
 
Four studies in the present review score nine (Fergusson et al., 2003; Henquet et al., 
2005; Kuepper et al., 2011; Mackie et al., 2013), six scored eight (Anglin et al., 2012; 
Arseneault et al., 2002; Gage et al., 2014; Jones et al., 2018; Mustonen, Niemela, et al., 
2018; Roessler, Hengartner, Angst, & Ajdacic-Gross, 2012), three scored seven 
(Bourque, O'Leary-Barrett, & Conrod, 2016; Ferdinand et al., 2005; Griffith-Lendering 
et al., 2013), four scored a total of six (Albertella, Le Pelley, Yucel, & Copeland, 2018; 
Miettunen et al., 2008; Shevlin et al., 2017; Stefanis et al., 2004), four scored five 
(Jones, Calkins, Scott, Bach, & Gur, 2017; Leadbeater, Ames, & Linden‐Carmichael, 
2019; Levy & Weitzman, 2019; Schubart et al., 2011), five scored four (Bechtold et al., 
2016; Bernardini et al., 2018; Fonseca-Pedrero et al., 2019; Hides, Lubman, Cosgrave, 
Baker, & Yung, 2008; Konings, 2009) and only one three (van Gastel et al., 2012). 
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Arseneault et al., 2002 3 2 3 8 
Fergusson et al., 2003 4 2 3 9 
Henquet et al., 2005 4 2 3 9 
Miettunen et al., 2008 3 2 1 6 
Kuepper et al., 2011 4 2 3 9 
Schubart et al., 2011 3 2 0 5 
Roessler et al., 2012 3 2 3 8 
Mackie et al., 2013 4 2 3 9 
Gage et al., 2014 3 2 3 8 
Bechtold et al., 2016 1 1 2 4 
Bourque et al., 2016 3 2 2 7 
Jones et al., 2017 2 2 1 5 
Shevlin et al., 2017 3 2 1 6 
Jones et al., 2018 4 1 3 8 
Mustonen et al., 2018 3 2 3 8 
Levy et al., 2019 3 1 1 5 
 









Stefanis et al., 2004 2 2 2 6 
Hides et al., 2009 2 2 0 4 
Konings et al., 2009 2 2 0 4 
Anglin et al., 2012 4 2 2 8 
Van Gastel et al., 2012 2 1 0 3 
Griffith-Lendering et al., 2013 3 2 2 7 
Albertella et al., 2018 3 2 1 6 
Leadbeater et al., 2018 2 1 2 5 
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Ferdinand, et al., 2005 4 1 2 7 
Bernardini et al., 2014 3 1 0 4 
Fonseca-Pedrero et al., 2019 3 1 0 4 
 
2.5.6. Synthesis of Results 
2.5.6.1. Cannabis Use and Psychotic-Like Experiences in Adolescents  
In the present systematic review, results showed that cannabis use during adolescence 
may increase the risk for experiencing psychotic-like experiences in the general 
population. Five studies, mainly examining the association of any adolescent cannabis 
use and psychotic-like experiences showed that even after adjustment for different 
confounders, cannabis use continued to be a significant risk factor for experiencing 
psychotic-like experiences (Henquet et al., 2005; Kuepper et al., 2011; Miettunen et al., 
2008; Roessler et al., 2012; Stefanis et al., 2004). 
 
Henquet et al., in 2005 found that cannabis use at baseline increased the incidence of 
psychotic-like experiences at follow-up, four years later. This finding remained 
significant while adjusting for age, gender, socioeconomic status, urbanicity, childhood 
trauma, predisposition for psychotic-like experiences and use of other drugs including 
tobacco and alcohol (OR=1.53, 95% CI=1.13-2.07). Overall, results showed that 
cannabis use increases the risk of psychotic-like experiences in young people, however, 
the effect appeared stronger in adolescents with predisposition for psychosis.  
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In line with these results, other studies continued to find that use of cannabis in 
adolescence increased the likelihood of appearance and persistence of psychotic-like 
experiences independent of age, gender, socioeconomic status, use of other drugs, urban 
or rural environment, childhood trauma and comorbidity (Miettunen et al., 2008; 
Roessler et al., 2012; Stefanis et al., 2004).  
 
Furthermore, one study that specifically examined to what extent the associations 
between cannabis use, cigarette use and psychotic-like experiences can be explained by 
confounding found that, after adjustment of pre-birth and childhood confounders, and 
after excluding experiences credited to cannabis intoxication, the association remained 
significant. There was a 48% increase (95%CI=1.18-1.86) in risk across different 
categories of psychotic-like experiences at age 18 for every unit of increase in cannabis 
use at age 16 (Gage et al., 2014). However, it is worth mentioning that when adjustment 
for use of other drugs was made, the association did not remain significant (OR=1.09, 
95%CI=0.65-1.82) between cumulative cannabis use at 16 years old and psychotic-like 
experiences at 18 while excluding psychotic-like experiences at age 12 and 16 years old 




Table 2.7 Cannabis Use and Psychotic-Like Experiences in Adolescents 
 








Age, gender, SES, smoking, 
alcohol use, IQ, emotional 
behavioural problems 
* Multiple measures paranoia and systematic use.  
  
Author & Year 
Adjusted 
95% p Covariates 
B OR 
Henquet, 2005 - 1.53 1.13-2.07 - 
Age, gender, SES, other drug use, 
depressive, symptoms, urbanicity, 
childhood trauma, predisposition for 
psychosis 
Miettunen, 2008 - 2.23 1.70-2.94 - 
Gender, family type, early emotional 
and behavioural symptoms, SES, 
tobacco use, other drug use, parental 
substance use disorder 
Kuepper, 2011 - 1.9 1.1-3.1 - 
Age, gender, SES, use of other 
drugs, childhood trauma, urbanicity, 
pre-existing psychotic symptoms 
Stefanis, 2004*  0.96 - - 0.000 Gender, school grade obtained, other drug use, CAPE dimensions 
Gage, 2014 - 1.09 0.65-1.82 - 
Pre-birth and childhood confounders, 
alcohol and cigarette use, use of 
other drugs and after excluding 
PLE’s at 12 and 16 
Shevlin, 2017 - 5.96 1.71-20.75 - 
Gender, parental psychosis and use 
of other drugs 
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On the other hand, Shelvin et al. in 2017, found that when separating participants by 
cannabis use only from cannabis use + use of other drugs, the use of cannabis alone was 
not significantly associated with psychotic-like experiences. However, cannabis use + 
use of other drugs showed a statistically significant association with the appearance of 
psychotic-like experiences. Initially, the bivariate association between cannabis use and 
psychotic-like experiences was significant. Nevertheless, when adjusting for gender and 
parental history of psychosis, logistic regression analyses showed that the association 
was no longer significant (Shevlin et al., 2017).  
 
Similarly, another study found that the link between cannabis use and psychotic-like 
experiences disappeared when adjusting for gender, age, socioeconomic status, use of 
tobacco and alcohol, behavioural and emotional problems and intelligence quotient 
(Fonseca-Pedrero et al., 2019). Researchers examined if emotional and behavioural 
problems may mediate the before mentioned association and it was found that cannabis 
use, firstly increased the risk for other types of psychopathology and, in result, the 
appearance of psychotic-like experiences (Fonseca-Pedrero et al., 2019). 
 
2.5.6.2. Early Onset of Cannabis Use 
Nine studies included in the systematic review, in addition to examining the association 
between cannabis use and psychotic-like experiences, examined if early onset of 
cannabis use had a stronger effect on the appearance of psychotic-like experiences 
(Albertella et al., 2018; Anglin et al., 2012; Arseneault et al., 2002; Jones et al., 2018; 
Konings, 2009; Mackie et al., 2013; Schubart et al., 2011; Stefanis et al., 2004; van 
Gastel et al., 2012).   
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Studies showed that using cannabis earlier in adolescence increased the risk of 
developing psychotic-like experiences later in life, and the association remained after 
adjusting for confounding factors. Confounder factors taken into account included in the 
analyses were the following; psychotic symptoms, use of other drugs (Arseneault et al., 
2002); other drug use, other dimensions of CAPE, gender, school grade, lifetime 
experience of distress associated with positive psychotic experiences (Stefanis et al., 
2004); age, school type, ethnicity, gender, current use of cannabis, use of other drugs 
(Konings, 2009); age, gender, level of education (Schubart et al., 2011); adolescent 
schizotypal symptoms, major depression, anxiety disorders, cigarette use, other drug use 
(Anglin et al., 2012); age, gender, household composition, family affluence, social 
support, alcohol use, daily smoking, ethnicity and urbanization (van Gastel et al., 2012); 
demographics, depression, cigarette, alcohol and other drug use and previous psychotic-
like experiences (Mackie et al., 2013).  
 
Furthermore, in a more recent study, cannabis use remained significantly associated 
with psychotic-like experiences after controlling for a significant number of 
confounding factors gender, family history of depression, schizophrenia, other drug use, 
maternal or parental smoking during pregnancy, maternal education, highest parental 
social class, IQ, childhood trauma or bullying, emotional and behavioural problems and 
alcohol use, cigarette use (Jones et al., 2018). Early cannabis use was classified as such 
if onset was prior age 12 to 16, depending on the study. However, there have been some 
exceptions where researchers have not found that earlier onset of cannabis use confers a 
greater risk for psychotic-like experiences than later onset of cannabis use. Two studies 
that examined the association between age of onset of use and risk of psychotic-like 
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experiences did not find any indicator that early onset had a stronger association than 
later onset of use (Jones et al., 2017; Leadbeater et al., 2019).  
 
Table 2.8 Early vs. Late Onset of Cannabis Onset and Psychotic-Like Experiences 
Authors & Year 
Early Cannabis Use Late Cannabis Use 
OR 95%CI B p OR 95%CI 
Arseneault, 2002 11.38 .84- 70.45 - - 1.95 0.76, 5.01 
Stefanis, 2004* - - 0.74 0.001 -0.18 0.25 
Konnings, 2008 - 0.22-1.19 0.71 - -0.11 -0.57-0.36 
Schubart, 2011 1.82 1.23-2.70 - - 1.18 0.90-1.55 
Anglin, 2012§ - - .18 .05 NR NR 
Van Gastel, 2011 - - 0.081 0.000 NR NR 
Mackie, 2013∞ 2.54 1.22-5.23 - - 1.66 0.67-4.15 
Albertella, 2018 - - 0.31 0.001 NR NR 
Jones, 2018 3.70 1.66-8.25 - - 2.97 1.63, 5.40 
*Only reported measure for the hallucinations scale, for data on all scales see the 
Appendix, adjusted for frequency of use and all scales remained significant after 
controlling for frequency of use. §For data on all models see the Appendix. ∞Trajectory 
class comparison of PLE’s: Elevated vs. Low. 
 
2.5.6.3. Frequent, Heavy and Cumulative Cannabis Use and Psychotic-
Like Experiences  
When conducting research in cannabis use and psychotic-like experiences, one 
important component in the link that has been found, is that frequent use, heavy use and 
cumulative history of use may play an important role in the association. From the 
included studies in the present review, five found a dose response relationship; 
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indicating that the risk of presenting psychotic-like experiences increased linearly with 
the increment of cannabis use (Bourque et al., 2016; Henquet et al., 2005; Miettunen, 
Niemelä, & Mustonen, 2018; Miettunen et al., 2008; van Gastel et al., 2012).  
  
Moreover, six studies found that frequent cannabis use had a significant effect on the 
appearance of psychotic-like experiences and, regular cannabis use predicted higher 
levels of psychotic-like experiences (Anglin et al., 2012; Bourque et al., 2016; Hides et 
al., 2008; Levy & Weitzman, 2019; Mustonen, Niemela, et al., 2018; Roessler et al., 
2012). Similarly, heavy cannabis use, including cannabis use disorders, were equally 
linked to an increased risk of presenting the before mentioned experiences compared to 
non-users or non-heavy, non-dependent cannabis users (Fergusson et al., 2003; Levy & 
Weitzman, 2019; Schubart et al., 2011; van Gastel et al., 2012). Research has shown 
that cannabis use may have a cumulative and sustained effect, and that regular cannabis 
use increases the risk in the appearance of psychotic-like experiences which may persist 




Table 2.9 Frequent, Heavy and Cumulative vs. Non-Frequent, Non-Heavy and Non-
Cumulative Cannabis Use 
Authors & Year Frequent, Heavy or Cumulative Non-Frequent, Heavy or 
Cumulative 
OR 95%CI p OR 95%CI 
Henquet, 2005 2.23 1.30-3.84 - 1.53 1.13-2.07 
Miettunen, 2008 1.42 1.23-1.64 - NR NR 
Schubart, 2011 3.54 2.94-4.26 - 0.96 0.82-1.13 
Roessler, 2012 2.29 1.32-3.97 - 1.80 1.22-2.66 
van Gastel, 2011 0.065 - 0.000 0.037 0.018 
Bourque, 2016 2.59 1.11-6.03 - NA NA 
Bechtold, 2016 1.51 1.08-2.11 - 1.15 0.91-1.46 
Levy et al., 2019 3.81 1.71-8.50 - NR NR 
Mustonen, 2018 HR 1.14-7.98 - 1.15 0.46-2.95 
3.02 
Fergusson, 2003 RR 1.2-2.6 - NA NA 
1.8 
Hides, 2009 M SD - <0.05 31.2 NR 
29.4 5.7 
Leadbeater, 2019 B 0.002-0.25 - NR NR 
0.13 
*HR= Hazard Ratio; RR= Risk Ratio; M=Mean; SD=Standard Deviation; B=Beta 
 
2.5.6.4. Bi-Directional Relationship between Cannabis Use and 
Psychotic-Like Experiences 
Lastly, two studies included in the present review found a bi-directional relationship 
between these variables; Ferdinand, in 2005 and Griffith-Lendering in 2012 found that 
cannabis use predicted psychotic-like experiences and that presence of these 
experiences also predicted subsequent cannabis use (Ferdinand et al., 2005; Griffith-
Lendering et al., 2013). Nevertheless, other studies did not find such bi-directionality, 
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showing that it was only cannabis use that predicted psychotic-like experiences later in 
life (Bechtold et al., 2016; Kuepper et al., 2011).  
 
2.6. Discussion and Conclusion 
2.6.1. Summary of Evidence  
This systematic review identified 27 studies that have examined the association between 
cannabis use and psychotic-like experiences in adolescents. Overall, most studies 
demonstrated that cannabis use in adolescence may increase the risk of presenting 
psychotic-like experiences later in life. Risk remained significant after adjusting for 
confounding factors. However, these findings were not consistent across all studies, 
results of two different studies indicated the opposite; once researchers adjusted for 
confounding factors the association disappeared.  
 
One consistent finding across all studies which examined frequent, heavy and 
cumulative use of cannabis was that there is a dose-response effect on the association 
between cannabis use and psychotic-like experiences. That is that the more frequent, the 
more quantity and the longer participants used cannabis, the higher the risk and the 
strength of the relationship with the development of psychotic-like experiences.  
 
Furthermore, some of the included studies, demonstrated that age of onset of cannabis 
use may have an increased impact in the association, indicating that earlier onset of 
cannabis use significantly increased the risk of presenting psychotic-like experiences. 
However, similarly to the findings regarding control for confounding factors, results of 
two studies did not find this increased risk, reporting that early onset of cannabis use 
was not significantly associated with psychotic-like experiences.  
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Lastly, the bi-directional relationship of cannabis use and psychotic-like experiences 
had also mixed findings. Whereas two studies did find this relationship, two other 
studies showed that cannabis use did predict psychotic-like experiences, however, 
psychotic-like experiences did not predict cannabis use later in life, indicating 
inconsistent results across said hypotheses.  
 
Twenty-seven of the twenty-nine included studies confirmed that cannabis use during 
adolescence is significantly associated with presence of psychotic-like experiences later 
in life. In spite of some studies not finding a significant association after controlling for 
confounding factors, most studies did, and these results should be considered and taken 
into account for the development of public policies and the information provided to the 
general population regarding cannabis use. A number of different factors may influence 
and shape the relationship between cannabis use and psychotic-like experiences, and 
unfortunately, not all studies took all factors into account. Some of the factors that have 
been shown to influence the appearance of said experiences are childhood trauma, 
family history of psychotic-spectrum disorders, use of other drugs, urbanicity, etc. 
Furthermore, research has shown that genetic vulnerability may play an important role 
in the development of psychotic-experiences or episodes when using cannabis (Løberg 
et al., 2014), which indicates that there are more than only environmental factors that 
may be interacting in the association between cannabis use and psychotic-like 
experiences. 
 
2.7. Limitations of Studies Included 
One of the main difficulties while conducting this systematic review was choosing the 
included studies, as the outcome of psychotic-like experiences or psychosis was 
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extremely heterogeneous. The assessments employed by each study were different and 
this made the process very complex. Furthermore, as each study adjusted for different 
confounds, this made analysing the data markedly difficult.  
 
Moreover, one limitation across studies is that there was no assessment of type of 
cannabis used. This is important to consider when examining the association between 
cannabis use and psychotic-like experiences as different studies have shown that high-
potency cannabis tend to increase risk for psychosis (Di Forti et al., 2009). Furthermore, 
some studies did not assess use of illicit drugs, which research has shown to be 
significantly associated with psychotic-like experiences and, when included in adjusted 
models, attenuates the association between cannabis use and psychotic-like experiences 
significantly.  
 
2.8. Strengths and Limitations 
To the best of my knowledge, this is the first systematic review examining cannabis use 
and psychotic-like experiences in an adolescent population. There have been previous 
systematics reviews conducted which examined cannabis use and psychosis, 
nevertheless the target populations were different (Large et al., 2011; Marconi et al., 
2016; Moore et al., 2007; Myles, Myles, & Large, 2016; Schoeler et al., 2016).  
Furthermore, eleven databases were searched, and this resulted in a substantial number 
of resources. A limitation to be considered is that only one author conducted the 
screening process and was responsible of extracting data from the included studies. The 
process was conducted at two separate times points in a very thorough and 




3.1. Overview of Study Design 
This is a cross-sectional study designed to examine the relationship between cannabis 
use and psychotic-like experiences in adolescents in Mexico City and Estado de 
Mexico. Data were collected from two adolescent samples: a general population sample 
recruited from state funded middle schools and a clinical sample of adolescents 
experiencing cannabis related problems recruited from drug use treatment services. 
Participants in both samples completed questionnaires describing a) sociodemographic 
characteristics; b) patterns of cannabis use; c) cannabis use after-effects; d) psychotic-
like experiences; e) potentially confounding variables including use of other drugs. A 
detailed description of the procedures used in this study is provided below. 
 
3.2. Adolescent Student Sample 
The school sample was recruited from seven different public middle schools located in 
four different boroughs in Mexico City and the surrounding county, Estado de Mexico; 
Iztapalapa, Tlanepantla, Gustavo A. Madero and Ecatepec. An in-depth description of 
the school system in Mexico is provided below as well as a detailed description of the 
boroughs from where data were collected. This description aims to help as background 
of how the school system works in Mexico, school attendance by age and borough, the 
sociodemographic characteristics of the boroughs from where data was collected and 
from the drug services attended.  
 
3.2.1. School System in Mexico 
Mexico has a total population of 119,938,473 of which 48.6% are men and 51.4% are 
women (INEGI, 2015). Part of the target age range of this study, 16 to 19 year olds, 
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comprise 9% of the total population in Mexico (INEGI, 2015). Mexico City has a total 
population of 8,918,653 which comprises 7.5% of the total population in Mexico; 
Estado de México is populated by 17,604,619 people which comprises 13.5% of 
Mexico’s total population being the most populated county in the country and it is 
characterised by its location, surrounding most parts of Mexico City (INEGI, 2017a).  
 
The percentage of 15 to 24-year olds in 2015 that reported attendance to some type of 
education centre was 44% (INEGI, 2015). The national school system in Mexico is 
structured of 3 different levels; a) basic education, b) middle education and c) higher 
education; which are also divided into public and private sectors, with 86% of pupils 
attending public schools at a national level and 14% to private schools (SEP, 2018). 
Basic education encompasses preschool, primary school and secondary school, which 
are all compulsory. Middle school includes A Levels, all levels equivalent to this and 
professional education that does not require A Levels or its equivalents. Compulsory 
ages for school attendance in Mexico are from 3 to 16 years old, the first level, 
preschool from the age of 3 to 5 years old. Next, primary school is structured by 6 
grades, where the age range is from 6 to 12 years old. Lastly, secondary school with 3 
grade levels, where age ranges from 12 to 16 years old. Middle school and graduate 
school are not compulsory. In order to provide a comparison of the school population 
with the general adolescent population in Mexico, school attendance data is provided 
below. Furthermore, specific school attendance data regarding each of the boroughs 
from where data was collected in the present study is included (SEP, 2018).  
 
In Mexico there are two different methods to obtain middle school education: on 
campus and by distance learning. On campus means that students are required to attend 
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school from Monday to Friday, full time during the duration of the school year; distance 
learning allows students to either only attend school part time or not to attend at all and 
only present exams to pass each subject, once all subjects have been completed, 
students can graduate from middle school. The most common method, however, is on 
campus with 92% of middle school students enrolled whereas only 8% are enrolled in 
distance learning (SEP, 2018). From the 92% of students enrolled on campus, 80% were 
in public schools and 20% reported attending private on campus middle schools. The 
drop-out prevalence in middle school throughout Mexico is of 13.3% (SEP, 2018). 
  
Specifically, in Mexico City there where 476,825 pupils enrolled in middle school in the 
school year 2017-2018. In total in the city there are 249 public middle schools and 403 
private schools. Sixty-five percent of students in the city in middle school were enrolled 
on campus from which 72% were in public schools and 28% in private schools. Thirty-
five percent were on the distance learning method from which 99% reported being in a 
public school and only 1% in private distance learning method. In Mexico City the total 
dropout rate of middle school students aged 15 to 19-year olds approximately, is 17.9% 
including both, on campus and distance learning (SEP, 2018). 
 
School attendance in Mexico by age in 2017 was reported as follows; 85% of 14-year 
olds reported attending school, 75% of 15-year olds, 72% of 16-year olds and 70% of 
17-year olds. From the age of 18 school attendance in the country decreases 
significantly with only 45% of 18-year olds and only 37% of 19-year olds reporting 
school attendance. When examining specifically school attendance in Mexico City, in 
2017 it was reported that 95% to 82% of 14 to 16-year olds were attending school, 
whereas only 78% to 56% of 17 to 19-year olds were attending school. In contrast, in 
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Edo. de Mexico, numbers were significantly different, with 93% to 76% of 14 to 16-
year olds and 70% to 44% of 17 to 19-year olds were attending to school this same year 
(INEGI, 2017b). 
 
However, when observing the specific boroughs from where data was collected it was 
observed that rates of school attendance by age were lower than the average of the city’s 
mean rates. In Gustavo A. Madero 93% to 78% of 14 to 16-year olds and 72% to 53% 
of 17 to 19-year olds reported school attendance. In Iztapalapa 92% to 73% of 14 to 16-
year olds and only 66% to 45% of 17 to 19-year olds reported school attendance 
(significantly lower than the city average). In Estado de Mexico, in both counties, 
Ecatepec and Tlanepantla only 55% of 15 to 17-year olds reported school attendance 
(SEP, 2018).  
 
3.2.2. Adolescent Student Sample: Recruitment and Sampling 
Schools were contacted and invited to participate in the study via Juvenile Inclusion 
Centres with the support of the workforce from each treatment centre. A detailed 
description of what Juvenile Inclusion Centres are and its role and involvement in the 
study is provided below.  
 
3.2.3. Adolescent Student Sample and Juvenile Inclusion Centres 
Juvenile Inclusion Centres (CIJ) is a non-profit organisation created in Mexico in 1969 
which provides prevention and treatment services for addiction related problems. Its 
main objective is to contribute in the reduction of drug use within the community, 
through their participation in prevention and treatment. Its national workforce is formed 
of 117 units across Mexico; eleven are inpatient centres and 2 of them are specifically 
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targeted to heroin users located in high risk areas; the remaining units are outpatient 
treatment services which also provide prevention workshops in schools and within the 
community. These centres are funded by the government and by private contributions 
(Juvenile Inclusion Centres, 2018). 
 
As previously mentioned, part of the prevention programmes this organisation provides 
to the community are liaisons with public schools, providing workshops on addiction 
prevention and other types of interventions. As a result of the ongoing collaboration 
between CIJs and government funded schools, it was possible to contact public middle 
schools through Juvenile Inclusion Centres. The head of the research department in CIJ 
was contacted and a meeting was organised, where it was agreed CIJ would take part 
and provided support for the project. Before data collection started, it was required to 
register the project within their research department and undergo ethical approval 
procedure in the institution as well.   
 
The school’s sample from where data was collected was randomly selected. Once 
schools were identified, a member of the service approached the head teacher in schools 
to extend an invitation to participate in the project. Once the school agreed to 
participate, the principal researcher and the head teacher met. During the meeting the 
aims and objectives of the study were explained in detail as well as the procedure of 
data collection and permission was requested to contact students (See Figure 3.1). 
 
Before contact with potential participants was made, the principal researcher explained 
the age range needed for the study to the school's headteacher to identify classrooms of 
students that were among that age range. Only classrooms in that age range were 
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approached. After permission from the head teacher was granted, dates and times were 
set taking into account timings and calendar of each school. Classrooms were selected 
according to the inclusion criteria, where students age range was from 15 to 19 years 
old. The principal researcher approached each classroom and explained in detail the 
aims and objectives of the study. It was clearly stated that their participation was 
completely voluntary, that there was no pressure to participate and that there would not 
be any consequences if they decided not to. Moreover, it was emphasized that all the 
information provided was confidential and anonymous. Lastly, if the students had 
questions regarding the study these were addressed by the principal researcher. 
 
Twenty-four hours before the questionnaires were given to participants, an information 
sheet and an informed consent were provided. The following day, if students had agreed 
to participate, the questionnaires were handed in and completed. The principal 
researcher stayed in the classroom while the students completed the questionnaires and 
if they had any question or query, she approached each student individually. 
Completion of the questionnaires took the students approximately from 35 minutes to 
one hour. During the survey students were asked to sit by themselves on their own desk 
and were reminded that the questionnaires need to be answered individually, it was 
ensured participants had enough space and were seating separately to prevent copying 
or viewing each other’s questionnaires. Moreover, the principal researcher gave the 
following statement during the initial informative talk to ensure participants completed 
questionnaires confidentially and without peer pressure. 
 
“One of the main things to remember is that all the information you 
provide is strictly confidential and anonymous, do not feel there is any 
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pressure to participate even if your classmates and friends decide to take 
part in the study. Your participation is completely voluntary and there 
will be no consequences if you decide not to take part.” 
 
It was decided that for better control of pressure to participate all students were advised 
to remain in the classroom even if they did not wish to participate in the study. The 
classroom teacher and the principal researcher gave instructions of other work students 
could do if they do not wish to complete the questionnaires. After the explanation the 
teacher was asked to leave the classroom, in some cases this was plausible and others 
this was not (some classrooms had much more disruptive students than others, 
therefore, sometimes the presence of the teacher was necessary in order to maintain 
group control). The principal researcher provided a booklet with the questionnaires to 
every student in the classroom. Afterwards, they decided individually if they wanted to 
complete or not the questionnaires without any of their classmates having to know. 
Each classroom comprised of 30 to 50 students depending on the school, grade and 
attendance.  
 
3.3. Adolescent Substance Misuse Clinical Sample 
3.3.1. Juvenile Inclusion Centres: Treatment Centres for Young People with 
Problematic Drug Use 
There are different ways to start treatment in these centres. People can be self-referred, 
if anyone believes they have an issue with substance abuse they can attend to any centre 
and request details regarding treatment, there are also telephone lines where people can 
call. There are, however, other ways to be referred, for example when someone who has 
been incarcerated and their crime was motivated by or related with substance abuse 
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police might oblige them to get treatment in order to be eligible for and maintain parole. 
Another way to receive treatment is through health services. When a patient presents to 
a health clinic reporting substance abuse, the Dr might suggest them to get treatment at 
CIJ.  Treatment services were selected alongside the head of the research department of 
Juvenile Inclusion Centres. The first three centres selected were CIJ Gustavo A. Madero 
Aragon, CIJ Tlanepantla and CIJ Iztapalapa Poniente. Two main reasons played part in 
the selection of these centres, firstly, it was identified which centres had the most 
available population in the age range of the study and, secondly, the availability of each 
centre. 
   
The names of the before mentioned centres include the name of the borough where they 
are located in. The first centre contacted was CIJ Gustavo A. Madero Aragón, located in 
the borough Gustavo A. Madero, where a total of 1,164,77 people resides. The crime 
rate in this borough is relatively high, with 10% of all crime committed in Mexico City, 
this borough holds the 3rd place in insecurity (the borough with the highest reported 
crime rate is Cuauhtémoc with 15%) (Justicia, 2018) (See Figure 3.2). 
  
3.3.1.1. Boroughs’ Description 
CIJ Iztapalapa Poniente and CIJ Iztapalapa Oriente are located in the borough of 
Iztapalapa with a total 1,827,868 habitants, this borough has the largest population in 
Mexico City. It is characterised by having one of the least developed infrastructures in 
the city with important deficits in access to clean drinking water. One of the main 
problems in this borough located east of Mexico City are the high rates in crime, being 
the second most dangerous borough with 14% of all crimes in the city committed here; 
it has the highest rates of drug trafficking, violence against women, and traffic of stolen 
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auto-parts (Justicia, 2018). CIJ Tlanepantla is located in the borough Tlanepantla in 
Estado de Mexico is one of the 125 boroughs in this county. With a total population of 
700,734 is one of the most industrialised boroughs (INEGI, 2015).  
 
After a couple of months collecting data from these centres it was observed that while 
they were very effective in providing participants for the school sample, they did not 
have enough flow-through of patients for the clinical sample. Therefore, the principal 
researcher contacted the head of the research department to suggested new centres to 
collect data from; CIJ Tlalpan and CIJ Iztapalapa Oriente. This decision was made after 
reviewing a patient report from JIC from 2015 where it was observed that those centres 
had more patients in the age range needed and where the main substance of abuse was 
cannabis. CIJ Tlalpan, located in Tlalpan borough, is the borough with the largest km in 
Mexico City, however its population is smallert than the other boroughs, with only 
667,104 residents. Regarding insecurity and crime, this borough accounted for 5.7% of 
offences in the city (Justicia, 2018).   
 
Ecatepec de Morelos is the most populated borough in Estado de Mexico with 
1,677,678 people. It is the second most populated borough in the country after 
Iztapalapa (INEGI, 2015). Ecatepec is considered the most dangerous borough in 
Estado de Mexico and one of the most dangerous in the country, with extremely high 
rates of crime including homicides, kidnaping, sexual assaults and home, business and 
car robbery (Justicia, 2018). Moreover, this borough has a permanent gender alert as it 
is the borough where more “feminicidios” (violent homicides against women) occur in 
the country (Gobernacion, 2018). In 2015 it was considered the borough with the 
highest rates of extreme poverty in the country (INEGI, 2015). 
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3.3.2. Adolescent Substance Misuse Clinical Sample: Recruitment and 
Sampling 
Before contact with potential participants was made, the principal researcher explained 
the inclusion criteria to the service personnel (age range 13 to 19-year olds, primarily 
cannabis users) to request their support with identifying potential eligible participants. 
Once personnel helped with the identification of participants that met the inclusion 
criteria, they were approached. The method of approach could differ depending on the 
service. In every service the above-mentioned strategy was used, however in some 
services an introductory talk was provided to all new patients on a particular day during 
the week. When a service provided this talk the principal researcher would participate in 
it, explaining the aims and inclusion criteria. By the end of the talk, if there was anyone 
interested in participating, they were advised to approach the researcher for further 
information and, if they agreed, complete the questionnaires.  
 
To ensure participants completed all questionnaires confidentially and without any 
pressure, the principal researcher gave the same statement to participants in the 
substance misuse clinical sample than in the school sample, excluding the part when 
specifying participation of “classmates”.   
 
The principal researcher arranged a specific day during the week to attend to each 
service, depending on the activities and the day of the week each service held the 
introductory talk. Once participants were approached, the aims and objectives of the 
study were explained, reassuring that all the information provided is anonymous and 
that there is no pressure to participate, it is completely voluntary and there will be no 
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consequences if they decide not to take part in the study. If the participants had 
questions regarding the study, those were answered by the principal researcher. 
 
Finally, an information sheet and an informed consent were provided and, 
questionnaires were administered in small groups by the principal researcher which took 
approximately 30 minutes to complete. During the assessment participants were seated 
separately one from another and were reminded to answer the questionnaires 
individually. When participants had questions or did not understood some of the items 
in the questionnaires, they approached the principal researcher for clarification. 
 
3.4. Questionnaires 
Participants in both the school sample and the substance misuse clinical sample, 
completed identical questionnaires describing patterns of cannabis use, psychotic-like 
experiences and associated factors. Questionnaires are described in detail below.  
 
3.4.1. Cannabis Use Questionnaire  
Cannabis use was assessed with a series of questions regarding lifetime, past six 
months, age of onset, amount, method and frequency of use.  
1. Have you ever used cannabis? 
2. Have you used cannabis in the last 6 months? 
3. How old were you when you first tried cannabis? 
4. How many joints do you smoke on a typical occasion (1/4 of a joint, ½ of a 
joint, one, two, three, four or more)? 
This was recoded into a two-category variable for analysis and categories were 
defined as less than one or one and two or more. 
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5. Do you mainly use cannabis (in a joint with tobacco, in a joint without tobacco, 
in a bong or waterpipe, eaten, e-cigarettes, other)? 
6. How often do you use cannabis (every day or almost daily, once or twice a 
week, once or twice a month, less than once a month, once or twice a year, only 
tried it once)? 
The primary variable of frequency of cannabis use was structured as a 6-
category variable.  
7. Do you mainly use cannabis alone or socially (with friends)? 
 
Moreover, additional questions regarding type of cannabis mainly used, type of 
cannabis they preferred to use and type of cannabis most available to them were 
included (i.e. herbal cannabis, hydroponic, redhead or skunk, hash or resin).  
8. Which of the following best describes the type of cannabis you mainly use? 
9. Which of the following best describes the type of cannabis that is most available 
for you to use? 
10. If you could choose one, which of the following would you prefer to use? 
1. Herbal cannabis 
2. Hydroponic, redhead or skunk 
3. Hash or resin 
4. Don´t know 
 
This was assessed by providing pictures of different types of cannabis to have more 








The cannabis use questionnaire was previously used to survey a general adolescent 
population sample of 467 adolescents (mean age 16.8) in UK secondary schools 
(Mackie, et al. under review), but subsequently adapted for use with adolescents in 
Mexico. There is no standardised questionnaire that examines types of cannabis in 
adolescents; however similar formats (self-report) have been used before (Di Forti et al., 
2014; Freeman & Winstock, 2015; Wilson, Freeman, & Mackie, 2019). Piloting among 
an adolescent Mexican sample was conducted months prior to the start of data 
collection; items are described in the Appendix. 
 
During data collection, some participants had queries regarding amount of cannabis 
mainly used, as they mentioned that they did use cannabis, but not in a joint. The 
principal researcher addressed this and requested participants to answer thinking of the 
average amount used and convert that into one of the given options. However, it was 
identified that the lack of a standard unit measure makes this assessment difficult, and it 
is difficult for participants to identify or calculate the exact number of grams using in 
each joint or in pipes and bongs. 
 
 
Herbal Cannabis Hydroponic, 
redhead or skunk 
Hash or resin 
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3.4.2. Cannabis Experience Questionnaire 
This scale was structured from the Cannabis Experiences Questionnaire (CEQ) which 
was developed by Barkus et al. in 2006, this questionnaire assesses the subjective 
effects of cannabis use and it is structured of 3 different subscales; pleasurable 
experiences, psychosis-like experiences and after-effects (Barkus, 2006). For brevity 
and in order to facilitate data collection four items assessing psychotic-like experiences 
and three items assessing after-effects were extracted from two subscales in the CEQ. 
The items attempt to quantify the effects experienced after the use of cannabis which are 
associated with anhedonia (characterised by users reporting feeling lack of motivation, 
passive and non-productive), cognition and psychotic-like experiences. The scale is 
formed by the following items: 
 
Have you experienced any of the following effects after smoking cannabis? Please 
choose only one option. 
A. Feelings of paranoia or suspiciousness 
B. Hearing voices 
C. Feeling like I am going crazy/mad 
D. Not wanting to do anything, lack of motivation 
E. Difficulty in concentrating 
F. Not able to think clearly 
G. Seeing visions 
H. Other: please specify  
 
Each of these potential after-effects were rated on a four-point scale: (1 = rarely or 
never, 2 = time to time, 3 = more often than not, 4 = almost always). Responses to the 
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eight questions were summed to form a single scale representing the extent to which 
participants reported experiencing negative effects after using cannabis.  
 
3.4.3. Psychotic-Like Experiences: The PRIME Screen Questionnaire for 
Prodromic Symptoms  
This questionnaire was elaborated by McGlashan, T. et al. by combining the Structured 
Interview of Prodromal Syndrome and an in-depth interview. The main objective was to 
develop a scale that could be used in the general population that measured prodrome 
symptoms (first signs, prior to the development of a psychotic disorder) which was not 
available then. The Spanish translation and reliability were conducted in Mexico City 
with a sample of 532 adolescents from 15 to 23 years old (Fresan, Apiquian, Ulloa, & 
Nicolini, 2007). With 12 items the approximate time of completion is from 10 to 20 
minutes. The internal consistency of the scale was of 0.88. To the best of my 
knowledge, this is the only questionnaire examining psychotic-like experiences 
translated (English to Spanish) and validated in adolescent Mexican population, which 
provides reassurance that the instrument is measuring psychotic-like experiences in the 
population recruited.  
 
3.4.3.1. The PRIME Screen Questionnaire for Prodromic Symptoms: 
Items 
1. I think that I have felt that there are odd or unusual things going on that I can’t 
explain. 
2. I think that I might be able to predict the future. 
3. I may have felt that there could possibly be something interrupting or controlling 
my thoughts, feelings or actions.  
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4. I have had the experience of doing something differently because of my 
superstitions.  
5. I think that I may get confused at times whether something I experience or 
perceive may be real or may be just part of my imagination or dreams. 
6. I have thought that it might be possible that other people can read my mind, or 
that I can read other’s mind. 
7. I wonder if people may be planning to hurt me or even may be about to hurt me.  
8. I believe that I have special natural or supernatural gifts beyond my talents and 
natural strengths. 
9. I think I might feel like my mind is “playing tricks” on me.  
10. I have had the experience of hearing faint or clear sounds of people or a persona 
mumbling or talking when there is no one near me.  
11. I think that I may hear my own thoughts being said out loud. 
12. I have been concerned that I might be going crazy.  
13. Have you ever seen something or someone that other people could not see? 
 
The PRIME Screen Questionnaire was rated in a 6-point rating scale (1=completely 
disagree, 2=disagree, 3=somewhat disagree, 4=not sure, 5=somewhat agree, 
6=completely agree). 
 
A further item to examine visual hallucinations was added as prior research indicate that 
these experiences are part of the continuum and may be of interest to analyse (van 
Gastel et al., 2012). 
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• Have you ever seen something or someone that other people could not see? 
(Visual hallucinations). This item was also assessed on the same six-point scale 
described above. 
 
Moreover, four items were added to the original scale. These items were added in order 
to obtain more detailed information of the participants experiences and if these occurred 
under the influence of any drug. The items added were the following:  
• How old were you the first time you experienced this symptom? 
• Did this symptom occur after using drugs? If it did,  
o Which drug? 
• Did you ever experience this symptom without the use of any drug? 
 
3.4.4. Demographic Questions 
• Age (years) 
• Gender (male, female) 
• Ethnicity 
 
Firstly, ethnicity was categorised as follows: “Caucasian”, “Hispanic or Latin”, 
“African-American”, “African-Mexican”, “Asian” and “Other”. Categories were 
identified when running the frequencies of the original variable. Afterwards, the main 
categories identified and selected for the following analyses were “Hispanic or Latin”, 
“Caucasian” “African Descent” and “Other”. Ethnicity was recoded as a 4-category 
variable instead of a 6-category variable. 
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3.4.5. Socioeconomic Questionnaire 
Socioeconomic level was assessed by using a questionnaire developed by the Marketing 
and Opinion Intelligence Mexican Association which is based on a statistical model 
which categorise Mexican homes in different levels according to their capacity to fulfil 
basic requirements of families (Asociación Mexicana de Agencias de Inteligencia de 
Mercado y Opinión, 2108). In the following page, next to each question of the 
questionnaire, the value, depending on the answer of the participant, can be found.  
1. How many rooms does your house have? Please do not include bathrooms, half 
bathrooms, hallways or courtyards. (1 = 0; 2 = 0; 3 = 0; 4 = 0; 5 = 8; 6 = 8; 7 or 
more = 14). 
2. How many complete bathrooms with shower and W.C. are in the house for 
exclusive use of your family? (1 = 16; 2 = 36; 3 = 36; 4 or more = 52). 
3. Does your home have a functioning shower in any of the bathrooms? (No = 0; 
Yes = 10). 
4. Considering all the lightbulbs that you and your family use to light your house, 
including ceilings, walls, bed lamps or floor lamps, how many lightbulbs are 
there in your house? (0-5 = 0; 6-10 = 15; 11-15 = 27; 16-20 = 32; 21 or more = 
46). 
5. The floor in your house is predominantly soil, cement or other type of material? 
(Soil or cement = 0; Other type of material = 11). 
6. How many cars do your family own, excluding taxis? (0 = 0; 1 = 32; 2 = 41; 3 or 
more = 58). 
7. Does your home have a gas or electric stove? (No = 0; Yes = 20). 
8. Thinking about the family member that contributes the most economically in 
your house, which was the last year of studies he/she completed? (Did not study 
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= 0; primary not completed = 0; primary completed = 22; secondary school not 
completed = 22; secondary school completed = 22; commercial degree = 38; 
technical degree = 38; high school not completed = 38; high school completed = 
38; undergraduate not completed = 52; graduate completed = 52; diploma or 
Master = 72; PhD = 72).  
 
3.4.5.1. Scores and Levels 
The following are the different socioeconomic levels depending on the score they had. 
Scores are calculated by adding the numbers in parenthesis above, depending on the 
answer. Levels are categorised as A/B, C+, C, C-, D+, D, E. 
• A/B: (193+) Highest living standards in the country, all needs are covered, and it 
is the only sector with resources to invest and plan ahead. Only 3.9% of homes 
in Mexico have this living standard.  
• C+ (155 – 192) All needs are covered; however, there might be difficulties to 
invest, save and plan ahead. Comprised by 9.3% of households in the country. 
• C (128 – 154) Practical living standard with certain commodities; however, 
basic in entertainment and technology. They comprise 10.7% of the country’s 
households.  
• D+ (80 – 104) Minimum sanitary home infrastructure in the house, 19% 
households in the country. 
• D (33 – 79) Might have a property but lack basic services like running water or 
gas. Comprised by 31.8% of households in the country. 
• E (0 – 32) Least quality of life and do not have any services (water, gas, 
electricity). Constitutes 12.5% of households in Mexico. 
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Initially, the variable was coded as a seven-category variable, however for further and 
more specific analyses it was recoded into a three-category variable. Categories were 
clustered according to the original questionnaire where the most similar levels were 
combined:(A/B) as one, (C+/C/C-) as two and (D+/D/E) as three. 
 
3.4.6. Use of Other Drugs 
As part of the questionnaires included in the present study, a systematic questionnaire 
regarding use of other drugs was administered. Research has continuously shown that 
cannabis use is associated with use of other drugs, licit and illicit (Hall, 2014), therefore 
the interest of including this questionnaire. Furthermore, it has been found that 
psychotic-like experiences and use of other drugs are significantly associated (Barkus & 
Murray, 2010; Shevlin et al., 2017). This questionnaire assessed use of: 
• Tobacco 
• Alcohol 
• Cocaine  
• Crack 
• Solvents  
• Hallucinogens 
• Ecstasy 
• Benzodiazepines / Sleeping Pills 
• Opioids (Not heroin, pain killers, etc.) 
• Heroin 
• Opium 
• Amphetamines / Methamphetamines  
• Other Drugs (Legal Highs, etc.)
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Use of other drugs was assessed through specific questions regarding:  
1. Lifetime use (Yes/No) 
2. Age of first use (Years) 
3. Frequency of use: every day or almost every day; once or twice a week; once or 
twice a month; less than once a month; once or twice a year; only tried it once. 
 
A guide to help identification was provided when requested to participants who did not 
know or were not sure of what each substance was. This guide included pictures and 
“common” or drug street names and examples, see the Appendix. 
 
3.5. Statistical Analysis 
This cross-sectional study in an adolescent student sample and adolescent substance 
misuse clinical sample (primarily cannabis users) examined the relationship between 
cannabis use and psychotic-like experiences. Data from the school sample were 
analysed separately from the clinical sample data. All analyses were conducted using 
the statistical package IBM Corp. Released 2017. IBM SPSS Statistics for Windows, 
Version 25.0. Armonk, NY: IBM Corp.  
 
The main independent variable was cannabis use and the main outcome variable was 
psychotic-like experiences (continuous); however, the following covariates were also 
included in the analyses: 
1. Age  
2. Gender  
3. Sociodemographic characteristics  
4. Use of other drugs 
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For statistical analyses, the following approaches were used. The principal dependent 
variable was psychotic-like experiences, assessed using the PRIME screen 
questionnaire. While the primary interest was the association between psychotic-like 
experiences and cannabis use, potential confounding covariates (i.e. age, gender, other 
drug use, and sociodemographic characteristics) were also assessed and included in the 
statistical models. My primary analytic approach involved the use of regression models. 
The variable psychotic-like experiences was conceptualized as a continuous variable 
(e.g., number of symptoms experienced), in which case linear regression analysis was 
conducted. Age, gender, sociodemographic characteristics and use of other drugs were 
included in each model. Statistical analyses are described below. Firstly, descriptive 
statistics were performed to explore prevalence of lifetime cannabis use by age, gender, 
ethnicity and socioeconomic status.  
 
Descriptive statistics were conducted to identify number of participants by age and 
gender, ethnicity and socioeconomic status. Analyses were conducted to identify mean 
age of onset of cannabis use, frequency and quantity of use, type of cannabis mainly 
used and preferred route of administration. Furthermore, chi-square analyses were 
conducted to identify differences between the before mentioned variables and 
sociodemographic characteristics.   
 
3.5.1. Patterns of Cannabis Use 
Analyses were conducted to identify differences in patterns of cannabis use and age, 
gender, age by gender interaction, ethnicity and socioeconomic status. Use of different 
types of cannabis among participants were examined using three different variables: the 
type of cannabis mainly used, the type of cannabis preferred by users and finally the 
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most available type of cannabis. The original categories included in the analysis were: 
herbal cannabis, skunk, hydroponic or redhead, hash or resin and don’t know. 
Prevalence of main type used, preferred type and most available type of cannabis were 
reported. In order to identify statistically significant differences in type of cannabis 
mainly used by age, gender, age by gender interaction, ethnicity and socioeconomic 
level chi-square analyses were performed. 
  
Prevalence of routes of administration were also analysed. The variable in the 
questionnaire comprised of 6 different categories, however, for further analyses the 
variable was recoded into a dichotomous measure assessing use in a bong or water pipe 
vs. any other. Analyses were conducted to identify significant differences by age, 
gender, age by gender interaction, ethnicity and socioeconomic status. To assess 
preference of participants between social or non-social use of cannabis participants were 
asked if they mainly used cannabis alone or with friends. Prevalence of use was 
reported, and differences were assessed with the dichotomous variable of social or non-
social use and all the sociodemographic characteristics previously described.  
 
3.5.2. Psychometric Properties of the Cannabis Experience Questionnaire and 
Differences by Sociodemographic Characteristics and Use of Other Drugs 
Principal components analysis was conducted on the seven items of the after-effects 
scale. The internal consistency in the scale was measured by Cronbach’s Alpha. 
Analyses of variance were conducted to identify if the total score of the cannabis 
experience questionnaire varied by age, gender, ethnicity and socioeconomic status. 
Linear regression analyses were performed to identify differences between the total 
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scores of the questionnaire while controlling for age of first use, age, gender and 
frequent or non-frequent use.  
 
3.5.3. Use of Other Drugs 
Analysis of prevalence of lifetime use, age of first use and frequency of use of other 
drugs were conducted. Both licit and illicit drugs were assessed, and descriptive 
statistics reported. Next a series of analyses were conducted to examine the associations 
between lifetime cannabis use and measures of use of other drugs. 
 
3.5.4. Associations between Patterns of Cannabis Use and Use of Other Drugs 
Analyses were conducted to identify associations between different patterns of cannabis 
use and use of other drugs in both samples.  
 
3.5.5. Associations between Different Patterns Cannabis Use, 
Sociodemographic Characteristics and Use of Other Drugs 
In order to identify differences between the continuous measure of cannabis use, 
sociodemographic characteristics and the use of other drugs analyses of variance were 
conducted. Different dichotomous measures of cannabis use (lifetime use, at least 
monthly use and type of cannabis mainly used) were employed to explore any 
associations with sociodemographic characteristics and use of other drugs. Odds ratios 
obtained from crosstabs, chi-square and logistic regression analyses were conducted. 
Furthermore, hierarchical regression models were conducted to identify the level of 
association between different patterns of cannabis use, sociodemographic characteristics 
and use of other drugs, while taking into account all variables. Firstly, 
sociodemographic variables were entered followed by use of other drugs, both licit and 
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illicit. Measures of psychotic-like experiences were not entered at this point of the 
analyses.  
 
3.5.6. Psychotic-Like Experiences 
In order to identify correlations between variables and to examine consistency of the 
questionnaire, principal component factor analysis and reliability analysis were 
performed to the PRIME Screen Questionnaire. Mean scores of each item of the were 
analysed, followed by descriptive statistics to identify prevalence of psychotic-like 
experiences by age and gender.  
 
3.5.7. Associations between Psychotic-Like Experiences, Sociodemographic 
Characteristics and Use of Other Drugs 
For the psychotic-like experiences analyses, in addition to the continuous measure of 
the total score of the PRIME Screen Questionnaire, a dichotomous measure was created 
(Yes/No Presence of PLE’s). Previous literature showed feasible to create a 
dichotomous outcome on the PRIME Screen Questionnaire (Kobayashi et al., 2008). In 
the version of the questionnaire used for this study a 40+ score would result in scoring 
as positive in the psychotic-like experiences assessment.  
 
For the continuous measure of the PRIME Screen questionnaire, analyses of variance 
were conducted to identify differences between psychotic-like experiences, 
sociodemographic characteristics and use of other drugs. Furthermore, similar to the 
analyses conducted with cannabis use, hierarchical regression analyses were conducted 
to identify the association between psychotic-like experiences, sociodemographic 
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characteristics and use of other drugs. The final model was fitted to consider all 
variables, except for cannabis use. 
 
3.5.8. Patterns of Use of Other Drugs and Associations between the Use of 
Other Drugs and Psychotic-Like Experiences 
Descriptive statistics were conducted to determine prevalence of psychotic-like 
experiences, overall and by gender. Furthermore, analyses were conducted to identify if 
use of other drugs were independently associated with psychotic-like experiences. 
Cross-tables were created to identify prevalence of use and odds ratio between 
psychotic-like experiences and daily and weekly use of tobacco; daily, weekly and 
monthly e-cigarette use; daily and weekly alcohol use; every day and weekly binge 
drinking; daily, weekly and monthly benzodiazepine use; daily, weekly and monthly 
methamphetamine use and daily, weekly and monthly solvent use. 
 
3.5.9. Multiple Regression Analyses: Association between Cannabis Use and 
Psychotic-Like Experiences Controlling for Sociodemographic 
Characteristics and Use of Other Drugs 
Lastly, hierarchical multiple regression analyses were conducted to identify associations 
between different patterns of cannabis use and psychotic-like experiences while 
controlling for sociodemographic characteristics and use of other drugs; these analyses 
are the main interest of the present study. Models were conducted with measures of 
cannabis use as main predictor, followed by sociodemographic characteristics and use 
of other drugs. The outcome variable was psychotic-like experiences.  
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3.6. Ethical Considerations 
The ethics application for this study was submitted on the 31st of October 2017. The 
approval was granted on the 18th of December 2017 by the Psychiatric, Nursing and 
Midwifery Research Ethics Subcommittee. Study Reference Number: HR-17/18-5256. 
The project was registered at Juvenile Inclusion Centres and their Ethics Committee 
reviewed the project in order to start data collection. This process started in December 
2017 and approval was granted in February 2018. Study Reference Number: 203-17. 
Questionnaires were anonymous and were only identified with previously assigned 
identification numbers. Documents do not contain personal data that may jeopardize 
confidentiality. Documents that might contain the participants’ name are the informed 
consents which are kept separate from the questionnaires. 
 
3.7. Power Analyses 
Power estimates were conducted in Gpower; each analysis took into consideration data 
extracted from studies regarding cannabis use and psychotic-like experiences in 
adolescent populations relevant to the present study.  
3.7.1. Adolescent Student Sample  
In the school setting with a sample size of N=500 participants, from which it is 
estimated that 30% (n=150) will be cannabis users and 70% (n=350) are non-cannabis, 
users based on the survey conducted in 2015 by Villatoro, et al. in Mexico City 
(Villatoro et al., 2015). I assume based on a systematic review and meta-analysis that 
the prevalence of psychotic-like experiences in non-cannabis users will be 
approximately 7.5% (Kelleher et al., 2012). Under these assumptions my proposed 
sample size of 500 participants will have .90% power to detect an odds ratio of 1.8 
between cannabis and non-cannabis users as statistically significant.  
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3.7.2. Adolescent Substance Misuse Clinical Sample 
In the clinical setting, based on a meta-analysis conducted in 2016 by Marconi, A. et al., 
the estimated prevalence of psychotic-like experiences in cannabis users will be 30% 
(Marconi et al., 2016). Under this assumption my proposed sample size of 120 will have 
.90% power to detect and odds ratio of 3.5 between severity of cannabis use and 
psychotic-like experiences (Faul, Erdfelder, Buchner, & Lang, 2009). 
 
3.7.3. Missing Data 
Out of 198 participants reporting lifetime cannabis use between 3 and 7 had missing 
data in frequency, quantity, method and type of cannabis mainly used, 1.5 to 3.5% of 
the sample, which is a small percentage of the 198 participants. Thirty participants had 
missing data on the total score of psychotic-like experiences 4.6% of the sample. To 
explore whether cannabis use predicted missing data on the PRIME Screen 
Questionnaire logistic regression analyses were conducted, results showed no 
significant associations between cannabis use and missing data (OR=1.29, 95%CI=.59-
2.85). Among sociodemographic characteristics, gender was the only variable 
associated with missing data, indicating that males were more likely to not respond in 
the psychotic-like experiences questionnaire (OR=2.18, 95%CI=1.00-4.77).  
 
3.8. Sample Description 
3.8.1. Adolescent Student Sample 
A total 657 participants among the age of 15 to 19-year olds completed the 
questionnaires. For data analysis 648 were included (participants excluded as age range 
criteria was not met). Fifty-three percent of the sample were females and 47% males. 
The mean age of the school sample was 16.51 (SD =1.05) and the median 17. The 
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response rate of the school sample was 95% as students were happy to participate. 
Regarding ethnicity, participants mainly indicated Hispanic or Latin as their ethnicity 
with 60.2% identifying themselves in this category, followed by African-Descent with 
25.3%, followed by 6.5% as Caucasian and 6% as Other. Regarding socioeconomic 
level in the school sample 62% scored as being part of level C+/C/C-, followed by 
21.9% in level D+/D/E and 16% in socioeconomic level A/B. 
 
3.8.2. Adolescent Substance Misuse Clinical Sample  
A total of 121 participants seeking treatment for problematic cannabis use, in the age 
range of 13 to 21-year olds completed the questionnaires. Participants were included if 
they reported cannabis as the primary drug of abuse, however they could also report use 
of other drugs. A total of 84.3% were male and 14.8% were female. The mean age of 
participants was 16.56 (SD=1.58) and the median age was 17. The response rate of the 
clinical sample was higher than the school sample, with 99% of participants approached 
and recruited accepting to participate and completing the questionnaires. Regarding 
ethnicity, 48.7% identified themselves as Hispanic or Latin, 24.3% as African-Descent, 
5.2% as Caucasian and 20% as Other. Regarding socioeconomic level, 16.5% scored in 
socioeconomic status A/B, 51.3% in C+/C/C- and 32.2% in D+/D/E.
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17 Juvenile Inclusion Centres in 
Mexico City
8 Juvenile Inclusion Centres in 
Estado de Mexico



























1. CIJ Gustavo A. Madero
2. CIJ Iztapalapa Poniente
3. CIJ Iztapalapa Oriente
4. CIJ Tlanepantla
5. CIJ Tlalpan 
6. CIJ Ecatepec
Figure 3.1 Adolescent Student Sample: Consort Diagram Data Collection 
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4. Patterns of Cannabis Use and Associated Factors in a Sample of School 
Students in Mexico City 
4.1. Introduction 
Cannabis use in the general population in Mexico has shown a steady increase in the 
last decade (Villatoro, 2017). It is the most commonly used illicit drug among 
adolescent students (14 to 19 years old) with 19.6% lifetime prevalence of use 
(Villatoro et al., 2015). High levels of cannabis use have not been seen exclusively in 
Mexico, in the United Kingdom in 2018 the prevalence of lifetime cannabis use was of 
30.7% among 16 to 24 year olds (Flatley, 2018). In the United States 15.3% of 
adolescents from 12 to 17 years old reported lifetime cannabis use in 2017 (CBHSQ, 
2017), however, contrary to what is seen in Mexico, prevalence of cannabis use in these 
countries is not increasing as rapidly.  
 
Despite the increase of prevalence of use and global changes in attitudes around 
legalisation (McGinty et al., 2017), research continues to show the adverse effects of 
cannabis use in both, adolescents and adults (Bloomfield et al., 2019; Hall et al., 2019). 
Furthermore, research has shown that early onset of cannabis use during adolescence, 
compared to later onset of use, may be detrimental to brain structure and cognitive 
function (Solowij, 2015). 
 
During adolescence, the brain is still undergoing development of neurological 
connections (Winters, 2011) and this might confer vulnerability when using drugs. 
Research has shown that some of the different repercussions adolescents may 
experience when using cannabis, include decreased executive functions (Gorey et al., 




to 4 weeks of abstinence (Lubman et al., 2015).  Furthermore, Gorey et al. examined 
whether the relationship between cannabis use and cognition differed between 
adolescents and adults in both, rodents and humans and it was found that, in humans, 
impairment was more sever in adolescent frequent and heavy cannabis users than in 
adults with the same patterns of use (Gorey et al., 2019), however, authors mention the 
need for further studies to support these findings.   
 
Despite these concerns there has been relatively little research into patterns of cannabis 
use and physical and mental health among adolescents in Mexico. While previous 
research has demonstrated a recent increase in the prevalence of cannabis use among 
adolescents in Mexico, less is known about patterns of use and adverse effects, e.g. 
mental health problems, executive function impairments and use of other drugs. 
Therefore, this Chapter addresses a number of important gaps in our understanding of 
cannabis use among adolescents in Mexico. In particular: age of first use of cannabis, 
types of cannabis (herbal cannabis, skunk, hydroponic, redhead or hash or resin) mainly 
used, preferred type and most available type and the assessment cannabis experience 
questionnaire. In addition, use of other drugs (licit and illicit) was assessed and this 




1. To identify the prevalence and extent of cannabis use among 15 to 19-year-old 
students in Mexico City and Estado de Mexico. Patterns of cannabis use to be 
examined include measures of lifetime use, frequency, quantity, routes of 




2. To examine potential sociodemographic differences in prevalence and extent of 
cannabis use. Sociodemographic factors include age, gender, ethnicity and 
socioeconomic status.  
3. To identify type of cannabis (high-potency, low-potency) mainly used, preferred 
and most available. 
4. To describe lifetime prevalence, age of first use and frequency of use of other 
drugs (licit and illicit) among the complete sample and specifically in cannabis 
users; and to identify potential differences in frequency of use of other drugs 
according to use or non-use of cannabis.  
5. To analyse the reliability of the cannabis experience questionnaire, to identify 
the mean scores and examine potential differences by patterns of cannabis use 
and sociodemographic characteristics.  
 
4.3. Methods 
Results presented in this chapter are based on the analysis of data collected from 648 
school students aged 15 to 19 years old who completed questionnaires on their patterns 
of cannabis use. A full detailed description of the procedures used for data collection 
has been provided in Chapter 3. Questionnaires were employed to collect data regarding 
participants’ use of cannabis, sociodemographic characteristics, a cannabis experience 
questionnaire (Barkus, 2006) and a specific questionnaire assessing use of other illicit 






4.4. Statistical Analysis 
4.4.1. Cannabis Use 
All analyses were conducted using the statistical package IBM SPSS Statistics Version 
25, Release 25.0.0.1 64-bit edition. Descriptive statistics were performed with crosstabs 
to identify the prevalence of lifetime cannabis use by age, gender, ethnicity and 
socioeconomic status. To ensure required assumptions to conduct regression-based 
statistical analyses were met I conducted to following checks.  
1. Linearity and additivity  




Chi-square and logistic regression analyses were conducted to identify significant 
differences and associations in frequency of cannabis use by age, gender, age by gender 
interaction, ethnicity and socioeconomic status. Similarly, these analyses were 
conducted to identify significant differences in quantity of cannabis use by age, gender, 
age by gender interaction, ethnicity and socioeconomic status.  
 
Use of different types of cannabis among participants was assessed using three different 
variables, type of cannabis mainly used, type of cannabis preferred by users and most 
available type of cannabis. The original categories of these variables included in the 
analyses were: herbal cannabis, skunk, hydroponic or redhead, hash or resin and don’t 
know. Prevalence of main type used, preferred type and most available type of cannabis 
were reported by participants. Chi-square and logistic regression analyses were 




cannabis mainly used by age, gender, age by gender interaction, ethnicity and 
socioeconomic status.  
 
Prevalence of routes of administration (method of use) were also analysed. The variable 
in the questionnaire comprised of 6 different categories, however, for further analyses 
the variable was recoded into a dichotomous variable (bong or water pipe vs. any other). 
Chi-square and binary logistic regression analyses were carried out to identify 
significant differences and associations by age, gender, age by gender interaction, 
ethnicity and socioeconomic status. Furthermore, to assess preference between social or 
non-social use of cannabis participants were asked if use of cannabis was mainly alone 
or with friends. Prevalence of use was reported, and differences and associations were 
assessed using chi-square and logistic regression analyses with the dichotomous social 
variable and all the sociodemographic characteristics previously described.  
 
4.4.2. Psychometric Properties of the Cannabis Experience Questionnaire 
Principal components analysis was conducted on the seven items of the cannabis 
experience questionnaire and Cronbach’s Alpha was conducted to assess the 
consistency of measure. Analyses of variance were conducted to identify if the total 
scores varied by age, gender, ethnicity and socioeconomic status. Moreover, patterns of 
cannabis use were analysed alongside the total score of the cannabis experience 
questionnaire scale to identify statistically significant differences among different 
patterns of cannabis use and the total score of the scale. Linear regression analyses were 
run to identify differences between the total scores of cannabis experience questionnaire 





4.4.3. Use of Other Drugs 
Analysis of prevalence of lifetime use, age of first use and frequency of use of other 
drugs were conducted. Both licit and illicit drugs were assessed, and descriptive 
statistics reported. Next, a series of analyses were conducted to examine the associations 
between lifetime cannabis use and patterns of use of other drugs including lifetime use, 
age of onset and frequency of use. The strength of the associations between different 
patterns of cannabis use and patterns of use of other drugs were assessed using odds 
ratios obtained from crosstabs. 
 
4.5. Results 
4.5.1. Prevalence of Lifetime Cananbis Use by Age and Gender 
Just under one third of the school student sample (N=192; 29.6%) reported using 
cannabis at least once in their lifetime. Mean age of fist use of cannabis was 14.4 years 
old. Figure 4.1 shows the prevalence of lifetime cannabis use by age and gender. 
Logistic regression analysis indicated that there was no significant difference in 
prevalence of lifetime cannabis use by age (OR=.891, 95%CI=.751–1.056; p=.183). 
However, significant gender differences in prevalence of lifetime cannabis use were 
found (OR=.694, 95%CI=.494 –.975; p=.035), with prevalence of lifetime use being 
higher in males (N=102; 33.8%) than in females (N= 89; 26.3%). There were no 
significant differences in the interaction between age and gender on prevalence of 





Figure 4.1 Prevalence of Lifetime Cannabis Use by Age and Gender 
 
4.5.2. Prevalence of Lifetime Cannabis Use by Ethnicity 
Chi-square analyses indicated that there were no significant differences in lifetime 
prevalence of cannabis use by ethnicity (χ2=3.413, df=4, p=.491). Lifetime cannabis use 
was reported by 33.3% (N=14) of all participants identified as Caucasian, 28.6% 
(N=111) of all Hispanic or Latin, 28.2% (N=46) of participants who identified 
themselves as African-Descent and 39.5% (N=15) identified as Other.   
 
























































4.5.3. Prevalence of Lifetime Cannabis Use by Socioeconomic Status  
There were no significant differences in the lifetime prevalence of cannabis use by 
socioeconomic status (χ2=4.166, df=2, p=.125). Thirty-seven-point nine percent (N=39) 
of participants in socioeconomic level A/B reported lifetime cannabis use, followed by 
30.3% (N=110) of participants in level D+/D/E and lastly, 27.6% (N=43) of participants 
in socioeconomic level C+/C/C-.  
 
Figure 4.3 Prevalence of Lifetime Cannabis Use by Socioeconomic Level 
 
 
4.5.4. Prevalence of Frequent Cannabis Use 
Frequency of use among those reporting lifetime cannabis use is summarized in Figure 
4.4. Most participants were using cannabis infrequently, with 38.1% reporting that they 
had used it only once and 28.6% reported using it only once or twice a year. In contrast, 
11.1% reported using once or twice a month, 3.7% were using it once or twice a week 

















Figure 4.4 Frequency of Cannabis Use 
 
Female students (48.3%) were more likely than males (29.7%) to report using cannabis 
only once. Five-point nine percent of males who reported cannabis use, reported using it 
every day or almost every day, whereas only 1.1% of females using cannabis reported 
this frequency of use. Figure 4.6 shows prevalence of frequency of cannabis use by 
gender.   
 
Figure 4.5 Frequency of Cannabis Use by Gender 
 
For subsequent analyses the six level variable of frequency of cannabis use was recoded 






Every day or almost daily
Once or twice a week
Once or twice a month
Less than once a month
Once or twice a year







































trying it once or using it once or twice a year (66.7% of lifetime cannabis users) or 
“frequent users” using cannabis at least monthly (33.3% of cannabis users). Frequent 
use was not significantly more prevalent among males than females (38.6% vs 26.4%; 
OR=.556, 95%CI=.296-1.046; p=.069) whereas results showed that frequent use was 
significantly more prevalent among older students than younger students (OR=.1.407, 
95%CI=1.028–1.927; p=.033). The difference in the age by gender interaction was not 
statistically significant (OR=1.424, 95%CI=.755–2.687; p=.275). 
 
Figure 4.6 Frequent Cannabis Use by Age and Gender 
 
 
4.5.5. Frequent Cannabis Use by Ethnicity and Socioeconomic Status 
Chi-square test indicated no significant differences between frequent cannabis use and 
ethnicity (χ2=.649, df=3, p=.885). Frequent cannabis use was reported by 33.6% (N=37) 
of Hispanic or Latin lifetime cannabis users, 25% (N=3) of Caucasian, 26.7% (N=4) of 
participants in Other category and 30.4% (N=14) of those identifying themselves as 
African-Descent. In contrast, there were significant differences between frequency of 


























percent of participants that reported ever using cannabis and that were classified as part 
of socioeconomic level A/B reported frequent cannabis use, 35.2% of participants 
classified as part of socioeconomic level C+/C/C- and 11.6% of participants classified 
as part of level D+/D/E reported frequent cannabis use. Results indicate that participants 
in the highest socioeconomic level were more likely to use cannabis frequently than 
participants in lower socioeconomic levels. 
 
4.5.6. Quantity of Cannabis Used by Age and Gender 
Quantity of cannabis use in the questionnaire was assessed by requesting participants to 
report the number of joints they use on a typical occasion. The most commonly reported 
quantities of use were one joint (37.3%) and ¼ of a joint (31.9%). For further analyses 
the original variable comprising six categories (see p. 7) was recoded into a 
dichotomous variable constructed as “less than one or one joint” and “two or more 
joints”. Overall, both female and male cannabis users showed similar rates of using less 
than one to one joint on any typical occasion, 83.1% and 80% respectively. No 
significant differences were found in quantity of use by age (OR=.895, 95%CI=.596–
1.342; p=.590), gender (OR=1.403, 95%CI=.617–3.192; p=.419) or by the interaction 
between age and gender (OR=.801, 95%CI=.352–1.820; p=.596). No significant 
associations were found between quantity of use and ethnicity (χ2=1.189, df=3, p=.756) 
or between quantity of use and socioeconomic status (χ2=5.690, df=2, p=.058). 
 
4.5.7. Types of Cannabis 
Students who reported lifetime cannabis use were further asked to identify the type of 
cannabis they mainly used, the type of cannabis that was most available to them and the 




almost half (48.9%) reported herbal cannabis as the type of cannabis they mainly used 
(Figure 4.7). Followed by skunk, hydroponic or redhead (39.4%). Eight percent 
reported not knowing the type of cannabis they were using and only 1.6% reported hash 
as their main type of cannabis used.  
 
Figure 4.7 Prevalence of Type of Cannabis Mainly Used 
 
 
Given previous literature (Chapter 1) suggesting that the use of high potency varieties of 
cannabis may confer increased risk for experiencing psychotic-like experiences, it was 
examined whether the use of this type of cannabis varied across age, gender or other 
sociodemographic factors and if this variation had an impact in the appearance of 
psychotic-like experiences. Statistically significant differences were found in the types 
of cannabis mainly used when comparing high potency (skunk, hydroponic or redhead) 
and low potency (herbal or hash or others) cannabis use by age (OR=.700, 
95%CI=.513-.956; p=.025) and by gender (OR=.438, 95%CI=.237-.810; p=.008). 
Results indicate that older participants were more likely to use skunk than younger 

























(22.7% vs. 12.3%). No significant differences were found between type of cannabis 
mainly used and the interaction by age and gender (OR=1.277, 95%CI=.680–2.400; 
p=.447), type of cannabis mainly used and ethnicity (χ2=.877, df=3, p=.831) or 
socioeconomic status (χ2=3.600, df=2, p=.165).  
 
4.5.8. Routes of Administration  
Regarding routes of administration or method of cannabis use, high rates of use in bong 
or water pipe were observed with 53.1% of students who had used cannabis reporting 
this as their preferred method of use. For further analyses the variable of routes of 
administration was recoded into a dichotomous variable categorised as bong or water 
pipe and any other. Odds ratios obtained from crosstabs and binary logistic regression 
analyses showed no significant associations in routes of administration by age 
(OR=1.083, 95%CI=.811–1.446; p=.590), gender (OR=.881, 95%CI=.492–1.575; 
p=.669) or by the interaction between age and gender (OR=1.237, 95%CI=.692–2.212; 
p=.473). Moreover, no statistically significant associations were found by ethnicity 
(χ2=.184, df=3, p=.980) and only a marginal significance by socioeconomic level 





Figure 4.8 Method of Cannabis Use 
 
 
4.5.9. Social and Non-Social Cannabis Use 
When analysing social or non-social cannabis use, data showed that 65.6% of 
respondents mentioned using cannabis mainly with friends and 20.3% reported non-
social cannabis use. Two-point six percent refused to select only one option, reporting 
that they used cannabis with the same frequency socially and non-socially.  
 
Figure 4.9 Social or Non-Social Cannabis Use 
 
 
For additional analyses the variable was recoded as a dichotomous measure considering 
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social use bye age (OR=.893, 95%CI=.626–1.275, p=.534), gender (OR=.830, 
95%CI=.400–1.724; p=.618) or the interaction by age and gender (OR=1.444, 
95%CI=.701–2.973; p=.319). No significant associations were found between social or 
non-social cannabis use and ethnicity (χ2=6.714, df=3, p=.082) or socioeconomic status 
(χ2=1.077, df=2, p=.583).  
 
4.5.10.  Cannabis Experience Questionnaire 
To examine the items selected for this scale, a principal component factor analysis was 
conducted in which a one factor model was fitted to the data on the seven items. This 
analysis identified a factor with an eigenvalue of 2.73 which explained 39.07% of the 
total variance. The factor loadings for each of the seven items are displayed in column 4 
of Table 4.1 which ranged from .552 to .694. Participants who reported lifetime 
cannabis use (N=192) completed this cannabis experience questionnaire. 
 
Furthermore, reliability analysis of the cannabis experience questionnaire was 
conducted. Mean ratings for each of the seven items, the corrected item total correlation 
for each item and Cronbach’s alpha if an item was deleted are summarised in Table 4.1. 
The seven-item scale had moderate to high reliability (Cronbach’s Alpha = .738). All 
items had moderate to high item total correlations (.355 - .568) and the analysis also 
indicated that deleting any of the items from the scale would not improve reliability. 
These analyses support the use of a single scale, combining ratings across the seven 





Table 4.1 Reliability Analysis: Cannabis Experience Questionnaire 
 
4.5.11.  Patterns of Cannabis Use, Sociodemographic Characteristics and Mean 
Scores of the Cannabis Experience Questionnaire 
As a next stage of analyses, a series of ANOVAS were conducted to test whether self-
reported mean scores in cannabis experience questionnaire differed among 
sociodemographic characteristics (age, gender, ethnicity, socioeconomic status) and 
patterns of cannabis use (age of first use of cannabis, main type of cannabis used, 
frequency of cannabis use and number of joints used on a typical occasion). The results 
of these analyses are summarised in (  









Feelings of paranoia or 
suspiciousness 
1.23 .55 .397 .713 .591 
Hearing voices 1.14 .46 .355 .722 .552 
Feeling like I am going crazy 
or mad 
1.17 .52 .445 .706 .637 
Not wanting to do anything or 
lack of motivation 
1.40 .70 .477 .694 .655 
Difficulty in concentrating 1.58 .86 .525 .684 .665 
Not able to think clearly 1.67 .86 .568 .670 .694 






These analyses indicated significantly higher mean scores on the cannabis experience 
questionnaire for participants who reported using cannabis frequently (defined as every 
day or almost daily, weekly or monthly use) compared with those who reported using 
the drug on only one or two occasions (F=11.543, df=1, p=.001). There was also a 
marginally significant difference in self-reported scores by socioeconomic status 
(F=3.052, df=2, p=.050); individuals from socioeconomic level C+/C/C- reported 
higher mean scores in the cannabis experience questionnaire (mean=9.97, SD=3.21) 
than those from either A/B (mean=9.19, SD=2.75) or D+/D/E (mean=8.74, SD=2.07) 
socioeconomic level. Analyses were conducted to understand the nature of these results 
and data showed that the prevalence of high quantities of cannabis use (two or more 
joints on any typical occasion) among participants in socioeconomic level C+/C/C- was 
higher (8.7%) than in participants in level A/B (5.4%) or level D+/D/E (1.6%), which 
explains the higher scores in the cannabis experience questionnaire. 
 
The remaining sociodemographic characteristics and aspects of cannabis use were not 
significantly associated with mean scores of the questionnaire. Furthermore, linear 
regression analyses were conducted to identify if there were statistically significant 
differences between scores of the questionnaire after controlling for age of first use, age, 
gender and frequent or non-frequent use. Results showed that the only variable that 
made a significant contribution to the cannabis experience questionnaire score was 






Table 4.2 Cannabis Experience Questionnaire Mean Scores by Sociodemographic 
Characteristics and Patterns of Cannabis Use 
Age (in years)  N Mean SD F df p 
15 29 10.83 3.29 2.387 3 .071 
16 62 9.34 2.78    
17 53 9.43 3.16    
18-19 41 9.54 2.93    
Gender       
Female 86 9.19 2.31 2.2 (1 .140 
Male 98 9.83 3.37    
Ethnicity       
Caucasian 12 9.67 2.74 .633 (3 .594 
Hispanic or Latin 107 9.62 2.72    
African-Descent 45 9.62 3.61    
Other 15 9.53 2.92    
SES Level       
A/B 36 9.19 2.75 3.052 2 .050 
C+/C/C- 107 9.97 3.21    
D+/D/E 42 8.74 2.07    
Age of First Use       
9 to 15 143 9.73 3.08 2.780  .097 
16 to 18 42 8.88 2.28    
Main Cannabis Type       
Herbal Cannabis 90 9.22 2.35 1.580 2 .209 
Skunk 71 10.03 3.46    
Hash/Mix/Don’t know 20 9.35 3.07    
Frequency of Cannabis Use       
Frequent 60 10.53 3.08 11.543 1 .001* 
Non-Frequent 123 9.02 2.69    
Number of Joints       
Less than 1 or 1 151 9.50 2.93 1.154 1 .284 
Two or more 29 10.14 3.02    
 
Lifetime prevalence and frequency of use of licit and illicit drugs was assessed and data 




Table 4.3. Results showed high prevalence of the use of licit drugs, with alcohol being 
the most widely used among participants (80.7%), lifetime binge drinking (more than 8 
units of alcohol in a single session for men, more than 6 units of alcohol in a single 
session for women; NHS, 2019) was reported by 64.5% of the sample. Fifty-four-point 
eight percent reported lifetime use of tobacco and 41.7% reported use of e-cigarettes. 
Regarding frequent use, alcohol was most frequently used with participants indicating 
using it once or twice a year (24.1%) and once or twice a month (21.6%); participants 
reported binge drinking once or twice a month (19.1%) and once or twice a year (18%).  
 
Regarding tobacco and e-cigarettes, participants reported mostly infrequent use (only 
used it once) with 53.9% reporting e-cigarette use and 34.6% tobacco use. Mean age of 
first use of licit drugs was 14 years old. Regarding illicit drugs, excluding cannabis, the 
drug most widely used among participants was cocaine with 9.6% of participants in the 
whole sample reporting lifetime use of this drug; followed by hallucinogens (4.3%), 
solvents (4.2%) and crack (4%). Mean age of first use of the before mentioned illicit 
drugs was 15 years old. Regarding frequency of illicit drug use, participants mainly 
reported infrequent use, “only tried it once”. Forty-two point six of cocaine users 
reported only tried it once, hallucinogens (53.6%), solvents (85.2%) and crack (46.2%). 
Lastly, the least common drugs used among the school sample were heroin, opium and 





Table 4.3 Lifetime Prevalence, Age of First Use and Frequency of Use of Other Drugs 
Drug Lifetime Use  
(% / N) 
Mean Age of 
First Use 
Every Day  
Almost Daily 
Once or Twice a 
Week 
Once or Twice a 
Month 
Less than Once 
a Month 
Once or 
Twice a Year 
Just Tried it 
Once 
Tobacco 54.8/ 355 13.98 13.1 12.3 12.8 12.8 14.2 34.6 
E-cigarettes 41.7/270 14.69 3.1 5.5 7.4 10.9 19.1 53.9 
Alcohol 80.7/523 14 1 16.9 21.6 19.3 24.1 17 
Binge Drinking 80.1/414 14 1 10.8 19.1 14.9 18 16.2 
Cocaine 9.6/62 15.22 8.2 4.9 16.4 11.5 16.4 42.6 
Crack 4/26 14.9 3.8 3.8 19.2 15.4 11.5 46.2 
Solvents 4.2/27 14.5 0 7.4 7.4 0 0 85.2 
Hallucinogens 4.3/28 15.23 3.6 3.6 10.7 10.7 17.9 53.6 
Ecstasy 3.1/20 14.86 0 10 10 15 15 50 
Benzodiazepines or Sleeping Pills 9/58 14.34 9.1 9.1 7.3 5.5 23.6 45.5 
Opioids 0.9/6 14 0 16.7 33.3 16.7 33.3 0 
Heroin or Opium 0.8/5 13.14 100 0 0 0 0 0 
Amphetamines or Methamphetamines 2.9/19 14.21 100 0 0 0 0 0 




4.5.12. Frequency of Use of Other Drugs in Lifetime Cannabis Users 
Frequency of use of other drugs among participants reporting cannabis use was 
analysed. Two categories were created; frequent use (at least monthly) and non-frequent 
use (only once or never).  
 
Figure 4.10 Prevalence of Use of Other Drugs Among Cannabis Users and Non-
Cannabis Users 
 
When analysing frequency of use of other drugs (frequent vs. non-frequent) among 
lifetime cannabis users, results showed that 40.9% reported using tobacco frequently, 
55.1% reported frequent alcohol use, 46% reported frequent binge drinking and 12.6% 
frequent e-cigarette use. As shown in Table 4.4 differences between frequent use of 
other drugs among cannabis users and non-users was noticeable. 
 
Given the low prevalence and low frequency of use of illicit drugs a single variable of 
lifetime use of any illicit drug was computed by combining reports of any use of the 
following drugs: cocaine, crack, solvents, hallucinogens, ecstasy, benzodiazepines or 








































examine the associations between lifetime cannabis use and use of other drugs a series 
of analyses were conducted to compare rates of at least monthly or less frequent use of 
the licit drugs (tobacco, e-cigarettes, alcohol and binge alcohol use) and lifetime use of 
any illicit drug among students reporting lifetime use of cannabis. The results of these 
analyses are summarized in Table 4.4. 
 
These results indicate that the use of other drugs was substantially higher in students 
who reported lifetime cannabis use with rates of use of these drugs being approximately 
2 to 4 times higher in cannabis users than in non-cannabis users. 
 
Table 4.4 Lifetime Cannabis Use and At Least Monthly Use of Other Drugs 
At Least Monthly Use of Yes (%) No (%) OR  95% CI 
Tobacco 40.9 11.6 2.6  2.17-3.31 
Alcohol 55.1 22 2.6  2.07-3.26 
Alcohol Binge 46 15.8 2.5  2.04-3.13 
E-Cigarettes 12.6 3.5 2.1  1.64-2.84 
Lifetime Use of Illicit Drugs 46 11.6 3.0  2.44– 3.71 
 
From the whole sample prevalence of lifetime cannabis use was 29.6%, cannabis use in 
the past six months was 14.2%. Regarding frequency of use, of the whole student 






This chapter examined patterns of cannabis use and related factors in a school sample of 
adolescents aged 15 to 19 years old in Mexico City and Estado de Mexico. Twenty-
nine-point six percent of participants from this sample reported using cannabis at least 
once in their lifetime; similar to the prevalence observed in the survey conducted by 
Villatoro et al. in 2015, where the prevalence among high school students was of 
30.1%. Moreover, results showed that prevalence of lifetime cannabis user has higher in 
males than in females. These results support previous surveys conducted in Mexico 
where prevalence of cannabis use  was higher among males than females (Villatoro et 
al., 2015).  
 
Regarding frequency of cannabis use analyses showed that in the overall sample, 
participants were more likely to report infrequent cannabis use (66.7%), particularly 
women, where 38.1% reported using cannabis only once. Older participants were more 
likely to have higher prevalence of frequent cannabis use than younger participants. 
Similar to these findings, international research has shown that older adolescents tend to 
have higher prevalence of lifetime cannabis use and higher prevalence of frequency of 
use (CBHSQ, 2017). Moreover, participants in higher socioeconomic levels tend to use 
cannabis more frequently than adolescents in lower socioeconomic levels. This might 
be as a result of more access to economic resources, therefore more access to obtain and 
use cannabis more frequently.   
 
As previously mentioned, one of the main strengths of this study is the assessment of 
type of cannabis mainly used. Results indicated that of participants reporting lifetime 




reported using skunk-type cannabis. Statistically significant differences were found 
when analyses were conducted among different types of cannabis and 
sociodemographic characteristics. Results showed that older participants were more 
likely to use skunk-type cannabis than younger participants and that males were more 
likely to use skunk-type cannabis than females. Initially, it was hypothesised that 
participants will report higher use of herbal cannabis and low prevalence of skunk-type 
cannabis. Overall, herbal cannabis use was higher than skunk, however the level of 
skunk use is much higher than expected. Research has shown that the use of skunk-type 
cannabis confers higher risk (OR=5.4, 95%CI=2.81-11.31, p=0.002) of psychotic 
disorders compared to other types of cannabis (Di Forti et al., 2015); therefore the 
importance of examining the association between type of cannabis used and psychotic-
like experiences in the following chapter. 
 
One noteworthy finding to emerge from these analyses that may be distinct to Mexico, 
was the high number of respondents who reported that they typically used cannabis via 
water pipes or bongs (53.1%). This estimate is substantially higher than that reported for 
the United Kingdom (Hindocha, Freeman, Ferris, Lynskey, & Winstock, 2016), where 
typical estimates have been in the region of 5%. Nonetheless, the current finding is 
consistent with previous estimates from the Global Drug Survey which reported that 
47% of adult cannabis users in Mexico reported they typically used bongs or water 
pipes without tobacco (Hindocha et al., 2016). 
 
Results of the assessment of use of other drugs, licit and illicit, showed high levels in 
lifetime prevalence of alcohol use (80.7%) and binge drinking behaviour (64.5%) 




alcohol, tobacco and e-cigarette use was 14 years old. Furthermore, participants 
reporting binge drinking, mostly reported doing it in frequent manner, with 19.1% 
reporting binge drinking once or twice a month. Fortnightly or monthly alcohol use was 
reported by 21.6% of participants and 24.1% reported using once or twice a year. The 
mean age of first use of any illicit drug was 14 years old. Cannabis is the primary illicit 
drug used by participants in the school sample (29.6%) followed by cocaine with 9.6% 
of prevalence of lifetime use.  
 
Results indicate that the use of other drugs was substantially higher in students who 
reported lifetime cannabis use with rates of use of these drugs being approximately 2 to 
4 times higher in cannabis users than in those who reported no lifetime cannabis use. 
Moreover, frequent use (at least monthly) of tobacco (40.9%), alcohol (55.1%) and 
binge drinking (46%) was particularly high among cannabis users compared with never 
users. Regarding illicit drugs, 46% of participants that reported lifetime cannabis use 
reported lifetime use of other drugs compared to 11.6% of lifetime use of illicit drugs 
among those who had never used cannabis; participants that reported cannabis use were 
almost 4 times more likely to have used illicit drugs than non-users. These findings are 
consistent with previous studies, conducted elsewhere, which reported strong 
associations between the use of cannabis and the use of other drugs (Hall, 2014; Hall & 
Lynskey, 2005). These findings highlight the high prevalence of cannabis use and, the 






5. Cannabis Use and Psychotic-Like Experiences in an Adolescent School 
Sample in Mexico City 
5.1. Introduction 
Cannabis use and its association with the appearance of psychotic-like experiences has 
been a subject of interest, with the first study published in 1987 (Andreasson, 1987). 
Research has shown there are different factors that may influence the association, for 
example, type of cannabis, frequency of use, adverse experiences during childhood, etc. 
(Bechtold et al., 2016; Morgan et al., 2014). The psychosis spectrum can range from a 
diagnosed clinical psychotic disorder to subclinical symptoms or experiences that may 
or may not disappear with time (van Os et al., 2009). Psychotic-risk symptoms include 
unusual thought content, suspiciousness, persecution, grandiosity, perceptual 
abnormalities of hallucinatory intensity and speech that is incoherent or unintelligible 
(McGlashan, 2001). These symptoms or experiences, when persistent can generate 
discomfort and lead to a more full-blown psychotic disorder later in life (Marshall & 
Rathbone, 2011). Similar to other psychiatric symptoms and disorders, psychotic-like 
experiences can be increased by other agents or circumstances e.g. trauma and family 
history of psychosis (Read, van Os, Morrison, & Ross, 2005), and these should be taken 
into account to protect individuals when at risk (Seidman et al., 2010). 
 
There has been growing interest in whether early onset of cannabis use may be linked to 
a wider range of mental health problems and, in particular, psychotic-like experiences 
(see Chapter 1). There have been extensive debates regarding the association between 
cannabis and psychosis; some argue that one of the main reasons the associations 
between cannabis and psychosis is untrustworthy is that, prevalence of cannabis use has 




disorders has not been seen (Murray & Di Forti, 2016); this argument can be overturned 
from different perspectives. There is scarce evidence on trends of schizophrenia 
worldwide, and research has shown that psychotic related problems might be more 
complex than considered until now. Psychotic-spectrum experiences are now considered 
as a continuum rather than a dichotomous, present or absent diagnosis. This would 
make prevalence of these experiences in the general population higher than considered 
before (van Os et al., 2009). Moreover, research has not argued that cannabis is the 
main and only risk factor for the development of psychotic-like experiences, on the 
contrary, authors have stated that cannabis is only one of many different risk factors 
(Van Os, 2001) which, when combined, may increase the risk in the appearance of these 
symptoms (Murray & Di Forti, 2016). Furthermore, when taking into consideration that 
the appearance of these symptoms might only be transitory and these can change over 
time, then the argument of higher prevalence in cannabis use but not in the spectrum of 
psychotic disorders does not stand.  
 
A consistent finding across studies is that cannabis use is associated with increased rates 
of psychotic-like symptoms or experiences (Barkus & Murray, 2010); and of specific 
interest is whether the association between cannabis use and rates of psychotic-like 
experiences vary according to age, with some studies suggesting that early onset of 
cannabis use may be associated with greater risk (Anglin et al., 2012). One of the first 
prospective longitudinal studies examining adolescent cannabis use as a risk factor for 
later diagnosis of schizophrenia while controlling for psychotic symptoms during 
childhood predating use of cannabis was conducted by Arsenault et al. in 2002. Results 
showed that participants who used cannabis by age 15 had higher risk (OR=4.65, 




2002), however one important limitation of that study was the small sample size in the 
<15 age group, with only 29 participants included in that group. 
 
Furthermore, a review conducted in 2015, where seventeen papers met the inclusion 
criteria, examining the relationship between adolescent onset of regular cannabis use 
and the onset of prodromal symptoms, concluded that the appearance of psychotic like 
experiences is associated with early onset and regular use of cannabis, particularly in 
participants at greater risk for developing psychotic disorders (Bagot et al., 2015). 
However, there is an important difficulty to be mention between age of onset of 
cannabis use and duration of use. Age of onset of cannabis use refers to the first-time 
participants tried cannabis; however, this differs significantly to the age of onset of 
regular cannabis use. This difference is important as research has shown, as stated 
below, that continuous use increases the risk of psychotic-like experiences. A meta-
analysis examining the association between level of cannabis use and risk for psychosis 
in participants without history of mental health problems (Marconi et al., 2016) 
identified a pooled estimate reported as the increased risk in the development of 
psychosis relative to a continuous level of cannabis exposure showing that cannabis 
users with higher frequency of use were 3.9 times at more risk of developing psychotic 
disorders or psychotic-like symptoms than non-users (unadjusted OR=3.9; 
95%CI=2.84–5.34). 
 
In addition, in 2014 a study explored the relationship between early onset of cannabis 
use, frequency of use, type of cannabis being used (high-potency / low-potency) and the 
age of onset of psychosis in a first episode psychosis sample (Di Forti et al., 2014). 




had an earlier age of onset of psychosis (m=27, SD=6.2; median=26.9) than those who 
started use after 15 (mean=29.1, SD=8.5; median=27.8) (HR=1.40; 95%CI=1.06 – 1.84; 
p=.050). Moreover, among all groups, daily users of high-potency cannabis had the 
earliest age of onset of psychosis (mean=25.2, SD=6.3; median=24.6) compared to non-
users (HR=1.99; 95%CI=1.50 – 2.65; p<.0001).  
 
To the best of my knowledge, research regarding cannabis use and psychotic-like 
experiences has not been conducted in Mexico, although cannabis use among 
adolescents has been increasing during the last decade (see Chapter 1). Therefore, the 
present study examines different patterns of cannabis use and its association with 
psychotic-like experiences.  
 
5.2. Objectives 
• To evaluate the psychometric properties of the PRIME Screen Questionnaire 
used to identify prevalence and extent of psychotic-like experiences.   
• To estimate the prevalence of psychotic-like experiences among 15 to 19-year-
old students in Mexico City. 
• To examine potential associations between patterns of cannabis use, type of 
cannabis mainly used and psychotic-like experiences. 
• Identify if cannabis use predicts presence of psychotic-like experiences. 
• Identify if high quantity of cannabis use predicts presence of psychotic-like 
experiences. 





• Identify if high scores in a combined quantity by frequency measure of cannabis 
predicts the presence of psychotic-like experiences. 
 
5.3. Statistical Analysis 
Analyses were conducted using the statistical package IBM SPSS Statistics Version 25, 
Release 25.0.0.1 64-bit edition.  
 
5.3.1. Prevalence of Psychotic-Like Experiences 
Firstly, mean scores of each item of the psychotic-like experiences assessment were 
analysed by gender to identify how prevalent each symptom was, and specifically 
identify if there were any differences by gender. Descriptive statistics were conducted to 
identify the prevalence of psychotic-like experiences by age and gender in the school 
sample. Subsequently, principal component factor analysis and reliability analysis were 
conducted to the PRIME Screen Questionnaire.  
 
5.3.2. Cannabis Use and Psychotic-Like Experiences’, Sociodemographic 
Characteristics and Use of Other Drugs 
Analyses of variance were conducted to identify the associations between cannabis use 
with sociodemographic characteristics and the use of other drugs. For these analyses a 
continuous variable of cannabis use was created by multiplying scores of two variables, 
quantity by frequency of cannabis use. Moreover, to identify associations between 
psychotic-like experiences with sociodemographic factors and use of other drugs same 




questionnaire employed for the analyses was the total score of the thirteen items in the 
questionnaire.  
 
A number of different dichotomous measures of cannabis use (lifetime use, at least 
monthly use and type of cannabis mainly used) were employed and some created to 
explore the associations these may have with sociodemographic characteristics and use 
of other drugs. Lifetime cannabis use was explored as one question and, in the analyses, 
this question remained the same. The at least monthly variable was created from the 
original question of frequency of use, which initially had 6 categories and was modified 
to only a two-category variable: at least monthly use and sometimes or never. Lastly, 
the variable of type of cannabis mainly used was modified to only consider non-users, 
skunk type of cannabis and any other type of cannabis used. Once these variables were 
created, odds ratios obtained from crosstabs, chi-square and logistic regression analyses 
were conducted.  
 
5.3.3. Associations between Psychotic-Like Experiences, Sociodemographic 
Characteristics and Use of Other Drugs 
For the psychotic-like experiences analyses, a dichotomous measure was created. As 
previous literature showed (Kobayashi, H. et al., 2008) it was feasible to create a 
positive/negative outcome of presence or absence of psychotic-like experiences using 
the PRIME Screen Questionnaire. In the questionnaire used for the present study, a 40+ 
score in the psychotic-like experiences assessment would result in having a positive 
score. Once this variable was created, odds ratio obtained from crosstabs, chi-square 




positive score in the PRIME Screen Questionnaire, sociodemographic characteristics 
and use of other drugs.  
 
5.3.4. Cannabis Use, Psychotic-Like Experiences, Sociodemographic 
Characteristics and Use of Other Drugs: Regression Models 
Following these analyses, independent regression models were structured. Firstly, with 
each of the different measures of cannabis use, sociodemographic characteristics and 
use of other drugs. These analyses were conducted to see how sociodemographic factors 
and use of other drugs interacted with cannabis use once all variables were included in 
one model. Then, the same model was applied for the psychotic-like experiences 
assessment to identify the associations while controlling for all the before mentioned 
variables.   
 
5.3.5. Associations between Cannabis Use and Psychotic-Like Experiences 
Preliminary analyses to identify associations between psychotic-like experiences and 
different measures of cannabis use were conducted. These analyses comprised of odds 
ratio obtained from crosstabs, using the dichotomous measure of the PRIME, lifetime 
cannabis use and at least monthly cannabis use. For the three-category variable of type 
of cannabis mainly used (non-users, skunk, any other type of cannabis), chi-square 





5.3.6. Association between Cannabis Use and Psychotic-Like Experiences 
while Controlling for Sociodemographic Characteristics and Use of Other 
Drugs 
To examine the associations between different measures of cannabis use and psychotic-
like experiences while controlling for sociodemographic characteristics and use of other 
drugs multiple regression analyses were conducted. Linear regression analyses were 
conducted for the continuous measure of the cannabis use (QFS) and the total score of 
the PRIME Screen questionnaire. Logistic regression analyses were run for the 
dichotomous measures of cannabis use and psychotic-like experiences, and multinomial 
logistic regression analyses were conducted for the type of cannabis mainly used, which 
included three different categories. Furthermore, multilinear regression analyses were 
conducted to identify differences among scales of quantity by frequency scales of 
cannabis use of the different types of cannabis. These analyses are the core and main 





5.4.1. Psychotic-Like Experiences Assessment: The PRIME Screen 
Questionnaire 
As previously mentioned, the questionnaire employed for the assessment of psychotic-
like experiences was the PRIME Screen Questionnaire. Analyses were conducted to 
obtain mean scores of each item according to gender, to identify differences and 
similarities between females and males. These analyses were conducted to acknowledge 
how participants responded, to comprehend how prevalent each symptom was, and to 
identify if there were statistically significant differences in responses by gender (Table 
5.1). The item with highest mean scores was exploring the presence of odd or unusual 
experiences (females=2.88; males=2.61), followed by the ability to discern if what its 
being experienced is real, just a product of their imagination or a dream (females=2.73; 
males=2.56). Concern regarding people planning to hurt them or about to hurt them was 
also one of the items with higher scores among participants (females=2.70; 
males=2.48). Overall, it was observed that females obtained higher mean scores than 
males, and to identify if differences were statistically significant, analyses of variance 
were conducted on each item by gender. Results show significant differences in two 
items. Firstly, the item related to predicting the future (F=4.29; df=1,640; p=.039) and, 
on the item related to hearing faint or clear sounds of people talking when no one is 





Table 5.1 Item Analysis on Mean Scores by Gender: PRIME Screen Questionnaire 
Item Mean F  df1, df2 p 
Females Males 
Odd or unusual things I can’t explain 2.88 2.61 3.171 1, 641 .075 
I might be able to predict the future 1.80 2.05 4.29 1, 641 .039* 
Something interrupting or controlling my 
thoughts, feelings or actions 
2.38 2.13 3.204 1, 641 .074 
Changed my behaviour because of my 
superstitions 
2.24 2.08 1.339 1, 639 .248 
Confusion about experiences being real, part 
of my imagination or dreams 
2.73 2.56 1.173 1, 638 .279 
Others can read my mind, or I can read 
other’s minds 
1.36 1.34 .079 1, 640 .778 
I wonder if people are planning to hurt me 
or about to hurt me 
2.70 2.48 2.119 1, 637 .146 
I have special natural or supernatural gifts 1.25 1.35 1.688 1, 640 .194 
My mind might be playing tricks on me 2.18 2.16 .025 1, 639 .874 
Faint or clear sounds of people talking when 
no one is around 
2.43 2.11 4.643 1, 639 .032* 
I may hear my own thoughts said out loud 2.52 2.29 2.286 1, 637 .131 
I might be going crazy 1.56 1.54 .059 1, 636 .808 
Visual hallucinations 2.12 1.87 3.291 1, 640 .070 
 
5.4.2. Factor Analysis  
For further exploration of the psychotic-like experiences assessment, factor analysis was 
conducted on the PRIME Screen questionnaire. Prior to performing the analysis, the 
suitability of data for factor analysis was assessed. Principal components analysis 
revealed the presence of 2 components with eigenvalues exceeding 1, explaining 38.1% 





Table 5.2 Total Variance of Factor Analysis PRIME Screen Questionnaire 
 
The two factors obtained from preliminary analysis explain a total of 46% of the 
variance. All items loaded strongly on the first factor (above .4), and five components 
out of thirteen loaded positively in both factors. Three of them having a higher load in 
factor number one (above .6) and two having a higher load on factor number two. 
However, loadings in factor one is strong (above .4), which suggest that one-factor 
solution can be appropriate (Table 5.3). 
 
As a strong correlation between the two components was shown (.473) and an 
inspection of the screeplot revealed a clear break from the second component onwards 
(the suggestion is to retain only the factors above the elbow as these factors contribute 
the most to the explanation of the variance) using Catell’s screeplot test it was decided 
to retain one component for further investigation.  
  
  Initial Eigenvalues Rotation Sums of 
Squared Loadings 
Component Total % of Variance Cumulative % Total 
1 4.915 37.809 38.809 4.687 




Table 5.3 Principal Components Analysis: PRIME Screen Questionnaire 
Items 1 2 
My mind might be playing tricks on me .743 -.093 
Confusion about experiences being real, part of my imagination or 
dreams 
.707 -.227 
Something interrupting or controlling my thoughts, feelings or actions .636 -.096 
I wonder if people are planning to hurt me or about to hurt me .649 -.179 
Visual hallucinations .654 -.104 
Changed my behaviour because of my superstitions .632 .005* 
I may hear my own thoughts said out loud .632 -.169 
Odd or unusual things that I can’t explain .596 -.181 
Faint or clear sounds of people talking when no one is around  .612 -.282 
I might be going crazy .580 .153* 
I might be able to predict the future .526 .412* 
Others can read my mind, or I can read other’s minds .504 .547* 
I have special natural or supernatural gifts .461 .602* 
Extraction Method: Principal Component Analysis (2 components extracted) 
 
The one-component solution explained a total of 38.1% of the variance. Moreover, 
general magnitude of factor loadings obtained from a principal component analysis 
ranged from .478 to .743 indicating all items load strongly in this component and are 









Figure 5.1 Factor Analysis Screeplot PRIME Screen Questionnaire 
 
In addition, reliability analysis of the PRIME Screen questionnaire was conducted. The 
twelve-item scale plus the extra item added to assess visual hallucinations, had high 
reliability (Cronbach’s Alpha = .860). Regarding the exploration of Cronbach’s Alpha, 
if any of the items was deleted, results indicated that the total alpha would not increase 
if any of the items were deleted. Moreover, the values obtained for the corrected item-
total correlation indicate all items are correlated and evaluate the same construct (.374 - 
.663). This evidence supports the use of a continuous measure of psychotic-like 





















Table 5.4 Reliability Analysis PRIME Screen Questionnaire and Principal Component 
Analysis 
*Principal Component Analysis 
 
  









Odd or unusual things I can’t explain .514 .851 .596 
I might be able to predict the future .436 .855 .526 
Something interrupting or controlling my 
thoughts, feelings or actions 
.549 .849 .636 
Changed my behaviour because of my 
superstitions 
.547 .849 .632 
Confusion about experiences being real, 
part of my imagination or dreams 
.629 .843 .707 
Others can read my mind, or I can read 
other’s minds 
.415 .857 .504 
I wonder if people are planning to hurt 
me or about to hurt me 
.564 .848 .649 
I have special natural or supernatural 
gifts 
.374 .859 .461 
My mind might be playing tricks on me .663 .841 .743 
Faint or clear sounds of people talking 
when no one is around 
.527 .850 .612 
I may hear my own thoughts said out 
loud 
.543 .849 .632 
I might be going crazy .489 .853 .580 




5.4.3. Prevalence of Psychotic-Like Experiences  
Using a cut-off from 40+ rating points or more on the PRIME Screen questionnaire 
described, 20.4% of the sample were classified as positive in presence of psychotic-like 
experiences. Figure 5.2 shows the prevalence of these experiences by age and gender. 
These analyses were conducted for the only purpose of examining the data and observe 
differences according to gender and age. Furthermore, research has shown that 
psychotic-like experiences, in some groups, tend to increase during early adolescence 
and decline over time (Mackie et al., 2013).  
 





































5.4.4. Cannabis Use and Psychotic-Like Experiences’, Sociodemographic 
Characteristics and Use of Other Drugs  
To further explore the extent to which cannabis use and psychotic-like experiences have 
similar associations with sociodemographic characteristics and use of other drugs, licit 
and illicit, further analyses were conducted. The continuous variable of the PRIME 
Screen Questionnaire, which was obtained by adding the scores of all the items in the 
questionnaire provided by participants and the continuous measure of cannabis use, 
obtained by multiplying quantity of use (number of joints or number of grams) by 
frequency of use, were employed. Afterwards, the variable was log transformed to 
account for the non-normal distribution of the variable.  
 
5.4.5. Mean Differences in Psychotic-Like Experiences by Sociodemographic 
Characteristics and Use of Other Drugs 
Regarding the psychotic-like experience assessment, as shown in Table 5.5, no 
significant differences were found in the mean scores of the PRIME scale by age 
(F=1.54, df=3, 639; p=.204), gender (F=2.37, df=1, 639; p=.124) or socioeconomic 
status (F=.404 df=2, 640; p=.668). On the other hand, significant differences were 
found in total scores of the psychotic-like experiences questionnaire and ethnicity 
(F=1.97, df=3, 629; p=.031), with higher mean scores in the PRIME among participants 
identifying themselves as ‘Other’. Furthermore, lifetime tobacco users had higher mean 
scores in the PRIME Screen Questionnaire than never users (F=15.05, df=1, 636; 
p=.000). Similarly, lifetime e-cigarette users (F=7.64, df=1, 628; p=.006), lifetime 
alcohol users  (F=8.12, df=1, 638; p=.005) and lifetime use of any illicit drug (F=13.35, 
df=1, 635; p=.000) had higher mean scores on the psychotic-like experiences 




5.4.6. Mean Differences between Cannabis Use, Sociodemographic 
Characteristics and Use of Other Drugs 
Analyses were conducted to identify differences and associations between different 
patterns of cannabis use (QFSA), sociodemographic characteristics and use of other 
drugs (Table 5.5). For the quantity by frequency scale (QFSA) results showed 
significant differences by gender in mean scores (F=4.17, df=1, 643; p=.042) with mean 
scores of cannabis use being higher among males (.33) than females (.25). No 
differences were shown in mean scores of the cannabis use scale by age  (F=.65, df=3, 
644; p=.585),  ethnicity (F=.34, df=3, 631; p=.800) or socioeconomic status (F=1.46, 
df=2, 645; p=.234). There were statistically significant differences in mean scores of the 
QFSA and the use of tobacco (F=91.80, df=1, 641; p=.000), e-cigarettes (F=50.47, 
df=1, 632; p=.000), alcohol (F=26.68, df=1, 644; p=.000), binge drinking (F=9.91, 
df=1, 526; p=.001) and use of any illicit drug (F=106.57, df=1, 623; p=.000). Across all 
these comparisons, mean levels of the quantity by frequency scale of cannabis use were 




Table 5.5 Differences in Mean Scores of the Quantity by Frequency Scale, Mean Scores 
of the Psychotic-Like Experiences, Sociodemographic Characteristics and Use of Other 
Drugs 
  PRIME (M) F df
1, df2 p *QFS (M) F df
1, df2 p 
Age 15 25.66 1.54 3, 639 .204 .24 .647 3, 644 .585 
 16 28.52    .29    
 17 27.77    .29    
 18-19 26.21    .32    
Gender Female 28.11 2.37 1, 639 .124 .25 4.17 1, 643 .042* 
 Male 26.47    .33    
Ethnicity Caucasian 23.19 1.97 3, 629 .031* .29 .34 3, 631 .800 
 Hispanic / Latin 28.19    .28    
 African-Descent 25.86    .28    
 Other 29.68    .36    
SES A/B 26.75 .404 2, 640 .668 .36 1.46 2, 645 .234 
 C+/C/C- 27.18    .27    
 D+/D/E 28.18    .29    
Tobacco Yes 29.21 15.05 1, 636 .000* .44 91.80 1, 641 .000* 
 No 25.10    .10    
E-
cigarette Yes 28.94 7.64 1, 628 .006* .44 50.47 1, 632 .000* 
 No 25.98    .18    
Alcohol Yes 28.09 8.12 1, 639 .005* .34 26.68 1, 644 .000* 
 No 24.28    .10    
Binge 
Drinking Yes 27.94 1.72 1, 632 .190 .38 9.91 1, 526 .002* 
 No 26.47    .21    
Other 
Drugs Yes 30.68 12.35 1, 635 .000* .61 106.57 1, 623 .000* 
 No 26.32    .19    




5.4.7. Associations between Cannabis Use, Sociodemographic Characteristics 
and Use of Other Drugs 
Analyses were conducted to identify associations between different patterns of cannabis 
use (lifetime cannabis use, at least monthly cannabis use, type of cannabis mainly used) 
and sociodemographic characteristics. Results are shown in Table 5.6. No significant 
differences were found between lifetime cannabis use and age (OR=1.12, 95%CI=.95-
1.33; p=.183) or age by gender interaction (OR=.86, 95%CI=.61-1.22; p=.401). 
Furthermore, no statistically significant differences were found in the chi-square 
analyses of lifetime cannabis use by ethnicity (X2=2.39, df=3, 631; p=.495) or 
socioeconomic status (X2=4.17, df=2, 644; p=.125). Significant differences were found 
in lifetime cannabis use by gender (OR=1.44, 95%CI=1.03-2.03), indicating that males 
were more likely to report lifetime cannabis use than females. 
 
Furthermore, analyses conducted to estimate associations between use of other drugs 
and lifetime cannabis use indicated that lifetime cannabis users were 6 times more likely 
to report lifetime tobacco use (OR=6.59, 95%CI=4.32-10.06) and 3 times more likely to 
have ever used e-cigarettes (OR=3.23, 95%CI=2.26-4.60). Furthermore, participants 
reporting lifetime cannabis use were four times more likely to have used alcohol 
(OR=4.90, 95%CI=2.63-9.13) and two times more likely to report lifetime binge 
drinking (OR=2.70, 95%CI=1.61-4.52). Moreover, participants that reported lifetime 
cannabis use were six time more likely to report use of any other illicit drug than never 






Table 5.6 Associations between Cannabis Use, Sociodemographic Characteristics and Use of Other Drugs: Logistic Regression, Odds Ratios 
and Chi-Square Analysis 
  Lifetime Monthly Type of Cannabis 
  % OR 95%CI p % OR 95%CI p % X2 df p 
Age 15 26.1 1.12 .95-1.33 .183 7.6 .933 .661-1.32 .691 6.7 6.83 6 .337 
 16 29.8    4.6    11    
 17 29.6    5.9    14    
 18-19 33.9    5    16.3    
Gender Female 26.3 1.44 1.03-2.03 .035* 3 2.94 1.39-6.23 .005* 8 10.75 2 .005* 
 Male 33.8    8.3    16.3    
  % X2 df p % X2 df p % X2 df p 
Ethnicity Caucasian 33.3 2.39 3 .495 2.5 1.17 3 .759 9.5 3.93 6 .687 
 Hispanic / Latin 28.6    5.2    11.8    
 African-Descent 28.2    5.5    12.2    
 Other 39.5    7.9    15.4    
SES A/B 37.9 4.166 2 .125 10.8 8.45 2 .015* 13.5 10.42 4 .034* 
 C+/C/C- 27.6    5.5    12.9    
 D+/D/E 30.3    2.1    8.5    
  % OR 95%CI p % OR 95%CI p % X2 df p 
Tobacco Yes 45.2 6.59 4.32-10.06* - 9.1 7.15 2.50-20.45* - 18 81.72 2 .000* 
 No 11.1    1.4    4.9    
E-cigarette Yes 43.7 3.23 2.26-4.60* - 10 4.92 2.20-11.02* - 17 47.25 2 .000* 
 No 19.4    2.2    8.2    
Alcohol Yes 34.6 4.90 2.63-9.13* - 6.4 2.72 .821-9.02 - 14 27.56 2 .000* 
 No 9.8    2.4    4.1    
Binge Drinking Yes 39.2 2.70 1.61-4.52* - 7.5 4.33 1.02-18.39* - 16.7 47.73 2 .000* 
 No 19.3    1.8    3.9    
Other Drugs Yes 62 6.85 4.59-10.23* - 16.9 10.48 4.77-23.03* - 32.5 111.75 2 .000* 
 No 19.2    1.9    5.8    
 156 
Significant differences were found between males and females in the prevalence of 
monthly cannabis use, which was higher among males than females (OR=2.94, 
95%CI=1.39-6.23; p=.005). Additionally, chi-square analyses showed significant 
associations between socioeconomic status (X2=8.45, df=2, 642; p=.015), and monthly 
cannabis use, being higher in socioeconomic status A/B than in socioeconomic status 
C+/C/C or D+/D/E. Among participants reporting monthly cannabis use, prevalence 
was higher in the use of other drugs, compared to experimental users or non-users. 
Significant associations were found with lifetime tobacco use (OR=7.15, 95%CI=2.50-
20.45), e-cigarette use (OR=4.92, 95%CI=2.20-11.02), binge drinking (OR= 4.33, 
95%CI=1.02-18.39) and use of any illicit drug (OR=10.48, 95%CI=4.77-23.03), 
meaning that monthly cannabis users were more likely to have ever used tobacco, e-
cigarettes, binge drink and any illicit drugs (Table 5.6). 
 
Lastly, chi-square analyses showed significant associations between type of cannabis 
mainly used and gender (X2=10.75, df=2, p=.005), indicating males were more likely to 
use skunk type cannabis than females. Furthermore, participants in socioeconomic level 
A/B had significantly higher prevalence of skunk use than participants in any other 
socioeconomic levels (X2=10.42, df=4, p=.034) Furthermore, participants using skunk-
type cannabis had higher prevalence of lifetime tobacco (X2=81.72, df=2, p=.000), e-
cigarette (X2=47.25, df=2, p=.000), alcohol (X2=27.56, df=2, p=.000), binge drinking 
(X2=47.73, df=2, p=.000) and use of other illicit drugs (X2=111.75, df=2, p=.000) than 




5.4.8. Associations between Psychotic-Like Experiences, Sociodemographic 
Characteristics and Use of Other Drugs 
Logistic regression, chi-square and odds ratios obtained through crosstab analyses were 
conducted to examine the associations between psychotic-like experiences, 
sociodemographic characteristics and lifetime use of other drugs (Table 5.7). A positive 
score in the psychotic-like experiences questionnaire was obtained with a score of 40+. 
Logistic regression analyses indicated no significant differences between psychotic-like 
experiences by age or gender. Significant associations were found by ethnicity 
(X2=8.21, df=3, 630; p=.042), with participants identified as ‘Other’ type of ethnicity 
obtaining higher mean scores in the PRIME Screen Questionnaire. 
 
Furthermore, chi-square analyses showed no association between psychotic-like 
experiences and socioeconomic status (X2=.615, df=2, 643; p=.735). Regarding use of 
other drugs, participants reporting lifetime tobacco use (OR=1.66, 95%CI=1.10-2.50) 
and e-cigarettes (OR=1.50, 95%CI=1.01-2.24) were more likely to have a positive score 
in the psychotic-like experiences assessment. Moreover, participants reporting use of 
any illicit drug were two times more likely (OR=2.01, 95%CI=1.32-3.08) to score 
positively in the PRIME. Overall, results indicated that participants reporting lifetime 
use of e-cigarettes and lifetime use of any illicit drugs were more likely to have higher 
mean scores in both, the quantity by frequency scale of any type of cannabis and the 
psychotic-like experiences assessment.   
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Table 5.7 Associations between Psychotic-Like Experiences, Sociodemographic 
Characteristics and Use of Other Drugs: Logistic Regression, Odds Ration and Chi-
Square Analysis 
   
PLE’s 
(%) OR 95%CI p 
Age 15 15.1 1.07 .88-1.31 .477 
 16 20.7    
 17 21.1    
 18-19 18.9    
Gender Female 19.5 1.00 .68-1.48 1.00 
 Male 19.5    
  % X2 df p 
Ethnicity Caucasian 14.3 8.21  3, 630 .042* 
 Hispanic or Latin 20.3    
 African-Descent 15    
 Other 34.2    
SES A/B 20.6 .615  2, 643 .735 
 C/C+/C- 18.5    
 D+/D/E 21.3    
  % OR 95%CI  
Tobacco Yes 23.1 1.66 1.10-2.50* - 
 No 15.3    
E-cigarette Yes 22.7 1.50  1.01-2.24* - 
 No 16.3    
Alcohol Yes 20.8 1.64  .94-2.86 - 
 No 13.8    
Binge Drinking Yes 20.1 1.07 .71-1.62 - 
 No 19    
Other Drugs Yes 28.7 2.01 1.32-3.08* - 




5.4.9. Association between Different Measures of Cannabis Use by 
Sociodemographic Characteristics and Use of Other Drugs: Regression 
Models 
To estimate associations between cannabis use, sociodemographic characteristics and 
use of other drugs regression analyses were conducted. Linear regression was conducted 
with the continuous measures of cannabis (QFSA). Logistic regression analyses were 
conducted with the dichotomous measures of cannabis use: lifetime cannabis use, at 
least monthly cannabis use; and for type of cannabis (3 category variable) multinomial 
regression analyses were conducted.  
 
To estimate associations between psychotic-like experiences, sociodemographic 
characteristics and use of other drugs, linear regression analysis was conducted with the 
continuous measure of the PRIME Screen Questionnaire. All models included nine 
independent variables: age, gender, ethnicity, socioeconomic status, lifetime tobacco 




Table 5.8 Association between Patterns of Cannabis Use, Sociodemographic Characteristics and Use of Other Drugs: Regression Models 
 QFSA Lifetime Use Monthly Use Skunk-Type vs Non-Users Skunk-Type vs. Herbal 
 B SE p OR 95%CI p OR 95%CI p OR 95%CI p OR 95%CI P 
Age .000 .02 .993 .97 .79-1.20 .760 .73 .48-1.10 .132 .88 .65-1.19 .406 .78 .56-1.09 .145 
Gender .056 .04 .113 1.52 1.00-2.29 .048* 2.92 1.22-7.02 .017* 2.51 1.39-4.56 .002* 2.70 .40-5.23 .003* 
Ethnicity .022 .03 .377 1.14 .85-1.52 .378 1.33 .77-2.29 .308 1.85 .38-9.04 .447 1.72 .33-8.92 .520 
SES -.010 .03 .737 .95 .68-1.32 .751 .48 .26-.89 .020* .64 .25-1.68 .367 .72 .26-1.99 .522 
Tobacco .189 .04 .000* 3.40 2.07-5.56 .000* 3.30 .93-11.68 .064 2.65 1.28-5.47 .008* .80 .33-1.92 .618 
E-cigarette .096 .04 .012* 1.56 1.02-2.39 .039* 2.98 1.09-8.16 .034* 1.41 .78-2.56 .262 .70 .35-1.39 .305 
Alcohol -.032 .06 .591 .87 .36-2.10 .758 .20 .03-1.49 .116 .35 .08-1.53 .161 .31 .06-1.72 .180 
Binge Drinking .105 .05 .030* 2.36 1.27-4.40 .006* 3.36 .72-15.67 .123 5.55 1.82-16.96 .003* 3.18 .95-10.65 .061 
Other Drugs .318 .04 .000* 4.45 2.87-6.90 .000* 7.78 3.20-18.82 .000* 8.08 4.45-14.66 .000* 2.71 1.41-5.22 .003* 
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Significant associations were found when conducting linear regression analyses  
between the quantity by frequency scale of cannabis use, sociodemographic 
characteristics and use of other drugs while controlling for confounding factors with 
lifetime tobacco use (B=.189, SE=.04, p=.000); lifetime use of e-cigarettes (B=.096, 
SE=.04, p=.012), lifetime history of binge drinking (B=.105, SE=.05, p=.030) and 
lifetime illicit drug use (B=.318, SE=.04, p=.000). Results are summarised in Table 5.8. 
Participants reporting lifetime use of cannabis were more likely to binge drink, use 
tobacco, e-cigarettes and other illicit drugs than never cannabis users. The logistic 
regression model estimated significant associations between lifetime cannabis use and 
gender (OR=1.52, 95%CI=1.00-2.29, p=.048), tobacco (OR=3.40, 95%CI=2.07-5.56, 
p=.000), e-cigarette (OR=1.56, 95%CI=1.02-2.39, p=.039), binge drinking (OR=2.36, 
95%CI=1.27-4.40), p=.006) and illicit drugs (OR=4.45, 95%CI=2.87-6.90, p=.000) 
after controlling for all confounding variables (Table 5.8).  
 
Additionally, at least monthly cannabis use was associated with gender (OR=2.92, 
95%CI=1.22-7.02, p=.017), socioeconomic status (OR=.48, 95%CI=.26-.89, p=.020), 
lifetime use of e-cigarettes (OR=2.98, 95%CI=1.09-8.16, p=.034) and lifetime use of 
any illicit drug (OR=7.78, 95%CI=3.20-18.82, p=.000). Males were two times more 
likely than women to report at least monthly cannabis use. Participants in higher 
socioeconomic status had higher prevalence of monthly cannabis use than participants 
from lower socioeconomic status. Furthermore, monthly users were two times more 
likely to report e-cigarette use and seven times more likely to have experimented with 
any illicit drug in their lifetime. Multinomial logistic regression analyses were 
conducted to identify associations between the three-category variable of different types 
of cannabis mainly used, sociodemographic factors and use of other drugs. Significant 
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associations were found between participants using skunk and gender (OR=2.51, 
95%CI=1.39-4.56, p=.002), tobacco (OR=2.65, 95%CI=1.28-5.47, p=.008), binge 
drinking (OR=5.55, 95%CI=1.82-16.96, p=.003) and other drugs (OR=8.08, 
95%CI=4.45-14.66, p=.000) compared with non-users. Furthermore, when examining 
associations between skunk type cannabis users vs. users of any other type of cannabis, 
analyses showed significant associations between skunk users with gender (OR=2.70, 
95%CI=1.40-5.23, p=.003) and use of any illicit drugs (OR=2.71, 95%CI=1.41-5.22, 
p=.003) (Table 5.8).  
 
Table 5.9 Association between Measures of Psychotic-Like Experiences, 
Sociodemographic Characteristics and Use of Other Drugs: Linear Regression Models 
 Total Score PRIME 
 B SE p 
Age -.284 .554 .609 
Gender -1.786 1.108 .108 
Ethnicity .389 .781 .618 
SES .466 .899 .604 
Tobacco 2.595 1.269 .041* 
E-cigarette 1.195 1.210 .324 
Alcohol 2.790 1.883 .139 
Binge Drinking -1.646 1.512 .277 
Other Drugs 2.844 1.328 .033 
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5.4.10. Associations between Different Measures of Cannabis Use and 
Psychotic-Like Experiences: Preliminary Analysis 
Firstly, analyses were conducted to identify the strength of the associations between 
cannabis use and psychotic-like experiences taking into account continuous variables. 
Pearson’s correlation analyses were conducted, results showed no correlation between 
the QFSA and the total score of psychotic-like experiences (R2=.016, p=.692).  
 
5.4.11.  Psychotic-Like Experiences, Lifetime Cannabis Use and Use of Other 
Drugs 
Hierarchical linear regression models were conducted to identify associations between 
psychotic-like experiences, lifetime cannabis use and use of other drugs. No 
sociodemographic characteristics were included in the initial unadjusted models as no 
associations were previously found with psychotic-like experiences.  
 
Table 5.10 Linear Regression Model: Total Score Psychotic-Like Experiences, Lifetime 
Cannabis Use and Use of Other Drugs 
Model 1 Unstandardized B SE p 
Lifetime cannabis use 2.18 1.17 .064 
Model 2    
Lifetime cannabis use .573 1.25 .645 
Lifetime tobacco use 4.08 1.14 .000* 
Model 3    
Lifetime cannabis use -.526 1.31 .688 
Lifetime tobacco use  3.64 1.15 .002* 
Lifetime use of any illicit drugs 3.52 1.36 .010* 
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Model 4    
Lifetime cannabis use -.604 1.31 .646 
Lifetime tobacco use  3.10 1.22 .012* 
Lifetime use of any illicit drugs 3.38 1.37 .014* 
Lifetime use of alcohol 1.86 1.47 .206 
Model 5    
Lifetime cannabis use -.716 1.32 .587 
Lifetime tobacco use  2.82 1.26 .026* 
Lifetime use of any illicit drugs 3.22 1.38 .020* 
Lifetime use of alcohol 1.73 1.48 .242 
Lifetime use of e-cigarettes 1.08 1.18 .361 
 
In the hierarchical linear regression model with psychotic-like experiences total score as 
outcome and lifetime cannabis use as main predictor, while controlling for confounding 
variables which were previously found to be associated with psychotic-like experiences, 
results showed that participants reporting lifetime tobacco use scored up to 2 points 
higher in the PRIME Screen Questionnaire than non-tobacco users (B=2.82, SE=1.26, 
p=.026). Furthermore, participants reporting lifetime use of any illicit drugs scored up to 
3 points higher in the questionnaire than participants reporting non-use of illicit drugs 
(B=3.22, SE=1.38, p=.02).  
 
5.4.12.  Association between Cannabis Use and Psychotic-Like Experiences 
Controlling for Sociodemographic Characteristics and Use of Other Drugs 
Multiple linear regression analyses were conducted to identify significant associations 
between different patterns of cannabis use and psychotic-like experiences while 
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controlling for sociodemographic factors and use of other drugs. These analyses are the 
core and main interest of the present study. Results are summarised in Table 5.11. 
 
Significant associations were found between cannabis use and psychotic-like 
experiences, firstly with lifetime tobacco use (B=2.94, SE=1.29; p=.025), as well as the 
use of illicit drugs (B=3.34, SE=1.39; p=.016) (Table 5.11). 
 
Table 5.11 Association between QFSA and Psychotic-Like Experiences Adjusted for 
Sociodemographic Characteristics and Use of Other Drugs: Multiple Linear Regression 
Analyses 
 B SE p 
QFSA -1.60 1.29 .218 
Age -.28 .55 .615 
Gender -1.70 1.11 .127 
Ethnicity .425 .78 .587 
Socioeconomic Level .450 .90 .617 
Tobacco* 2.94 1.29 .025* 
E-cigarettes 1.35 1.22 .268 
Alcohol 2.74 1.88 .146 
Binge Drinking -1.48 1.52 .329 
Illicit Drugs* 3.34 1.39 .016* 
 
5.5. Summary 
Prevalence of psychotic-like experiences in the adolescent student sample was of 
20.4%, similar to what research has found in the general adolescent population 
(Kelleher et al., 2012). Cannabis use was more prevalent among males than females and 
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was significantly associated with lifetime use of licit and illicit drugs. Lastly, psychotic-
like experiences were associated with lifetime tobacco and use of licit and illicit drugs. 
 
No significant associations between cannabis use and psychotic-like experiences. A 
number of reasons may explain the nature of these results. First, the quantity and 
frequency of cannabis reported by participants in the school sample was very low. Most 
participants reported using once in their lifetime and using less than one joint on a 
typical occasion. Research has shown that one of the main patterns of cannabis use 
linked with psychotic-like experiences is high quantity and high frequency of use 
(Fergusson, D., et al., 2003), which would then explain the non-significant associations 
in the present study. However, it could be a possibility that in Mexico, low frequency of 
cannabis use might not be associated with the development of psychotic-like 
experiences. This could be due to type of cannabis or method of use (without tobacco), 
nevertheless, further research is needed to fully understand the nature of the obtained 
results. 
 
The main interest of the present study, and one of the main hypotheses of this project 
was that higher scores of psychotic-like experiences would be observed in adolescents 
using cannabis than in non-using adolescents. Results did not corroborate said 
hypothesis once all sociodemographic factors and use of other drugs were controlled 
for. Furthermore, higher levels of psychotic-like experiences were not observed in high-
potency cannabis users than in low-potency cannabis users or non-using adolescents. 
This hypothesis, as the previously mentioned, was not corroborated as there were no 





Small sample size of participants using cannabis frequently is something to be 
considered. Power analyses were conducted to ensure that the sample size recruited 
could detect an association between cannabis use and psychotic-like experiences. 
Nevertheless, these power analyses were conducted with data extracted from studies 
that had been conducted in western countries, with larger samples, and prevalence of 
use considered to detect an association was lifetime cannabis use. Bayesian statistics 





6. Cannabis Use and Psychotic-Like Experiences in an Adolescent 
Substance Misuse Clinical Sample in Mexico City 
6.1. Introduction 
6.1.1. Rationale for Examining Psychotic-Like Experiences in a Substance 
Misuse Clinical Sample 
Research has shown that cannabis use is associated with the presence of psychotic-like 
experiences (see Chapters 1 and 2). However, studies have mainly been conducted in 
populations presenting with a first psychotic episode or in the general population. Few 
studies have focused on substance misuse populations; hence the interest in the present 
study.  
 
One study in Sweden examining three different samples from a substance misuse 
treatment service were identified and data were extracted from clinical files, 1,992 
participants treated from 1986 to 1971 and followed up to age 50; 1,576 individuals 
treated from 1980 to 1984 and followed up to age 35 and 180 treated in 2004 followed 
up to age 22.  Each clinical sample was then matched on all sociodemographic 
characteristics with randomly selected individuals from the general population (Hodgins 
et al., 2016). Results showed that adolescents treated for substance misuse were at 
increased risk for developing schizophrenia than participants in the general population, 
in both males and females (OR=4.24, 95%CI=2.18-8.24; OR=7.04, 95%CI=2.45-2.25) 
respectively.  
 
This was the only study found through different searches of databases where the 





To examine potential associations between different measures of cannabis use 
(frequency of use, quantity of use, quantity by frequency use scales, age of first use, 
type of cannabis mainly used, preferred method of use) and psychotic-like experiences 
in a substance misuse clinical sample.  
 
6.3. Methods 
Assessments used in the clinical sample were identical to the ones used in the school 
sample. For in-depth description see Chapter 3.  
 
6.4. Statistical Analysis 
Analyses were conducted, as in the previous chapter, using the statistical package IBM 
SPSS Statistics Version 25. Descriptive statistics were conducted to identify number of 
participants by age and gender, ethnicity and socioeconomic status. Analyses were 
conducted to identify mean age of onset of cannabis use, frequency and quantity of use, 
type of cannabis mainly used and preferred method of use. Chi-square analyses were 
conducted to identify differences between different patterns of cannabis use and 
sociodemographic characteristics.   
 
6.4.1. Patterns of Use of Other Drugs and Associations with Psychotic-Like 
Experiences 
Descriptive statistics were conducted to determine prevalence of psychotic-like 
experiences in the clinical sample, overall and by gender. Furthermore, analyses were 
conducted to identify if use of other drugs were independently associated with 
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psychotic-like experiences. Both, continuous and dichotomous variables of the PRIME 
Screen Questionnaire were included in these analyses. Odds ratio were calculated using 
a two-by-two contingency table to identify associations between psychotic-like 
experiences and daily and weekly use of tobacco; daily, weekly and monthly e-cigarette 
use; daily and weekly alcohol use; every day and weekly binge drinking; daily, weekly 
and monthly benzodiazepine use; daily, weekly and monthly methamphetamine use and 
daily, weekly and monthly solvent use. 
 
6.4.2. Independent Associations between Different Patterns of Cannabis Use 
and Psychotic-Like Experiences 
The main interest of the present study was to identify plausible associations between 
cannabis use and psychotic-like experiences. Odds ratios were calculated using a two-
by-two contingency table to examine associations between different measures of 
cannabis use and psychotic-like experiences (dichotomous measure 40+ positive score). 
Dichotomous measures of cannabis use included frequent vs. non-frequent cannabis 
use, quantity of use (less than one or one joint vs. two or more), method of use (water 
pipe or bong vs. any other) and type of cannabis (herbal-type vs. skunk-type).  
 
6.4.3. Multiple Linear Regression Analyses: Association between Cannabis 
Use and Psychotic-Like Experiences Controlling for Sociodemographic 
Characteristics and Use of Other Drugs 
Multiple linear regression models were conducted to identify plausible associations 
between different measures of cannabis use and psychotic-like experiences while 
controlling for sociodemographic characteristics and use of other drugs. A linear 
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regression model was fitted with the total score of the psychotic-like experiences 
assessment as outcome and the total score of the quantity by frequency scale of cannabis 
used (QFSA). Age, gender, ethnicity and socioeconomic status and the same variables 
of use of other drugs included in the logistic analyses were included in the linear model.  
 
6.5. Results 
A total of 114 adolescents aged from 13 to 21-years old completed the questionnaires in 
the clinical sample. Mean age was 16.56 (SD=1.58). A total of 85% (N=96) of 
participants were male and 15% (N=17) were female. The response rate of the clinical 
sample was higher than the school sample; 99% of clinic attendees referred to the study 
consented to participate in the study. 
 
Figure 6.1 Number of Participants by Age and Gender 
 
Almost half of the sample identified themselves as Hispanic or Latin (48.7%), followed 
by African Descent with 24.3% and 20% as Caucasian. Five-point two percent 
identified themselves as being part of ‘Other’ ethnicity. More than half of participants 
scored in socioeconomic level C+/C/C- (51.3%), 32.2% in D+/D/E and 16.5% in level 
A/B. 
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6.5.1. Frequency of Cannabis Use 
Mean age of first use of cannabis was 13.75 (SD=1.64), with age of onset starting from 
9 up to 17 years old.  Frequency of cannabis use among the clinical sample was 
relatively high, although not as high as expected, (see Figure 6.2) with 83.3% reported 
using cannabis every day or weekly. Every day or almost daily use was reported by 
58.3% of males and 58.8% of females. These data are not presented separated by gender 
as chi-square tests revealed no significant differences in frequency of cannabis use by 
gender (X2=4.27, df=5; p=.511), ethnicity (X2=12.70, df=15, p=.625) or socioeconomic 
level (X2=14.60, df=25, p=.950). However, significant differences were found in 
frequency of cannabis use by age (X2=62.83, df=40; p=.012) indicating that older 
participants were more likely to use cannabis daily or almost daily.  
 
Figure 6.2 Frequency of Cannabis Use 
 
 
6.5.2. Quantity of Cannabis Use 
Just over one quarter of the sample reported using three to four joints on any typical 
occasion (27.2%) and almost half (46.5%) reported using one or two joints (Figure 6.3). 
There were no significant differences in quantity of cannabis use by age (X2=52.06, 
df=40; p=.096), gender (X2=3.87, df=5; p=.568), ethnicity (X2=9.45, df=15, p=.853) or 




Almost every day /
weekly
At least monthly
Once or twice a year /
only tried it once
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Figure 6.3 Quantity of Use: Number of Joints  
 
 
6.5.3. Types of Cannabis Mainly Used 
Regarding type of cannabis, skunk had the highest prevalence of use among participants 
with 72.8% (83 participants) reporting skunk as the type mainly used. As shown in  
 
Figure 6.4 herbal cannabis was reported by 25.4% (29 participants) and only 1.8% (2 
participants) reported hash as the mainly type of cannabis used. Chi-square analyses 
with the original 3 category variable showed no significant differences between type of 
cannabis mainly used and age (X2=16.59, df=16, p=.413), gender (X2=.432, df=2, 
p=.806), ethnicity (X2=4.85, df=6, p=.564) or socioeconomic level (X2=9.41, df=10, 













6.5.4. Method of Use 
Water pipe or bong was the preferred method of use, followed by 30.7% reporting using 
cannabis in joints without tobacco. All other preferred methods of use were much lower 
(see Error! Reference source not found.). Chi-square analyses showed no differences 
between preferred method of use and age (X2=39.21, df=40, p=.506), gender (X2=5.81, 
df=5, p=.326), ethnicity (X2=10.28, df=15, p=.802) or socioeconomic level (X2=26.78, 
df=25, p=.367).   
 












In a joint with tobacco
In a joint without tobacco







6.5.1. Cannabis Use Experience Questionnaire, Sociodemographic 
Characteristics and Use of Other Drugs 
Analyses were conducted to identify differences between the cannabis use experience 
questionnaire, sociodemographic characteristics and use of other drugs. No significant 




Table 6.1 Cannabis Use Experiences Questionnaire Mean Scores by Sociodemographic 
Characteristics and Use of Other Drugs 
 % Mean SD F df p 
Age    .142 3 .935 
<15 28.7 10.84 2.70    
16 20 10.65 2.42    
17 29.6 10.97 3.10    
18-19 21.7 11.24 4.48    
Gender    3.60 1 .060 
Female 14.8 12.29 4.06    
Male 84.3 10.71 3.00    
Ethnicity    2.96 3 .035* 
Caucasian  9.00 1.27    
Hispanic or Latin  10.34 2.58    
African Descent  11.21 3.00    
Other  12.26 4.37    
Socioeconomic Level    .084 2 .919 
A/B 16.5 1.11 3.32    
C+/C/C- 51.3 10.81 3.49    
D+/D/E 32.2 11.03 2.72    
Use of Other Drugs       
Tobacco Use 50.9 11.26 3.55 .993 1 .321 
At Least Weekly       
Binge Drinking 20.2 11.74 2.14 1.85 1 .176 
At Least Weekly       
Solvent Use 21.1 11.96 3.51 3.20 1 .077 
At Least Monthly       
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Benzodiazepine Use 9.6 12.00 2.45 1.36 1 .245 
At Least Monthly       
Use of Other Drugs 6.1 11.57 2.51 .297 1 .587 
At Least Monthly       
Table 6.2 Patterns of Cannabis Use and Mean Scores of the Cannabis Experiences 
Questionnaire 
Age of First Use % Mean F df p 
Early Onset (9 – 14) 73% 11.18 1.22 1 .271 
Later Onset (15 – 17) 41% 10.49 2.92   
Frequent vs. Non-Frequent  11.36 2.89   
Frequent Use (daily) 57.9% 10.33 .017 1 .090 
Non-Frequent Use  
(weekly to only once) 
42.1% 11.46 1.13   
Quantity of Use (Joints)  10.45 1.22   
Two or more 47.4% 10.90 2.92 1 .092 
Less than one or one 52.6% 10.98 2.89   
Routes of Administration  10.73 .017   
Bong or water pipe 60.5% 11.45 1.13 1 .898 
Any Other 39.5% 11.18 1.22   
Type of Cannabis  10.49 2.92   
Skunk 72.8% 11.36 2.89 1 .290 
Herbal or Hash 27.2% 10.33 .017   
 
 
6.5.2. Patterns of Cannabis Use and Cannabis Use Experience Questionnaire 
Analysis of variance was conducted to identify if different patterns of cannabis use were 
significantly associated with higher levels of unpleasant effects experienced by 
participants after the use of cannabis (Table 6.2). No significant differences were found 
in mean scores of the CEQ and different patterns of cannabis use, indicating that 
participants experienced similar levels of unpleasant effects disregarding patterns of 






Table 6.3 Lifetime Use, Age of Onset and Frequency of Use of Other Drugs 
*Values shown as % and (N) in lifetime use 
 Lifetime Use  
%(N) 













Just Tried it 
Once 
Tobacco 91.2 (104) 12.96 28.9 21.9 13.2 9.6 7.0 12.3 
E-cigarettes 67.5 (77) 14.36 3.5 7.9 5.3 13.2 14 25.4 
Alcohol 93 (106) 13.39 2.6 21.1 31.6 17.5 13.2 7.9 
Binge Drinking 84.2 (96) 13.39 2.6 17.5 22.8 21.1 10.5 8.6 
Cocaine 48.2 (55) 15.29 2.6 6.1 9.6 6.1 9.6 14 
Crack 33.3 (38) 15.37 2.6 3.5 7.0 4.4 6.1 10.5 
Solvents 47.4 (54) 14.57 6.1 9.6 5.3 4.4 11.4 12.3 
Hallucinogens 37.7 (43) 15.48 0 2.6 6.1 9.6 10.5 10.5 
Ecstasy 14.9 (17) 15.67 0 .9 1.8 0 6.1 8.8 
Benzodiazepines-Sleeping Pills 23.7 (27) 14.75 8.8 0 .9 .9 3.5 9.6 
Opioids 2.6 (3) 14.60 0 .9 0 .9 .9 1.8 
Heroin or Opium 5.3 (6) 15 0 0 0 1.8 0 4.4 
Amphetamines-
Methamphetamines 
19.3 (22) 15.40 0 3.5 1.8 4.4 4.4 5.3 
Other Drugs 13.2 (15) 15.67 1.8 .9 3.5 .9 3.5 4.4 
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6.5.3. Patterns of Use of Other Drugs: Licit and Illicit 
Mean age of onset of alcohol use was 13.39 years old and for 12.96 for tobacco use, 
prevalence of lifetime use of alcohol was reported by 93% of participants and 91.2% 
reported lifetime tobacco use (
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Table 6.3). Prevalence of daily or almost daily use of tobacco was reported by 28.9% of 
participants. Among illicit drugs, powder cocaine was the most commonly used with 
48.2% reporting lifetime use, followed by solvents with 47.4%. Furthermore, daily use 
of benzodiazepines was reported by 8.8% and 6.1% reported daily solvent use. Mean 
age of first use of any illegal drug was 15.18 years old. Overall, it can be observed that 
frequent use of illicit drugs was, to some degree, uncommon. 
 
6.5.4.  Prevalence of Psychotic-Like Experiences 
Prevalence of positive scores in the psychotic-like experiences assessment in the clinical 
sample was of 27.2%. According to gender, 27.1% of females and 29.4% of men had 
scored positively in the PRIME Screen Questionnaire. No statistically significant 
 Lifetime Use  
%(N) 













Just Tried it 
Once 
Tobacco 91.2 (104) 12.96 28.9 21.9 13.2 9.6 7.0 12.3 
E-cigarettes 67.5 (77) 14.36 3.5 7.9 5.3 13.2 14 25.4 
Alcohol 93 (106) 13.39 2.6 21.1 31.6 17.5 13.2 7.9 
Binge Drinking 84.2 (96) 13.39 2.6 17.5 22.8 21.1 10.5 8.6 
Cocaine 48.2 (55) 15.29 2.6 6.1 9.6 6.1 9.6 14 
Crack 33.3 (38) 15.37 2.6 3.5 7.0 4.4 6.1 10.5 
Solvents 47.4 (54) 14.57 6.1 9.6 5.3 4.4 11.4 12.3 
Hallucinogens 37.7 (43) 15.48 0 2.6 6.1 9.6 10.5 10.5 
Ecstasy 14.9 (17) 15.67 0 .9 1.8 0 6.1 8.8 
Benzodiazepines-Sleeping Pills 23.7 (27) 14.75 8.8 0 .9 .9 3.5 9.6 
Opioids 2.6 (3) 14.60 0 .9 0 .9 .9 1.8 
Heroin or Opium 5.3 (6) 15 0 0 0 1.8 0 4.4 
Amphetamines-
Methamphetamines 
19.3 (22) 15.40 0 3.5 1.8 4.4 4.4 5.3 
Other Drugs 13.2 (15) 15.67 1.8 .9 3.5 .9 3.5 4.4 
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differences were found by age (X2=5.62, df=8, p=.690) or gender (OR=.90, 95%CI=.29-
2.78). Moreover, no significant differences were found between the total score of the 
PRIME and ethnicity (X2=3.10, df=3, p=.377) or socioeconomic level (X2=2.44, df=5, 
p=.785).   
 
6.5.5. Associations between Psychotic-Like Experiences and Use of Other 
Drugs 
Analyses were conducted to identify if frequency of use of other drugs were 
significantly associated with psychotic-like experiences. Significant differences were 
found in mean scores of the PRIME Screen Questionnaire and daily, weekly and 
monthly use of benzodiazepines (F=5.66, df=1, 112; p=.019) compared to less frequent 
use of benzodiazepines. Moreover, statistically significant differences were found in 
mean scores of the PRIME Screen questionnaire and daily, weekly and monthly use of 
solvents (F=8.01, df=1, 112; p=.006), compared to less frequent use of solvents Error! 
Reference source not found..  
Table 6.4 Psychotic-Like Experiences and Frequent Use of Other Drugs 
 
Mean F df1, df2 p Prevalence 
PLE’s (%) 
Tobacco Use      
Daily and Weekly 1.48 .441 1, 104 .523 46.7 
Monthly or Less 1.46     
Alcohol Use      
Daily and Weekly 1.50 1.86 1, 112 .176 32.3 
Monthly or Less 1.45     
Binge Drinking      
Daily and Weekly 1.51 1.68 1, 112 .198 25.8 
Monthly or Less 1.45     
E-cigarette Use      
Daily, Weekly and Monthly 1.50 1.12 1, 112 .292 19.4 
Less than Monthly 1.45     
 
 204 
Benzodiazepine Use      
Daily, Weekly and Monthly 1.59 5.66 1, 112 .019* 19.4 
Less than Monthly 1.45     
Methamphetamine Use      
Daily, Weekly and Monthly 1.57 1.95 1, 112 .166 6.5 
Less than Monthly 1.45     
Solvent Use      
Daily, Weekly and Monthly 1.56 8.01 1, 112 .006* 32.3 
Less than Monthly 1.43     
 
 
Table 6.5 Patterns of Cannabis Use and Psychotic-Like Experiences 
 
Mean 
Scores  F df
1, df2 p Prevalence PLE’s (%) 
Frequent vs. Non-
Frequent 
     
Frequent Use 1.50 5.68 1, 112 .019* 30.3 
Non-Frequent Use 1.41    22.9 
Quantity of Use      
Two or more 1.52 7.70 1, 112 .007* 31.5 
Less than one or one 1.42    23.3 
Routes of Administration      
Bong or water pipe 1.44 .94 1, 112 .334 23.2 
Any Other 1.49    33.3 
Type of Cannabis      
Skunk 1.44 2.88 1, 112 .093 21.7 
Herbal or Hash 1.51    41.9 
Age of Onset of Cannabis 
Use 
     
9 to 14 1.48 1.86 1,112 .175 26 





6.5.6. Independent Associations between Different Patterns of Cannabis Use 
and Psychotic-Like Experiences 
Analyses were conducted to identify associations between different measures of 
cannabis use and psychotic-like experiences. Analyses of variance were conducted to 
identify differences in mean scores of the psychotic-like experiences questionnaire and 
different patterns of cannabis use. Analyses indicated statistically significant differences 
between psychotic-like experiences and frequent cannabis use (every day or almost 
daily) (F=5.68, df=1, 112, p=.019) and using two or more joints on any typical occasion 
(F=7.70, df=1, 112, p=.007)  compared with non-frequent users (from weekly to only 
tried it once)  and participants using less than one or one joint on a typical occasion. 
Further analyses were conducted to identify if age of onset of cannabis use was 
significantly associated with age of onset of psychotic-like experiences. Results showed 
a significant association between age of onset, indicating that participants who starting 
using cannabis at an earlier age, reported earlier onset of psychotic-like experiences 
(F=2.25, df=8, 96; p=,030) compared to participants reporting later onset of cannabis 
use.  
 
 B SE p 
QFSA .003  .002 .104 
Age -.02  .01 .247 
Gender .01  .05 .872 
Ethnicity .04  .02 .074 
Socioeconomic Leve .00  .01 .746 
At Least Weekly Tobacco Use .01  .04 .768 
At Least Weekly Binge Drinking .01  .05 .891 
At Least Monthly Benzodiazepine Use .14  .07 .039* 
At Least Monthly Solvent Use .06  .05 .222 
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Table 6.6 Cannabis Use and Psychotic-Like Experiences 
*QFSA: Quantity by frequency scale any type of cannabis.  
 
Table 6.7 Type of Cannabis and Psychotic-Like Experiences 
 OR 95%CI p 
Type of Cannabis .24 .08-.73) .011* 
Age .96 .69-1.36 .832 
Gender 1.36 .32-5.86 .680 
Ethnicity 1.42 .80-2.52 .235 
Socioeconomic Leve .84 .63-1.13 .247 
At Least Weekly Tobacco Use .37 .13-1.02 .055 
At Least Weekly Binge Drinking .95 .29-3.08 .927 
At Least Monthly Benzodiazepine Use 4.07 .88-18.93 .073 
At Least Monthly Solvent Use 2.76 .83-9.20 .099 
6.5.7. Associations between Cannabis Use and Psychotic-Like Experiences 
Controlling for Sociodemographic Characteristics and Use of Other Drugs 
Multiple linear regression analysis including the total scores of the PRIME as outcome 
and the quantity by frequency scale of any type of cannabis used as main predictor were 
conducted. No significant associations were found between the total score of the 
psychotic-like experiences assessment and the total score of the quantity by frequency 
scale of cannabis use. However, associations remained significant between daily, 
weekly and monthly use of benzodiazepines and psychotic-like experiences after 
controlling for sociodemographic characteristics and use of other drugs (B=.14, SE=.07; 
p=.035), indicating that participants reporting daily, weekly or monthly use of 
benzodiazepines were more likely to have higher mean scores in the psychotic-like 





Furthermore, when including type of cannabis as main predictor, significant 
associations were found between a positive score in the psychotic-like experiences 
questionnaire and type of cannabis (OR=.24, 95%CI=.08-.73, p=.011), indicate that 
participants reporting herbal cannabis as the main type used, were more likely to have a 
positive score in the PRIME Screen Questionnaire than participants reporting skunk. 
 
 
6.6. Summary  
Overall, mean age of cannabis use onset was (13.8). Skunk-type cannabis was the most 
reported type in the clinical sample (72.8%) compared to herbal-type cannabis (25.4%). 
Results derived from these analyses were not expected. Firstly, it was expected that 
frequent cannabis use, heavy cannabis use, skunk-type cannabis use and the total score 
of the quantity by frequency scale of cannabis use were significantly associated with 
psychotic-like experiences before and after controlling for sociodemographic 
characteristics and use of other drugs.  
 
However, these associations were not found. Initially, frequent cannabis use was 
significantly associated with the total score of the PRIME Screen Questionnaire, 
nevertheless in the first stepwise model fitted, where frequent cannabis use was 
included as the main predictor, followed by sociodemographic characteristics and then, 
by use of other drugs, with the dichotomous measure of the psychotic-like experiences 
assessment as outcome, this association did not remain significant. These results were 
not anticipated, as previous research has shown that increased frequency of cannabis use 
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is strongly linked to the presence psychotic-like experiences (Fergusson et al., 2003; 
Mustonen, Niemela, et al., 2018). Similarly, quantity was, initially, significantly 
associated with psychotic-like experiences when analysed separately, however once the 
model was fitted this association was no longer significant.  
 
Furthermore, there was a significant association between herbal-type of cannabis and 
psychotic-like experiences, before and after controlling for sociodemographic 
characteristics and use of other drugs. This result contradicts previous research 
regarding type cannabis mainly being used and an increased risk of psychosis (Di Forti 
et al., 2009). In the final model, where the QFSA was included as the main predictor, in 
the first block of the stepwise model, before all other variables were included, there was 
a significant association between the QFSA and the total score of the PRIME Screen 
Questionnaire. However, this association did not remain significant when all the 
variables were included. In this linear model the only variable that remained 
significantly associated with psychotic-like experiences while controlling for 
sociodemographic factors and use of other drugs was frequent use of benzodiazepines.  
 
One important thing to mention that from the whole sample, only 29 participants 
reported using ‘herbal’ type cannabis. This reduces statistical power as the sample size 
of herbal cannabis users is smaller than participants reporting ‘skunk’ type cannabis, 
with 83 participants reporting use of this type of cannabis. There are significant 
differences between the present study and previous research that may account for these 
results. Firstly, most studies have been conducted in different clinical populations, e.g. 
subjects presenting with a first psychotic-episode (Di Forti et al., 2009). Few studies 
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have been done in adolescents as shown in Chapter 1 and fewer in substance misuse 
clinical samples (Hodgins et al., 2016). Similar studies, to the best of my knowledge, 
have never been conducted in Mexico and, furthermore, there is no research regarding 
different types of cannabis available in Mexico. This is a major limitation as it is 
difficult to estimate the potency of cannabis in the country and to what extent herbal 
cannabis is low potency or if its potency is higher than the average of potency in herbal 





7. Discussion  
7.1. Introduction 
In the final chapter, a discussion of the results will be presented, along with different 
hypotheses which will attempt to explain the results obtained in the present study. 
Overall, results were unexpected and, in some ways, contradictory to what has been 
previously found in similar studies. Results from the systematic review conducted are 
used to compare and contrast the findings of the present study to what has been 
previously found. An in-depth examination of the methodology and results of these 
studies is presented to identify how the present study may differ from previous research.  
 
Additional results from both samples are summarised to better understand patterns of 
cannabis use and psychotic-like experiences and to identify associations with covariates. 
This is considered relevant as, although there were no associations between cannabis 
and psychotic-like experiences found, other associations were identified. And although 
these were not part of the main objectives of this project, it is important to consider 
them for future research, prevention and public policies. Lastly, implications for future 
research are discussed, with focus on the different outcomes obtained from the study. 
Implications of findings for public policies are suggested and recommendations are 




7.2.  Summary of Findings: Cannabis Use and Psychotic-Like Experiences 
No associations were found between different patterns of cannabis use and psychotic-
like experiences in the adolescent student sample. Not when associations were looked at 
independently, nor when full adjusted models were conducted with different patterns 
and measures of cannabis use as main predictor, psychotic-like experiences as main 
outcome and sociodemographic characteristics and use of other drugs as covariates 
(Table 7.1). 
 
On the other hand, in the adolescent substance misuse clinical sample significant 
differences were found in the total score of the PRIME Screen Questionnaire and 
frequent vs. no frequent cannabis use. Quantity of use was also significantly associated 
with psychotic-like experiences, with higher mean scores in participants reporting use 
of two or more joints on any typical occasion compared to participants reporting one or 
less than one joint. However, these associations disappeared once sociodemographic 
characteristics and use of other drugs were included in the full adjusted model (Table 
7.1). Moreover, in the substance misuse clinical sample, type of cannabis used was 
significantly associated with the psychotic-like experiences questionnaire, when 
examined independently and after controlling for all other confounding variables and 
covariates. However, the association that remained was negative, which indicates that 
herbal-type cannabis users were more likely to obtain a positive score in the PRIME 
Screen Questionnaire than participants using skunk-type cannabis. These results are 





Analyses were conducted in the substance misuse clinical sample to identify 
associations between age of onset of cannabis use and age of onset of psychotic-like 
experiences. Results showed that participants with earlier onset of cannabis had earlier 
onset of psychotic-like experiences. This result supports previous studies which have 
found that early onset of cannabis use might impact on an earlier onset of psychotic-like 
experiences or first episode psychosis (Bagot et al., 2015; Di Forti et al., 2014). 
However, one of the studies referred to previously, was conducted in a sample of 
patients presenting for first episode psychosis, which differs from the clinical sample in 
the present study; therefore, comparisons should be made with caution. Table 7.1 show 
variables included in the adjusted model and if a significant association was found.  
 
Due to the unexpectedness of the results obtained, a number of different hypothesis are 
provided to attempt to explain why the difference between results in present study 
compared to previous studies which examined the association between cannabis use and 






Table 7.1 Significant Associations between Cannabis Use and Psychotic-Like 
Experiences in Adjusted Models  
A=Associations; (-)=no association; (+)=positive association;  
*Association with herbal-type cannabis   
Student Sample Substance Misuse Clinical Sample 
Cannabis Use A Cannabis Use A 
Lifetime (-) Frequent (-) 
Monthly (-) Heavy (-) 
Type (-) Type* (+) 
QFSA (-) QFSA (-) 
Sociodemographic Characteristics  Sociodemographic Characteristics  
Age (-) Age (-) 
Gender (-) Gender (-) 
Ethnicity (-) Ethnicity (-) 
Socioeconomic Level (-) Socioeconomic Level (-) 
Use of Other Drugs: Lifetime  Use of Other Drugs: Frequent  
Tobacco (-) Tobacco (-) 
E-cigarettes (-) Binge Drinking (-) 
Alcohol (-) Benzodiazepines  (+) 
Binge Drinking (-) Solvents (-) 
Illicit Drugs (+)   
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7.3. Differences in Patterns of Use and Type of Cannabis 
7.3.1. Prevalence of Lifetime and Frequent Cannabis Use 
One hypothesis which might serve as explanation to the results obtained in the 
adolescent student sample is that lifetime prevalence of cannabis use is not as high as 
prevalence of use reported in previous studies. Results in the present study showed a 
lifetime prevalence of cannabis use of 29.6% in the adolescent student sample. Below, a 
table with studies previously conducted in an adolescent population which examined the 
associations between cannabis use and psychotic-like experiences is presented; 
alongside, prevalence of lifetime cannabis use can be observed.  
 
As shown in Error! Reference source not found. prevalence of lifetime cannabis use 
in the adolescent student sample of present study is not markedly lower than lifetime 
prevalence reported in previous studies. Around a third of the studies reported a similar 
lifetime prevalence of use. Furthermore, when examining prevalence of lifetime 
cannabis use and the association between cannabis use and psychotic-like experiences 
in those studies, it was found that some studies which reported lower prevalence of use 
did find a significant association (Henquet et al., 2005; Stefanis et al., 2004; van Gastel 
et al., 2012). Therefore, differences in prevalence of lifetime cannabis use between the 
present study and previous research cannot serve as a plausible explanation for the 
results obtained regarding the lack of association between cannabis use and psychotic-





An additional hypothesis regarding patterns of cannabis use is that frequency of use 
may have been lower than in previous studies. To examine this hypothesis Error! 
Reference source not found. describes the definition and prevalence of frequent 
cannabis use in each of the studies reported in the systematic review. In the present 
study, frequent use (monthly to daily use) among lifetime cannabis users was reported 
by 33.3%; and by 10.7% in all the adolescent student sample.  
 
Overall, frequency of cannabis use among previous studies is not noticeably different 
compared to the frequency of use reported in the present study; and in comparison to 
some of the studies presented (Arseneault et al., 2002; Miettunen et al., 2018; Miettunen 
et al., 2008), frequency of use in this adolescent sample was higher. Nevertheless, these 
studies did find an association between cannabis use and psychotic-like experiences. 
Therefore, the lack of association between cannabis use and psychotic-like experiences 
could not be explained either from a low prevalence of lifetime or frequency of cannabis 
use. 
 
However, sample size is something to be considered. In the present study, power 
analyses were conducted to ensure that the sample size recruited could detect an 
association between cannabis use and psychotic-like experiences. Nevertheless, these 
analyses were conducted with data extracted from studies that had been conducted in 
western countries and with larger samples. As discussed below, cultural differences 




7.3.2. Preferred Method of Use by Country 
Another hypothesis to account for results obtained, is that the preferred method of 
cannabis use in Mexico is different from the preferred method of use in countries where 
previous studies have been conducted. Most studies have been conducted in countries 
where cannabis is mainly smoked with tobacco (Gage et al., 2014; Jones et al., 2018; 
Mackie et al., 2013), however this is not how cannabis is mainly used in Mexico. The 
most prevalent method of use reported in the present study was via water pipe or bong, 
with 53.1% of participants reporting this as their preferred method of use and 20.3% in 
a joint without tobacco in the student sample. Similar to this, 60.5% of participants in 
the clinical sample reported water pipe or bong as their preferred method of use, 
followed by 30.7% in a joint without tobacco.  
 
Previous research has shown that in Mexico and the United States of America, water 
pipe and/or bong are the most prevalent method of use among cannabis users and it is 
mainly used without tobacco (Hindocha et al., 2016). This is an outstanding difference, 
and one that could help in the understanding of the results obtained as tobacco has been 
associated with psychotic-like experiences and psychotic disorders, such as 
schizophrenia (Gurillo, Jauhar, Murray, & MacCabe, 2015). The direction of the 
association is still in debate, however there is a considerable amount of research in this 
area which undoubtedly show that there is an association between tobacco use and 
different spectrum of psychosis (Gurillo et al., 2015).  
 
Error! Reference source not found. lists the different countries where studies 
examining the association between cannabis use and psychotic-like experiences in 
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adolescents have been conducted and the most prevalent method of cannabis used. From 
the twenty-seven studies included in the systematic review, only eight studies were 
conducted in countries where, similar to Mexico, cannabis is used without tobacco: 
New Zealand, United States of America and Canada (Anglin et al., 2012; Arseneault et 
al., 2002; Bechtold et al., 2016; Bourque et al., 2016; Fergusson et al., 2003; Jones et 
al., 2017; Leadbeater et al., 2019; Levy & Weitzman, 2019). 
 
A study recently conducted in the United States which examined the association 
between cannabis use and “psychosis spectrum” found that once confounds were 
adjusted for, cannabis use by itself was not significantly associated with an increase of 
being classified as part of the psychosis spectrum (Jones et al., 2017), however, the 
combination of tobacco and cannabis use was. Furthermore, one study conducted in the 
United Kingdom, a country where cannabis is mainly used with tobacco, examined the 
associations between cannabis use, cigarette use and psychotic-like experiences. Results 
showed that in the adjusted model, with cannabis use as main predictor and psychotic-
like experiences as outcome, the association between cannabis use with psychotic-like 
experiences decreased when controlling for frequency of cigarette use and use of other 
drugs and was no longer significant. However, when the model included cigarette use as 
main predictor and cannabis use was controlled for, even when the association dropped, 
cigarette use and psychotic-like experiences remained significantly associated (Gage et 
al., 2014).  
 
It can be observed in Table 7.2 that most studies did not find the same results. A large 
variability among studies and findings can be observed. Moreover, each study assessed 
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cannabis use and psychotic-like experiences outcome differently, which may account 
for the differences in findings. Might be of interest to develop and structure a 
standardised single measure of cannabis use, similar to the one we currently have for 
alcohol use. Similarly, structuring or coming to an agreement of using one specific 
measure of psychotic-like experiences or psychotic outcome could help to homologise 
methodology and findings.  
 
These studies could help to explain the unexpected results obtained. Both were 
conducted in adolescents and both examined the same associations assessed in the 
present study. Particularly when taking into account the results summarised in the 
section of “Additional Findings”, it can be observed that one of the only significant 
associations that remained with psychotic-like experiences, with all different measures 
of cannabis use as main predictor in the fully adjusted model in the student sample was 
with tobacco use.  
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Table 7.2 Studies included in Systematic Review: Cannabis Use and Psychotic-Like Experiences in Adolescents 
+ (Positive) Association: A=Any cannabis use, E=Early onset, C=Cumulative Use; Other drug use is marked with and X if included as a covariate
Author, Year & Country Prevalence Cannabis Use Method of Use + Association Other Drugs 
 Lifetime Frequent/Heavy  A E C  
Arseneault et al. 2002, New Zealand 31.3% 3.8% Joint / bong with tobacco - X - X 
Fergusson et al. 2003, New Zealand 10% 10% Joint / bong with tobacco - - X X 
Stefanis et al. 2004, Greece 4.9% 1.5% NR X X X X 
Henquet et al. 2005, Germany 13.1% NR Joint with tobacco X - X X 
Ferdinand et al. 2005, Netherlands 23.3% NR Joint with tobacco X - - - 
Konings et al. 2008, Trinidad y Tobago 21% 10% NR - X - X 
Miettunen et al. 2008, Finland 5.6% 0.9% NR X - X X 
Hides et al. 2009, Australia 9.5% 2.2% Bong / joint with tobacco - - X X 
Kuepper et al. 2011, Germany 13% 28% Joint with tobacco X - X X 
Schubart et al. 2011, Netherlands 66% 25% Joint with tobacco X X - - 
Roessler et al. 2011, Switzerland NR NR Joint with tobacco X - - X 
Van Gastel et al. 2011, Netherlands 14% 1.5% Joint with tobacco X - - - 
Anglin et al. 2012, USA 70% 17.1% Pipe / bong without tobacco - X - X 
Griffith-Lendering et al. 2012, Netherlands 5.8% 1.3% Joint with tobacco X - - - 
Mackie et al. 2013, UK 25% 11% Joint with tobacco X - - - 
Gage et al. 2014, UK 27.4% 3.3% Joint with tobacco - - - X 
Bechtold et al. 2016, USA NR 27% Pipe / bong without tobacco - - X X 
Bourque et al. 2017, Canada 8.9% NR Joint / pipe without tobacco - - X - 
Jones et al. 2017, USA 28% 5% Pipe / bong without tobacco - - - - 
Shevlin et al. 2017, Denmark 31.6% NR Joint with tobacco - - - X 
Jones et al. 2018, UK NR NR Joint with tobacco X X - - 
Mustonen et al. 2018, Finland 5.7% 1% NR - - X X 
Albertella et al. 2018, Australia 35% 13% Bong / joint with tobacco - X X X 
Leadbeater et al. 2018, Canada & USA 36% 10% Pipe/ bong/ joint without tobacco - - X - 
Bernardini et al. 2018, Brussels 46.3% 35% Joint with tobacco X - - - 
Levy et al. 2019, USA 52.1% 47.9% Pipe / bong without tobacco X - - - 
Fonseca-Pedrero et al. 2019, Spain 23.7% 6.5% Joint with tobacco - - - - 
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7.3.3. Cumulative and Early Onset of Cannabis Use 
One of the main findings that research has shown when examining cannabis use and 
psychotic-like experiences is that early onset is an important factor that strengthens the 
association when found. And similarly, this has been shown with cumulative use, with 
studies showing that there is a linear association where for every increase in cannabis 
use there is an increase in risk of psychotic-like experiences.  
 
Some studies included in the systematic review found that the association between 
cannabis use and psychotic-like experiences, was limited to either earlier onset of 
cannabis use, with later onset not associated, or to cumulative and persistent use. Three 
studies found the association when cannabis use was early onset, and in seven the 
association only remained with cumulative use of cannabis (see Error! Reference 
source not found.).  
 
These results confirm the cumulative hypothesis, where research has shown that risk of 
presenting psychotic-like experiences increases linearly with the quantity and frequency 
of cannabis use (Bourque et al., 2016; Henquet et al., 2005; Miettunen et al., 2008; 
Mustonen, Niemela, et al., 2018; van Gastel et al., 2012). Furthermore, as the present 




7.3.4. Type of Cannabis 
Another unexpected finding was the association between herbal-type cannabis and 
psychotic-like experiences in the fully adjusted model in the adolescent substance 
misuse clinical sample. Given that there has been no research into cannabis potency in 
Mexico, it is very difficult to know accurately if what participants identified as ‘herbal’ 
is really low potency cannabis.  
 
Research has shown that different types of cannabis confer different level of risk of 
reporting psychotic-like experiences. Normally, skunk-type cannabis or cannabis with 
high levels of THC has the highest risk of presenting PLE’s. (Di Forti et al., 2015). 
Furthermore, experimental studies have continuously showed that THC increases acute 
levels of psychotic-symptoms (D'Souza et al., 2004; Morgan & Curran, 2008; Morgan 
et al., 2018) and produces psychomimetic-like experiences.  
 
This is why it is so unexpected and difficult to explain this particular result. A possible 
explanation could be that the type of cannabis participants use looks similar to the 
pictures provided, but that does not necessarily mean that that type of cannabis is low 
potency. The present study was designed considering previous research conducted in 
Europe and the US where ‘herbal cannabis’ or ‘grass’ is low potency, however, without 
research on cannabis potency in Mexico, it is difficult to accurately estimate the content 





7.4. Inclusion of Covariates and False Positives 
Another possible explanation for the results obtained in the present study is that the 
adjustment of all the covariates included attenuated the strength of the association. 
Some studies have initially found a significant association between cannabis use and 
psychotic-like experiences; however, once adjustments were made to the final models 
these associations disappeared or significantly attenuated. The variable which produced 
the most amount of attenuation was use of other illicit drugs. 
 
For instance, a study where lifetime cannabis use was associated with lifetime 
psychotic-like experiences, there was no control for confounding variables, e.g. use of 
other drugs (Ferdinand et al., 2005). Similarly, another study conducted in the 
Netherlands, found that amount of cannabis was associated with psychotic experiences, 
with higher amounts showing higher risk of scoring in the highest 10% of the psychotic-
like experiences assessment, however no adjustment for use of other drugs was made in 
the complete sample (Schubart et al., 2011).  
 
Moreover, a study recently conducted found no evidence of association between 
cannabis use alone and psychotic-like experiences after adjusting for confounding 
factors. Researcher found that it was the interaction of cannabis with other drugs that 
conferred significant risk for psychotic-like experiences results (Jones et al., 2017). 
 
Twelve studies included in the systematic review did not control for use of other illicit 
drugs. Of those studies most found a significant association between cannabis use and 
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psychotic-like experiences (Error! Reference source not found.). It has been shown 
that when use of other illicit drugs is controlled for, the association tends to decrease. 
Possibly, one of the reasons all these studies did find a significant association is because 
they did not take into account use of other illicit drugs when conducting the analyses. 
This could explain why in the present study, no association between cannabis and 
psychotic-like experiences was found.  
 
On the other hand there have been studies that did control for use of other drugs and still 
found a significant association between cannabis use and psychotic-like experiences 
(Henquet et al., 2005; Kuepper et al., 2011; Mackie et al., 2013; Miettunen et al., 2008; 
Rossler et al., 2007; Stefanis et al., 2004). When studies have reported adjustment for 
use of other illicit drugs, the association between cannabis use and psychotic-like 
experiences tends to attenuate. This can be observed in Error! Reference source not 
found., where is shown that in only five studies that did control for use of other drugs 
found a significant association between any use of cannabis and psychotic-like 
experiences.  
 
7.5. Are unexpected results due to cultural differences in prevalence or 
understanding of psychotic-like experiences in Mexico? 
Another possible explanation for the unexpected results may due to cultural differences. 
Most of the previous research has been conducted in countries culturally different from 
Mexico, mainly in Europe and the United States. It is possible that prevalence of 
psychotic-like experiences differs in Mexico compared to other countries and that the 
understanding of these experiences’ changes across different cultures.  
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For example, there are certain beliefs and cultural traditions in Mexico which differ 
significantly from Western countries, e.g. ‘Day of the Death’. Were it is believed that 
once a year, people who have died come to visit and an offering is set for them, 
including food, sweets and personal belongings of the ones who have died. This might 
seem to some degree delusional to other cultures, however it is a tradition that has 
remained in Mexico for centuries. The flexibility or openness in these ideas might 
increase in traditional western assessments the prevalence of psychotic-like experiences 
among the Mexican population. Therefore, a comparison on prevalence of psychotic-
like experiences in this study and in other countries is made.  
 
Prevalence of psychotic-like experiences in the school sample was 20.4%, this was in 
line with previous international research, where it has been found that prevalence of 
psychotic-like experiences in the general population is of approximately 20% (Kelleher 
et al., 2012; van Os et al., 2009). Prevalence of psychotic- like experiences in the 
substance misuse clinical sample was 27.2%, higher than in the school sample, 
nevertheless expected. However, as shown above, prevalence of psychotic-like 
experiences in the student sample was not higher that what has been found in previous 
results, therefore it is unlikely that the unexpected results were due to cultural 
differences and perceptions on psychotic-like experiences. Furthermore, the reliability 
analyses conducted to the PRIME Screen Questionnaire support that the Spanish 
version used in the study is reliable. As previously mentioned, prevalence of psychotic-
like experiences in the clinical sample was notably higher, however, this could easily be 




7.6. Additional Findings 
7.6.1. Sample Characteristics 
7.6.1.1. Adolescent Student Sample 
The mean age of the school sample was 16.51 (SD =1.05) and the median 17. The 
response rate of the school sample was 95% as students were happy to participate. 
Regarding ethnicity, participants mainly indicated Hispanic or Latin as their ethnicity 
with 60.2% identifying themselves in this category, followed by African-Descent with 
25.3%, followed by 6.5% as Caucasian and 6% as Other. Regarding socioeconomic 
level in the school sample 62% scored as being part of level C+/C/C-, followed by 
21.9% in level D+/D/E and 16% in socioeconomic level A/B. 
 
Higher prevalence of lifetime cannabis use was observed among participants in 
socioeconomic level A/B and although these differences are not statistically significant, 
it is noteworthy to mention that these results are not the norm, with previous research 
indicating that populations in lower socioeconomic levels usually have higher 
prevalence of drug use than populations in higher socioeconomic levels (Daniel et al., 
2009). Furthermore, participants in higher socioeconomic levels were more likely to use 
cannabis more frequently than participants in lower socioeconomic levels. Different 
reports that have been referenced to in the present study describe numerous data, the 
manuscript even report having included a socioeconomic questionnaire in the survey, 
however, there were no data reported regarding these associations. To the best of my 





7.6.1.2. Adolescent Substance Misuse Clinical Sample 
A total of 114 adolescents aged from 13 to 21-years old completed the questionnaires in 
the clinical sample. Mean age was 16.56 (SD=1.58). A total of 85% (N=96) of 
participants were male and 15% (N=17) were female. The response rate of the clinical 
sample was higher than the school sample; 90% of clinic attendees referred to the study 
consented to participate in the study. Almost half of the sample identified themselves as 
Hispanic or Latin (48.7%), followed by Africa Descent with 24.3% and 20% as 
Caucasian. Five-point two percent identified themselves as being part of ‘Other’ 
ethnicity. More than half of participants scored in socioeconomic level C+/C/C- 
(51.3%), 32.2% in D+/D/E and 16.5% in level A/B. 
 
7.6.2.  What other factors were associated with cannabis use?  
7.6.2.1. Adolescent Student Sample 
Significant association were found between the total score of the QFSA and lifetime 
tobacco use, lifetime e-cigarette use, lifetime binge drinking and lifetime use of illicit 
drugs independently of sociodemographic characteristics and use of other drugs. 
Furthermore, participants reporting lifetime use of cannabis were more likely to be 
male, binge drink, use tobacco, e-cigarettes and other illicit drugs than non-lifetime 
cannabis users. Additionally, at least monthly cannabis use was associated with gender, 
socioeconomic level, lifetime use of e-cigarettes and lifetime use of any illicit drug. 
Indicating that males were two times more likely than women to report at least monthly 
cannabis use. Participants with higher socioeconomic status had higher prevalence of 
monthly cannabis use than participants from lower socioeconomic status. Furthermore, 
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monthly users were two times more likely to report e-cigarette use and seven times 
more likely to have experimented with any illicit drug in their lifetime.  
 
Significant associations were found between participants using skunk-type cannabis and 
gender, tobacco, binge drinking and other drugs compared with non-users. Furthermore, 
when examining associations between skunk type cannabis users vs. users of any other 
type of cannabis, analyses showed significant associations between skunk users, gender 
and use of any illicit drugs. These results support previous research that suggest that 
cannabis users are more likely to use other drugs (Hall, 2016). A comprehensive review 
recently conducted, numbered three possible explanations for this association: cannabis 
users have more opportunities to obtain other illicit drugs from where they buy the 
illegal cannabis, the earlier onset of cannabis use makes the probability of use of other 
drugs more likely or that the pharmacological effects of cannabis makes users more 
prone to use other illicit drugs (Hall et al., 2019). 
 
7.6.2.2. Adolescent Substance Misuse Clinical Sample 
There was one significant association between frequent cannabis use and frequent use of 
methamphetamines compared to non-frequent cannabis users, indicating that all 
participants that reported frequent use of methamphetamines were using cannabis daily. 
Participants reporting high quantities of cannabis use were more likely to report 
frequent use of methamphetamines and solvents. Moreover, type of cannabis was 





7.6.3.  What other factors were associated with psychotic like experiences? 
Although no associations were found between cannabis use and psychotic-like 
experiences once models were adjusted, results showed associations between psychotic-
like experiences and use of other drugs. In the student sample, lifetime tobacco use, e-
cigarettes and use of illicit drugs were continuously associated with either higher levels 
in the total score of the PRIME. 
 
Furthermore, in the substance misuse clinical sample, psychotic-like experiences were 
significantly associated with frequent use of benzodiazepines, and solvents. 
Benzodiazepines were referred in the questionnaire as tranquillisers, which is the term 
most widely used in Spanish to refer to benzodiazepines. It would be of interest to know 
if participants were in fact using benzodiazepines and not anti-psychotic medication or 
other type of prescriptions. If they were in fact using benzodiazepines it would be of 
interest to know the reason participants were prescribed this medication, as it could be 
that they have a more complex diagnose of other mental health problems apart from 






Table 7.3 Associations with Psychotic-Like Experiences 
Student Sample Substance Misuse Clinical Sample 
Sociodemographic Characteristics  Sociodemographic Characteristics  
Age - Age - 
Gender - Gender - 
Ethnicity - Ethnicity - 
Socioeconomic Level - Socioeconomic Level - 
Use of Other Drugs: Lifetime  Use of Other Drugs: Frequent  
Tobacco + Tobacco - 
E-cigarettes + E-cigarettes - 
Alcohol - Alcohol - 
Binge Drinking - Binge Drinking - 
Illicit Drugs + Benzodiazepines  + 
  Methamphetamines - 
  Solvents + 
 
Results are consistent with previous studies that have found a significant association 
between psychosis and tobacco use (Gurillo et al., 2015). Research around psychosis 
and tobacco use has been of interest for many decades, showing that there is a 
significant association between schizophrenia and tobacco use, and that this association 
is stronger than with other menta health disorders, e.g. mood disorders (de Leon & 
Diaz, 2005). The possible mechanisms for tobacco being related to psychosis are 
several. Initially it was thought that patients were self-medicating, from negative 
symptoms (Dalack, 1998), to improve cognitive processes or through antipsychotic side 
effects of smoking (Quigley & MacCabe, 2019). However, recently different 
hypotheses have been suggested, e.g. shared liability, confounding factors or causal 
relationship (Quigley & MacCabe, 2019). The association has not been completely 
understood, but further research in the field continue to prove the existence of this 
association (de Leon & Diaz, 2005). There were no studies found regarding e-cigarette 
use and psychosis, however, considering that there has been research around nicotine 
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and psychosis, this could only confirm that what could be a risk factor in the 
development of psychotic-like experiences is nicotine (Quigley & MacCabe, 2019).  
 
Furthermore, illicit substance use has been shown to increase prevalence of psychotic-
like experiences (Barkus & Murray, 2010; Miettunen et al., 2018). Recently a study 
conducted in Finland found that solvent use was independently associated with 
psychosis in adolescents, with 80% of participants using solvents being diagnosed with 
psychosis (Mustonen, Niemelä, et al., 2018). Solvent use in Mexico started to decline 
after a prolonged period of time where use was increasing (Villatoro, 2017). Findings 
from the present study suggest that efforts should be made to continue with prevention 
strategies around awareness of drug use during adolescence and adverse consequences, 
e.g. psychotic-like experiences; particularly when considering that in some cases 
subclinical psychotic-like experiences can be associated with a later clinical diagnosis 
of psychotic illness. A study conducted in the Netherlands found that, psychotic-like 
experiences when combined with environmental exposures, can result in abnormal 
persistence of psychotic-like experiences (Cougnard et al., 2007).    
 
7.7. Implications for Future Research 
Findings from the present study have demonstrated a gap in knowledge regarding 
cannabis use and psychotic-like experiences in adolescents, particularly around type of 
cannabis used and potency. Research assessing levels of THC in cannabis and 
psychotic-like experiences has continuously found (Di Forti et al., 2015; Di Forti et al., 
2009; Di Forti et al., 2019; Di Forti et al., 2014; Morgan & Curran, 2008; Morgan et al., 
2012) that high-potency cannabis use increases the risk for psychosis. However, studies 
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that have been conducted in adolescents have not assessed type of cannabis used until 
now. It is relevant to determine if the association found in adults between high-potency 
cannabis use and psychotic-like experiences replicates in adolescent population, 
particularly with the increase of cannabis legalisation, for medicinal and recreational use 
(Hall et al., 2019).  
 
This is the first study conducted in Mexico that examined the association between 
cannabis use and psychotic-like experiences. Furthermore, it is the first one to assess 
type of cannabis used. This highlighted the importance of conducting further research as 
there is little understanding and education around cannabis. When conducting data 
collection, one particular thing that drew my attention was that, even when adolescents 
did know about different types of cannabis, most of the adult population, who supported 
me during data collection, did not. Most of them were clinicians working in substance 
misuse treatment services and teachers in middle schools. Moreover, it was not a factor 
to be considered when entering treatment, in the case of the substance misuse clinical 
sample. Cannabis was simply identified as cannabis, without regard of potency and how 
this could be impacting the adolescent’s mental health.  
 
Most research conducted in Mexico in substance use has been of epidemiological nature 
and, unfortunately results are limited to publications in government reports (Villatoro et 
al., 2012). There is not wide dissemination of scientific research, and unless there is a 
particular interest in the topic, data is hardly disseminated to the general population. 
More research has to be conducted around substance use and, particularly in mental 
health. During the development of this study I continuously searched for publications 
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addressing mental health in adolescents in Mexico and nothing was found. Not even 
government document that stated prevalence of mental health problems in adults or 
adolescents.  
 
As show in Chapter 1, there is an increasing prevalence of cannabis use among the 
adolescent population and is important to understand the effects of cannabis use in 
Mexican population. Research around prevalence of cannabis use is not sufficient, there 
is an urgent need for updated knowledge around substance use and mental health, which 
unfortunately, is not a priority. Despite substance use being a matter of public health 
concern in the country, there has not been much research conducted in Mexico. 
Undoubtedly, it is more a matter of lack of funding from the government to research, 
than a lack of interest from researchers in the country. Further exploration on the 
association between cannabis use and psychotic-like experiences in suggested. 
However, a longitudinal design may be more informative of the association alongside 
assessment of mental health problems. A more comprehensive assessment of 
psychopathology, childhood trauma and family history of mental health problems. 
Assessment at different time points alongside biological measures.   
 
7.8. Public Health and Policy Implications 
7.8.1.  Public Health: Prevention 
Findings show cannabis use among the adolescent student sample is significantly 
associated with use of other drugs, and that, similarly, psychotic-like experiences are 
significantly associated with use of other drugs. Overall, age of onset of cannabis use is 
prior to onset of use of illicit drugs, and the use of cannabis might be a risk factor for 
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the onset of use of other drugs. As previously mentioned, illicit drug use is linked with 
psychotic-like experiences, therefore, it is important to design prevention strategies to 
reduce use of illicit drugs in the adolescent population. However, prevention should 
come from early stages, and education around drug use might help, however, research 
has shown that there are other factors that may have a more significant impact in 
preventing drug use (Wills, Ainette, Stoolmiller, Gibbons, & Shinar, 2008) for example, 
an enhanced ability to solve problems and planned ahead. Cannabis use might not 
represent a feasible target for psychosis prevention by itself. As previously discussed, 
psychosis is an illness with no determined ethology. There are a number of risk factors 
that could influence the development of psychosis. A successful prevention strategy 
should include different targets rather than just a specific one, in this case cannabis and 
other drug use. 
 
For example, the Icelandic Model of Adolescent Substance Use Prevention is one of the 
most effective programmes in place, it has been developed from an evidence based 
perspective and it comprises a much broader scope than only substance use education, 
e.g. family and community involvement (Sigfúsdóttir, Thorlindsson, Kristjánsson, Roe, 
& Allegrante, 2009). Prevalence of daily tobacco use, past month alcohol and lifetime 
use of hashish declined almost 50% in 10 after the implementation of the prevention 
programme (Sigfusdottir, Kristjansson, Thorlindsson, & Allegrante, 2008).   
 
There are strategies in place reported by the government in Mexico and, from what it 
has been found, it is a priority that is being addressed from the start of the new 
government (Sanchez Guerrero, 2019). These strategies intend to standardize actions 
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conducted by all different federal entities and councils. However, the government report 
cited was published in 2019, before it was made public the intention to pass a legislation 
to regulate cannabis and there is nothing regarding this matter in the document (Sanchez 
Guerrero, 2019).   
 
7.8.2.  Policy Implications 
In January 2020 the Mexican Senate informed that a new legislation to legalise and 
regulate cannabis in the country will take effect. Debates around legalising cannabis 
started in 2016, but this is the first time an end date has been announced, being April of 
2020 the date it will be decided the effect of the law (Republica, 2020). The official 
document states that main intention of this law is to legally regulate use, cultivation, 
distribution, exportation, possession, and transportation, promote scientific research, 
among many others (Republica, 2020). The government, through the creation of a 
Mexican Cannabis Institute will regulate cannabis and every matter related to it, for 
example limits around potency. Levels have not yet been mentioned in the document; 
however, it states that any product that exceeds the proposed limit stated by the institute 
will be prohibited. 
 
Results from the present study show that cannabis use is associated with lifetime use of 
other drugs in the student sample, particularly with illicit drugs; and, in the substance 
misuse clinical sample, daily cannabis use was significantly associated with frequent 
use of methamphetamines. These results, alongside age of onset of cannabis and illicit 
drugs reported by participants, suggest that cannabis use may be a risk factor for use of 
other drugs in adolescence. Now that this legislation is in place, it would be advised that 
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the government stablish effective and consistent substance use prevention programmes 
across the country (Faggiano, Minozzi, Versino, & Buscemi, 2014). Moreover, to set 
these programmes particularly from an early age, as research has shown that prevention 
at an early age is better than later in life (Lubman, Hides, Yücel, & Toumbourou, 2007). 
Furthermore, public policies should be encouraged to prevent increase of use, for 
example taxation (Hall et al., 2019). 
 
Several states in the US have legalised recreational cannabis, with Washington and 
Colorado being the first ones in 2012 (Hall & Lynskey, 2016). Recently, results from 
the Washington Health Youth Survey were publishes, comparing their results with 
results from the Monitoring the Future National Survey Results on Drug Use (Johnston, 
2018). The later had reported an increase in cannabis use among adolescents; however 
researchers from the Washington Health Youth Survey reported a decrease in cannabis 
use in that particular state (Dilley et al., 2019). It still difficult to assess if legalisation 
has had an impact on use (Leung, Chiu, Stjepanović, & Hall, 2018), however, there are 
some important critics around how cannabis has been regulated in the US, e.g. there is 
no clear regulation on promotion, availability and taxation on high-potency products 
(Hall & Lynskey, 2016). These concerns should be taken into account now that 
cannabis is to be legal in Mexico, and the government should regulate it does not 
happen.  
 
Canada legalised cannabis in 2018, making it the second country in legalising cannabis 
for recreational use, with Uruguay being the first in 2013 (Faccio, 2019). However, 
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contrary to what has been seen in the US, Canada’s implementation seems much more 
focused on minimizing harms related with legalisation. 
 
The National Council against Addictions in Mexico (CONADIC) is responsible of 
overlooking substance misuse problems in the country and in charge of designing and 
set different strategies in the matter. However, during the time this study was 
conducted, when data were collected and during the time I have had the chance of 
working in the addictions field in Mexico, there are not enough resources given to 
institutions to deal with substance use; not for prevention strategies and not for 
treatment services. 
 
In the clinical sample results show a strong association between daily and heavy use of 
cannabis with frequent use of methamphetamines and solvents. Considering mean age 
of first use of cannabis and mean age of onset of solvents and methamphetamine use it 
can be observed that cannabis use precedes use of methamphetamines and solvents. As 
previously mentioned, research has shown a that cannabis is associated with use of 
other drugs (Hall & Lynskey, 2005), furthermore, a study analysing data from 17 
countries found that initiation of drugs considered as ‘gateway drugs’ (tobacco, alcohol, 
cannabis) was associated with later onset of illicit drugs (Degenhardt et al., 2010).  
 
The significantly high associations found between cannabis use and use of illicit drugs, 
particularly in the school sample is unsettling, especially when considering data from 
the substance misuse sample. This raises the question of how many of the students using 
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cannabis and other drugs will end in a substance misuse treatment service from where 
the clinical data was collected or other type of substance misuse treatment service. 
There is an urgent need of evidence-based prevention strategies and substance use 
treatment services.  
 
Having cannabis legalised in Mexico could have a number of benefits, for example; 
regulation, access to cannabis for research purposes, taxation, which could result in 
increased availability of resources for prevention and intervention strategies for 
substance misuse problems and probably a significant decrease in drug-related violence 
in the country. However, there could be some difficulties in the process of legalising 
cannabis. For example, not having an evidenced-based regulation strategy; meaning that 
the government do not take into consideration what research has found regarding 
different types of cannabis and the risk of mental health problems among others. As 
previously mentioned, this can be observed in the United States of America, where there 
is no cap in concentrations of THC in commercial cannabis which increases the risk of 
adverse effects among users. Therefore, the importance of making an informed and 
evidenced-based decision. 
 
7.9. Strengths and Limitations 
7.9.1. Strengths 
To the best of my knowledge, this is the first study conducted in Mexico which 
examines the association between cannabis use and psychotic-like experiences. 
Therefore, results are novel and add significant value to the addictions and mental 
health field in Mexico. Furthermore, it assesses type of cannabis used in an adolescent 
 
 216 
sample (13-18-year olds) something that has not been assessed in previous studies 
around the world.  
 
As the study was conducted in two different adolescent samples there is substantial 
addition to knowledge; firstly, from the perspective of prevention in the general 
population and from the harm reduction in treatment services for substance misuse. For 
both samples the minimum number of participants required to have enough statistical 
power was obtained. This is a significant accomplishment as data was collected from 
two different settings, schools and substance misuse treatment services. Time and 
resources invested were substantial in the process of collecting data. Furthermore, 
boroughs from where data was obtained were situated in very different areas in the city, 
which made the process difficult, but in the end, it was accomplished.  
 
Questionnaires were selected carefully, particularly the psychotic-like experiences 
questionnaire. It was considered very important to use a questionnaire that had been 
previously validated in Mexico or in a population similar to the one in Mexico. 
Fortunately, thorough contacting the first author of a paper that reported validation of 
the PRIME Screen in an adolescent Mexican sample of the general population (Fresan 
et al., 2007), the questionnaire was obtained. Furthermore, there was minimum missing 
data in both, the student and the substance misuse clinical sample. Lastly, as previously 
mentioned, the systematic review conducted to identify previous research published 
around cannabis use and psychotic-like experiences in adolescents is an important 
addition of knowledge in the field, as this had not been examined before.  
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7.9.2.  Limitations 
Strengths of this work do not come without limitations. One important limitation is the 
cross-sectional design of the study, where sociodemographic characteristics, cannabis 
use, use of other drugs and the PRIME Screen Questionnaire were only assessed in one 
time period. Because of its cross-sectional nature, it is not possible to assume causality 
in the association between cannabis use and psychotic-like experiences. Furthermore, 
the nature of the study makes the detection of changes in psychotic-like experiences 
among participants impossible, for better understanding of the development on trends in 
cannabis use and psychotic-like experiences a longitudinal design would be more 
desirable. 
 
Another limitation was the lack of biological measures to validate self-report measures 
of cannabis use. Self-report measures might be a source of bias for a number of reasons 
e.g. under report or recall bias (Althubaiti, 2016). However, previous studies have used 
similar formats (Di Forti et al., 2014; Freeman & Winstock, 2015; Mackie et al., Under 
Review). The reason for the selection of self-report measure was limited resources and 
difficulty in transporting biological samples from Mexico to the United Kingdom. 
Furthermore, not including a questionnaire on mental health symptoms e.g. SCL-90 
(Derogatis, Lipman, & Covi, 1973) and trauma, as research has shown that trauma is an 
important risk factor for the development of psychotic-like experiences and other 
psychotic-spectrum disorders (Read et al., 2005). However, as time was limited, a 
careful and thorough selection of the questionnaires that were to be included in the 
study had to be made. Moreover, although the full set of questionnaires did not include 
assessment of mental health or trauma, considerable amount of data was collected from 
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each participant. This gives the opportunity to conduct further analyses, however there 
was limited time for data analysis prior to submission, therefore it was difficult to 
examine every single aspect of the data collected.  
 
One important limitation regarding the cannabis questionnaire was the use of specific 
pictures to portray the type of cannabis participants reported to use. These pictures were 
used in the first stage of the project, during the piloting of questionnaires. Participants 
referred that the pictures did resembled to the type of cannabis they were meant to 
portray, however this might have been subjective as it is very difficult to be completely 
certain that the type of cannabis participants chose just by looking at the pictures was 
actually low-potency or high-potency. Moreover, as previously mentioned research 
regarding potency of cannabis in Mexico has never been done; making the research on 
this field more difficult. 
 
Lastly, another limitation could be that as data from the student sample were collected 
in schools inside classrooms, this might have had an impact on reporting drug use and 
presence of psychotic-like experiences. However, during data collection students were 
not allowed to share their answers or look at other student’s questionnaires. In the 
clinical sample, groups were significantly smaller, with a maximum of 5 participants 





Adolescent cannabis use is Mexico is a matter of concern and has been for over a 
decade. Currently, with recreational use about to be legal, efforts should be made to 
prevent youth, and prevent increase of use. Better treatment services should be provided 
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9.1.1. Demographic Questionnaire  









c. Ethnicity: To which of the following do you identify the most? 
Caucasian 
1 











d. Do you consider yourself part of an indigenous group?  
Yes No 
 
e. How many rooms does your house have? Please do not include bathrooms, half bathrooms, hallways or 
courtyards.  
1 2 3 4 5 6 7 or more 
 
f. How many complete bathrooms with a shower and a W.C. are in the house for exclusive use of you and 
your family?  
1 2 3 4 or more 
 
g. Does your home have a functioning shower in any of the bathrooms? 
Yes No 
 
h. Considering all the lightbulbs that you and your family use to light your house, including ceilings, walls, 
bed lamps or floor lamps, how many lightbulbs are there in your house? 
0-5 6-10 11-15 16-20 21 or more 
 
i. The floor in your house is predominantly soil, cement or other type of material? 
Soil or cement Other type of material 
 
 
j. How many cars do your family own, excluding taxis? 
0 1 2 3 or more 
 








l. Thinking about the family member that contributes the most economically in your house, which was the 
last year of studies she/he completed? 
 
1. Did not study 
2. Some Primary 
3. Primary 
4. Some Secondary School 
5. Secondary School 
6. Commercial Degree 
7. Technical Degree 
8. Some High School 
9. High School 
10. Some Undergraduate 
11. Undergraduate 
12. Diploma or Master 
13. PhD 
 
m. Do you have siblings?  
Yes No 
 
n. How many?  
1 2 3 4 5 or more 
 
o. What place do you hold in your family?  
First Second Third Fourth Other 
 







9.1.2. Cannabis Use Assessment  
The following questionnaire contains several questions regarding cannabis use, please answer each question with 
complete honesty. Remember that all your answers are anonymous and confidential. 
 





IF “NO” END OF QUESTIONNAIRE 
 










4. Which of the following best describes the type of cannabis that you mainly use? (Please, choose only one). 
 








































7. How often do you use cannabis?  
 
Every day or 
almost daily 
1 
Once or twice 
a week 
2 
Once or twice a 
month 
3 
Less than once a 
month 
4 
Once or twice a 
year 
5 








8. Do you mainly use cannabis? 
 
In a joint with 
tobacco 
1 
In a joint 
without tobacco 
2 













If other, please specify:  
___________________________ 
 
9. How many joints do you smoke on a typical occasion? 
 
¼ of a joint 
 
1 
































































*If you do not use this type of cannabis go to question 14 
 
11. How long would the amount of herbal cannabis you buy per week (mentioned in the previous question) last 




1) Don’t know  
 
12. How many joints can you make with would the amount of herbal cannabis you buy per week (mentioned in 




1) Don’t know 
 
13. On average how many grams of herbal cannabis per week do you smoke/use?  
 
Less than 1 
gram 
1 
1 - 2 grams 
 
2 
2 - 3 grams 
 
3 
3 - 4 grams 
 
4 
4 - 5 grams 
 
5 
























































*If you do not use this type of cannabis go to question 18 
 
15. How long would the amount of hydroponic/redhead/skunk cannabis you buy per week (mentioned in the 








2) Don’t know  
 
16. How many joints can you make with would the amount of hydroponic/redhead/skunk cannabis you buy per 




2) Don’t know 
 
 
17. On average how many grams of hydroponic/redhead/skunk cannabis per week do you smoke/use?  
 
Less than 1 
gram 
1 
1 - 2 grams 
 
2 
2 - 3 grams 
 
3 
3 - 4 grams 
 
4 
4 - 5 grams 
 
5 



























































*If you do not use this type of cannabis go to question 22 
 





1) Don’t know  
 





1) Don’t know  
 
 
21. On average how many grams of hash per week do you smoke/use?  
 
Less than 1 
gram 
1 
1 - 2 grams 
 
2 
2 - 3 grams 
 
3 
3 - 4 grams 
 
4 
4 - 5 grams 
 
5 
























23. Have you experienced any of the following effects after smoking cannabis? (Please choose only one option) 
 
A. Feelings of paranoia or suspicious  
 
Rarely or Never 
1 
Time to time 
2 





B. Hearing voices  
 
Rarely or Never 
1 
Time to time 
2 





C. Feeling like I’m going crazy/mad  
 
Rarely or Never 
1 
Time to time 
2 





D. Not wanting to do anything/ lack of motivation  
 
Rarely or Never 
1 
Time to time 
2 





E. Difficulty in concentrating  
 
Rarely or Never 
1 
Time to time 
2 





F. Not able to think clearly  
 
Rarely or Never 
1 
Time to time 
2 





G. Seeing visions  
 
Rarely or Never 
1 
Time to time 
2 












9.1.3. Yale University PRIME Screen Questionnaire 
Please read the following information before completing the questionnaire. 
The following questionnaire is made of questions regarding your personal experiences. Some of 
these questions may be extremely related with some experiences you have had and other might 
not. Please answer all questions. 
 

















IF YOU ANSWERED DEFINITELY DISAGREE #1 CONTINUE TO QUESTION NUMBER 2. OTHERWISE 
CONTINUE WITH THE FOLLOWING QUESTIONS.  
 
1.1 How old were you the first time you experienced this symptom?  
______________________ 
 







1.2.1 Which drug?  
______________________ 
 

























IF YOU ANSWERED DEFINITELY DISAGREE #1 CONTINUE TO QUESTION NUMBER 3. OTHERWISE 
CONTINUE WITH THE FOLLOWING QUESTIONS.  
 
2.1 How old were you the first time you experienced this symptom? 
______________________ 
 







Which drug?  
________________________ 
 





























IF YOU ANSWERED DEFINITELY DISAGREE #1 CONTINUE TO QUESTION NUMBER 4. OTHERWISE 
CONTINUE WITH THE FOLLOWING QUESTIONS.  
 
3.1 How old were you the first time you experienced this symptom?  
_______________________ 
 







Which drug?  
________________________ 
 
























IF YOU ANSWERED DEFINITELY DISAGREE #1 CONTINUE TO QUESTION NUMBER 5. OTHERWISE 
CONTINUE WITH THE FOLLOWING QUESTIONS.  
 











Which drug?  
______________________ 
 







5. I think that I may get confused at times whether something I experience or perceive may be real or may be just 

















IF YOU ANSWERED DEFINITELY DISAGREE #1 CONTINUE TO QUESTION NUMBER 6. OTHERWISE 





5.1 How old were you the first time you experienced this symptom?  
______________________ 
 







Which drug?  
_______________________ 
 

























IF YOU ANSWERED DEFINITELY DISAGREE #1 CONTINUE TO QUESTION NUMBER 7. OTHERWISE 
CONTINUE WITH THE FOLLOWING QUESTIONS.  
 
 
6.1 How old were you the first time you experienced this symptom?  
______________________ 
 







Which drug?  
______________________ 
 

























IF YOU ANSWERED DEFINITELY DISAGREE #1 CONTINUE TO QUESTION NUMBER 8. OTHERWISE 
CONTINUE WITH THE FOLLOWING QUESTIONS.  
 
7.1 How old were you the first time you experienced this symptom?  
______________________ 
 











Which drug?  
_______________________ 
 

























IF YOU ANSWERED DEFINITELY DISAGREE #1 CONTINUE TO QUESTION NUMBER 9. OTHERWISE 
CONTINUE WITH THE FOLLOWING QUESTIONS.  
 
8.1 How old were you the first time you experienced this symptom?  
______________________ 
 







Which drug?  
________________________ 
 
























IF YOU ANSWERED DEFINITELY DISAGREE #1 CONTINUE TO QUESTION NUMBER 10. 
OTHERWISE CONTINUE WITH THE FOLLOWING QUESTIONS.  
 
9.1 How old were you the first time you experienced this symptom?  
______________________ 
 





















10. I have had the experience of hearing faint or clear sounds of people or a person mumbling or talking when there 

















IF YOU ANSWERED DEFINITELY DISAGREE #1 CONTINUE TO QUESTION NUMBER 11. 
OTHERWISE CONTINUE WITH THE FOLLOWING QUESTIONS.  
 
10.1 How old were you the first time you experienced this symptom?  
_______________________ 
 







Which drug?  
________________________ 
 

























IF YOU ANSWERED DEFINITELY DISAGREE #1 CONTINUE TO QUESTION NUMBER 12. 
OTHERWISE CONTINUE WITH THE FOLLOWING QUESTIONS.  
 
11.1 How old were you the first time you experienced this symptom?  
_______________________ 
 







Which drug?  
________________________ 
 





























IF YOU ANSWERED DEFINITELY DISAGREE #1 CONTINUE TO QUESTION NUMBER 13. 
OTHERWISE CONTINUE WITH THE FOLLOWING QUESTIONS.  
 
12.1 How old were you the first time you experienced this symptom?  
_______________________ 
 







Which drug?  
________________________ 
 
























IF YOU ANSWERED DEFINITELY DISAGREE #1 END OF QUESTIONNAIRE 
 
13.1 How old were you the first time you experienced this symptom?  
_______________________ 
 







Which drug?  
________________________ 
 
















9.1.4. Other Substance Use  
A. Tobacco  
 
a. Have you ever smoked tobacco?  
 
Yes No 
(Go to section B) 
 
b. How old were you when you first smoked tobacco?  
___________________________ 
 
c. How often do you smoke tobacco? 
 




Once or twice 
a week  
 
2 


















B. Alcohol  
 
a. Have you ever drunk alcohol?  
Yes No 
(Go to section B) 
 
 
b. How old were you when you had your first sip of alcohol? 
 __________________________ 
 
c. How old were you when you had your first whole glass of alcohol? 
 __________________________ 
 
d. How often do you drink alcohol?  
 




Once or twice 
a week  
 
2 




































twice a year 
 
5 










C. Cocaine  
 




(Go to section B) 
 











c. How often do you use cocaine? 
 




Once or twice 
a week  
 
2 




















a. Have you ever smoked crack?  
 
Yes No 
(Go to section B) 
 
 
b. How old were you when you first smoked crack?  
___________________________ 
 
c. How often do you smoke crack? 
 




Once or twice 
a week  
 
2 

























(Go to section B) 
 
b. How old were you when you first tried solvents? 
 __________________________ 
 
c. How often do you use solvents?  
 




Once or twice 
a week  
 
2 



















F. Hallucinogens  
 
a. Have you ever tried hallucinogens?  
 
Yes No 
(Go to section B) 
 
b. How old were you when you first tried hallucinogens?  
___________________________ 
 
c. How often do you use hallucinogens?  
 




Once or twice 
a week  
 
2 




















G. Ecstasy   
 
a. Have you ever tried ecstasy?  
 
Yes No 
(Go to section B) 
 
b. How old were you when you first tried ecstasy?  
__________________________ 
 
c. How often do you use ecstasy? 
 




Once or twice 
a week  
 
2 



















H. Benzodiazepines or Sleeping Pills  
 




(Go to section B) 
 
b. How old were you when you first tried benzodiazepines or sleeping pills? 
__________________________ 
 
c. How often do you use benzodiazepines or sleeping pills?  
 




Once or twice 
a week  
 
2 



















I. Opioids  
 
a. Have you ever tried opioids?  
 
Yes No 
(Go to section B) 
 
b. How old were you when you first tried opioids? 
_________________________ 
 
c. How often do you use opioids? 
 




Once or twice 
a week  
 
2 



















J. Heroin or Opium  
 









b. How old were you when you first tried heroin or opium? 
 ___________________________ 
 
c. How often do you use heroin or opium? 
 




Once or twice 
a week  
 
2 



















K. Relevin  




(Go to section B) 
 
b. How old were you when you first tried relevin?  
___________________________ 
 
c. How often do you use relevin? 
 




Once or twice 
a week  
 
2 



















L. Amphetamines or Methamphetamines  
 




(Go to section B) 
 
b. How old were you when you first tried amphetamines or methamphetamines? 
____________________________ 
 
c. How often do you use amphetamines or methamphetamines?  
 




Once or twice 
a week  
 
2 



















M. Other Drugs  
 




(Go to section B) 
 
b. Which?  
___________________________ 
 









d. How often do you use this drug? 
 




Once or twice 
a week  
 
2 




























9.1.5. Cuestionario Demográfico   
 
Por favor completa las siguientes preguntas. 
 









3. Etnicidad: ¿Con cuál de los siguientes grupos te identificas más? 
Caucásico 
1 

















5. ¿Cuál es el total de cuartos, piezas o habitaciones con que cuenta tu hogar? Por favor no incluyas baños, 
medio baños, pasillos, patios y zotehuelas. 
1 2 3 4 5 6 7 o más 
 
6. ¿Cuántos baños completos con regadera y W.C. (excusado) hay para uso exclusivo de los integrantes de tu 
hogar?  
1 2 3 4 o más 
 






8. Contando todos los focos que se utilizan para iluminar tu hogar, incluyendo los de techos, paredes y 
lámparas de buro o piso, ¿cuántos focos tiene tu hogar? 
0 – 5 
1 
6 – 10 
2 
11 – 15 
3 
16 – 20 
4 
21 o más 
5 
 
9. ¿El piso de tu hogar es predominantemente de tierra, cemento o de algún otro tipo de acabado? 
Tierra o cemento 
1 
Otro tipo de material o acabado 
2 
 
10. ¿Cuántos automóviles propios, excluyendo taxis, tienen en tu hogar? 
0 1 2 3 o más 
 






12. Pensando en la persona que aporta la mayor parte del ingreso económico a tu hogar, ¿cuál fue el último año 
de estudios que él o ella completó? 
1. No estudió 
2. Primaria incompleta 
3. Primaria completa 
4. Secundaria incompleta 
5. Secundaria completa 





7. Carrera técnica 
8.Preparatoria incompleta 
9. Preparatoria completa 
10. Licenciatura incompleta 
11. Licenciatura completa 










14. ¿Cuántos?  
1 2 3 4 5 o mas 
 

















FIN DEL PRIMER CUESTIONARIO
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9.1.6. Cuestionario De Uso De Marihuana  
El siguiente cuestionario contiene preguntas acerca del uso de marihuana, por favor responde cada pregunta 
honestamente. Recuerda que tus respuestas son anónimas y confidenciales. 






*SÍ TU RESPUESTA FUE “NO”, FIN DE ESTE CUESTIONARIO, POR FAVOR CONTINUA 
CON EL SIGUIENTE CUESTIONARIO 
 






3. ¿Qué edad tenías la primera vez que probaste la marihuana? 
 
 
4. ¿Cuál de las siguientes imágenes representa mejor el tipo de marihuana que utilizas con mayor frecuencia? 





5. ¿Cuál de las siguientes opciones es el tipo de marihuana que te es más fácil conseguir? 
Marihuana herbal 
1 
Hidropónica, Pelirroja, Skunk 
2 
Hash o Resina 
3 
 
6. De las siguientes opciones, ¿Cuál es el tipo de marihuana que prefieres consumir? 
Marihuana herbal 
1 
Hidropónica, Pelirroja, Skunk 
2 
Hash o Resina 
3 
 
7. ¿Qué tan seguido consumes marihuana?  
Todos los días o 
casi todos los 
días 
1 








Menos de una 
vez al mes 
 
4 









8. Generalmente, ¿De qué forma consumes marihuana? 
En un cigarro 
con tabaco 
1 
En un cigarro 
sin tabaco 
2 













*Si tu respuesta fue “Otra” por favor especifica: 
 
9. Cuando consumes marihuana, aproximadamente, ¿Cuántos cigarros consumes? 

























































*SI NO CONSUMES ESTE TIPO DE MARIHUANA, POR FAVOR PASA A LA PREGUNTA #14. 
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11. Aproximadamente, la cantidad de marihuana herbal que compras por semana, ¿Cuántos días te dura? 
(Cantidad mencionada en la pregunta anterior).  
 
1) No lo sé 
 
12. ¿Cuántos cigarros puedes hacer con la cantidad de marihuana herbal que compras por semana? (Cantidad 
mencionada en la pregunta 10). 
 
1) No lo sé 
 
13. En promedio, ¿Cuántos gramos de marihuana herbal consumes por semana?  
Menos de 1 
gramo 
1 
1 - 2 gramos 
 
2 
2 - 3 gramos 
 
3 
3 - 4 gramos 
 
4 
4 - 5 gramos 
 
5 
Más de 5 
gramos 
6 




14. En promedio, ¿Cuánto dinero gastas a la semana en marihuana hidropónica, pelirroja o skunk?  
No 
consumo 




































*SI NO CONSUMES ESTE TIPO DE MARIHUANA, POR FAVOR PASA A LA PREGUNTA #18. 
 
15. Aproximadamente, la cantidad de marihuana hidropónica, pelirroja o skunk que compras por semana, 
¿Cuántos días te dura? (Cantidad mencionada en la pregunta anterior).  
 
1) No lo sé 
 
16. ¿Cuántos cigarros puedes hacer con la cantidad de marihuana hidropónica, pelirroja o skunk que compras 
por semana? (Cantidad mencionada en la pregunta 14). 
 
1) No lo sé 
17. En promedio, ¿Cuántos gramos de marihuana hidropónica, pelirroja o skunk consumes por semana?  
Menos de 1 
gramo 
1 
1 - 2 gramos 
 
2 
2 - 3 gramos 
 
3 
3 - 4 gramos 
 
4 
4 - 5 gramos 
 
5 












































*SI NO CONSUMES HASH, POR FAVOR PASA A LA PREGUNTA #22. 
 
19. Aproximadamente, la cantidad de hash que compras por semana, ¿Cuántos días te dura? (Cantidad 
mencionada en la pregunta anterior).  
 
2) No lo sé 
 
20. ¿Cuántos cigarros puedes hacer con la cantidad de hash que compras por semana? (Cantidad mencionada 
en la pregunta 18). 
 
2) No lo sé 
 
21. En promedio, ¿Cuántos gramos de hash consumes a la semana?  
Menos de 1 
gramo 
1 
1 - 2 gramos 
 
2 
2 - 3 gramos 
 
3 
3 - 4 gramos 
 
4 
4 - 5 gramos 
 
5 



















23. ¿Alguna vez has experimentado alguno de los siguientes síntomas después de consumir marihuana? (Por 
favor elige sólo una opción).  
 
I. Paranoia o suspicacia  









J. Escuchar voces  









K. Sentir que te estas volviendo loco / loca   









L.  Sin ganas o sin motivación  









M. Dificultad para concentrarte  









N. No pensar claramente 









O. Ver visiones (ver cosas de forma alterada pero que si están ahí)  













FIN DEL TERCER CUESTIONARIO  
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9.1.7. Tamizaje De Síntomas Prodrómicos PRIME  
El siguiente cuestionario hace preguntas acerca de tu experiencia personal. Preguntamos acerca de algunas experiencias 
sensoriales, psicológicas, emocionales y sociales. Algunas de estas preguntas pueden estar muy relacionadas con 
experiencias que has vivido y otras no. Por favor contesta TODAS las preguntas.  
 






















SÍ RESPONDISTE “TOTALMENTE EN DESACUERDO” PASA A LA PREGUNTA 2. DE LO 
CONTRARIO CONTINUA CON LAS SIGUIENTES PREGUNTAS. 
 
1.5 ¿Qué edad tenías la primera vez que experimentaste esto?  
______________________ 
 






Sí tu respuesta fue si, por favor especifica: 
 
1.2.1 ¿Qué droga?  
______________________ 
 



























SÍ RESPONDISTE “TOTALMENTE EN DESACUERDO” PASA A LA PREGUNTA 3. DE LO 
CONTRARIO CONTINUA CON LAS SIGUIENTES PREGUNTAS. 
 
2.1 ¿Qué edad tenías la primera vez que experimentaste esto?  
______________________ 
 






Sí tu respuesta fue si, por favor especifica: 
2.2.1 ¿Qué droga?  
______________________ 
 




























SÍ RESPONDISTE “TOTALMENTE EN DESACUERDO” PASA A LA PREGUNTA 4. DE LO 
CONTRARIO CONTINUA CON LAS SIGUIENTES PREGUNTAS. 
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3.1 ¿Qué edad tenías la primera vez que experimentaste esto?  
______________________ 
 






Sí tu respuesta fue si, por favor especifica: 
 
3.2.1 ¿Qué droga?  
______________________ 
 




























SÍ RESPONDISTE “TOTALMENTE EN DESACUERDO” PASA A LA PREGUNTA 5. DE LO 
CONTRARIO CONTINUA CON LAS SIGUIENTES PREGUNTAS. 
 










Sí tu respuesta fue si, por favor especifica: 
 
4.2.1 ¿Qué droga?  
______________________ 
 






























SÍ RESPONDISTE “TOTALMENTE EN DESACUERDO” PASA A LA PREGUNTA 6. DE LO 
CONTRARIO CONTINUA CON LAS SIGUIENTES PREGUNTAS. 
 
5.1 ¿Qué edad tenías la primera vez que experimentaste esto?  
______________________ 
 






Sí tu respuesta fue si, por favor especifica: 
 































SÍ RESPONDISTE “TOTALMENTE EN DESACUERDO” PASA A LA PREGUNTA 7. DE LO 
CONTRARIO CONTINUA CON LAS SIGUIENTES PREGUNTAS. 
 
6.1 ¿Qué edad tenías la primera vez que experimentaste esto?  
______________________ 
 






Sí tu respuesta fue si, por favor especifica: 
 
6.2.1 ¿Qué droga?  
______________________ 
 



























SÍ RESPONDISTE “TOTALMENTE EN DESACUERDO” PASA A LA PREGUNTA 8. DE LO 
CONTRARIO CONTINUA CON LAS SIGUIENTES PREGUNTAS. 
 
7.1 ¿Qué edad tenías la primera vez que experimentaste esto?  
______________________ 






Sí tu respuesta fue si, por favor especifica: 
 
7.2.1 ¿Qué droga?  
______________________ 
 



























SÍ RESPONDISTE “TOTALMENTE EN DESACUERDO” PASA A LA PREGUNTA 9. DE LO 
CONTRARIO CONTINUA CON LAS SIGUIENTES PREGUNTAS. 
 
8.1 ¿Qué edad tenías la primera vez que experimentaste esto?  
______________________ 
 








Sí tu respuesta fue si, por favor especifica: 
 
8.2.1 ¿Qué droga?  
______________________ 
 




























SÍ RESPONDISTE “TOTALMENTE EN DESACUERDO” PASA A LA PREGUNTA 10. DE LO 
CONTRARIO CONTINUA CON LAS SIGUIENTES PREGUNTAS. 
 
9.1 ¿Qué edad tenías la primera vez que experimentaste esto?  
______________________ 
 






Sí tu respuesta fue si, por favor especifica: 
 
9.2.1 ¿Qué droga?  
____________________ 
 







10. He tenido la experiencia de escuchar cosas o la voz de una persona(s) susurrándome o hablándome cuando no hay 





















SÍ RESPONDISTE “TOTALMENTE EN DESACUERDO” PASA A LA PREGUNTA 11. DE LO 
CONTRARIO CONTINUA CON LAS SIGUIENTES PREGUNTAS. 
 
10.1 ¿Qué edad tenías la primera vez que experimentaste esto?  
______________________ 
 






Sí tu respuesta fue si, por favor especifica: 
 
10.2.1 ¿Qué droga?  
______________________ 
 





























SÍ RESPONDISTE “TOTALMENTE EN DESACUERDO” PASA A LA PREGUNTA 12. DE LO 
CONTRARIO CONTINUA CON LAS SIGUIENTES PREGUNTAS. 
 
11.1 ¿Qué edad tenías la primera vez que experimentaste esto?  
______________________ 
 






Sí tu respuesta fue si, por favor especifica: 
11.2.1 ¿Qué droga?  
______________________ 
 



























SÍ RESPONDISTE “TOTALMENTE EN DESACUERDO” PASA A LA PREGUNTA 13. DE LO 
CONTRARIO CONTINUA CON LAS SIGUIENTES PREGUNTAS. 
 










Sí tu respuesta fue si, por favor especifica: 
 
12.2.1 ¿Qué droga?  
______________________ 
 



























SÍ RESPONDISTE “TOTALMENTE EN DESACUERDO” FIN DEL CUESTIONARIO. DE LO 
CONTRARIO CONTINUA CON LAS SIGUIENTES PREGUNTAS. 
 
13.1 ¿Qué edad tenías la primera vez que experimentaste esto?  
______________________ 
 










13.2.1 ¿Qué droga?  
______________________ 
 







Consumo de Otras Drogas   
 
 
A. TABACO  




(Pasa a la sección B) 2 
 
a. ¿Qué edad tenías la primera vez que probaste el tabaco?  
___________________________ 
 
b. ¿Con qué frecuencia consumes tabaco? 
Todos los días o 
casi todos los 
días 
1 








Menos de una 
vez por mes 
 
4 










B. ALCOHOL  




(Pasa a la sección C) 2 
 
b. ¿Qué edad tenías la primera vez que probaste el alcohol? 
 __________________________ 
 
c. ¿Qué edad tenías la primera vez que tomaste una copa de alcohol? 
 __________________________ 
 
d. ¿Con qué frecuencia consumes alcohol?  
Todos los días o 
casi todos los 
días 
1 








Menos de una 
vez por mes 
 
4 









e. ¿Con qué frecuencia consumes más de 4 copas de alcohol por ocasión si eres mujer o más de 5 copas de 
alcohol si eres hombre? 
Todos los días 
o casi todos 
los días 
1 




Una o dos 
veces por mes 
 
3 
Menos de una 
vez por mes 
 
4 
Una o dos 
veces al año 
 
5 










C. COCAÍNA EN POLVO  




(Pasa a la sección D) 2 
 
e. ¿Qué edad tenías la primera vez que consumiste cocaína en polvo?  
_________________________ 
 
f. ¿Con qué frecuencia consumes cocaína en polvo? 
Todos los días o 
casi todos los 
días 
1 








Menos de una 
vez por mes 
 
4 










D. COCAÍNA BASE, CRACK O PIEDRA 




(Pasa a la sección E) 2 
 
e. ¿Qué edad tenías la primera vez que consumiste cocaína base, crack o piedra?  
___________________________ 
 
f. ¿Con qué frecuencia consumes cocaína base, crack o piedra? 
Todos los días o 
casi todos los 
días 
1 








Menos de una 
vez por mes 
 
4 










E. INHALABLES O SOLVENTES 




(Pasa a la sección F) 2 
 
e. ¿Qué edad tenías la primera vez que consumiste inhalables o solventes?  
 __________________________ 
 
f. ¿Con qué frecuencia consumes inhalables o solventes?  
Todos los días o 
casi todos los 
días 
1 








Menos de una 
vez por mes 
 
4 










F. ALUCINÓGENOS   




(Pasa a la sección G) 2 
 
 
e. ¿Qué edad tenías la primera vez que consumiste alucinógenos?  
_____________________________ 
 
f. ¿Con que frecuencia consumes alucinógenos?  
Todos los días o 
casi todos los 
días 
1 








Menos de una 
vez por mes 
 
4 









G. ÉXTASIS   




(Pasa a la sección H) 2 
 
e. ¿Qué edad tenías la primera vez que consumiste éxtasis?  
__________________________ 
 
f. ¿Con qué frecuencia consumes éxtasis? 
Todos los días o 
casi todos los 
días 
1 








Menos de una 
vez por mes 
 
4 










H. TRANQUILIZANTES O PASTILLAS PARA DORMIR 








e. ¿Qué edad tenías la primera vez que consumiste tranquilizantes o pastillas para dormir?  
__________________________ 
 
f. ¿Con qué frecuencia consumes tranquilizantes o pastillas para dormir?  
Todos los días o 
casi todos los 
días 
1 








Menos de una 
vez por mes 
 
4 









I. OPIÁCEOS  




(Pasa a la sección J) 2 
 
e. ¿Qué edad tenías la primera vez que consumiste opiáceos? 
_________________________ 
f. ¿Con qué frecuencia consumes opiáceos? 
Todos los días o 
casi todos los 
días 
1 








Menos de una 
vez por mes 
 
4 










J. HEROÍNA U OPIO  




(Pasa a la sección K) 2 
 
e. ¿Qué edad tenías la primera vez que consumiste heroína u opio? 
 ___________________________ 
 
f. ¿Con qué frecuencia consumes heroína u opio? 
Todos los días o 
casi todos los 
días 
1 








Menos de una 
vez por mes 
 
4 










K. RELEVIN  




(Pasa a la sección L) 2 
 
e. ¿Qué edad tenías la primera vez que consumiste relevin?  
___________________________ 
 
f. ¿Con qué frecuencia consumes relevin? 
Todos los días o 
casi todos los 
días 
1 








Menos de una 
vez por mes 
 
4 












L. ANFETAMINAS O METANFETAMINAS  




(Pasa a la sección M) 2 
 
e. ¿Qué edad tenías la primera vez que consumiste anfetaminas o metanfetaminas? 
 ____________________________ 
 
f. ¿Con qué frecuencia consumes anfetaminas o metanfetaminas?  
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Todos los días o 
casi todos los 
días 
1 








Menos de una 
vez por mes 
 
4 










M. CIGARROS ELECTRÓNICOS 




(Pasa a la sección N) 2 
 
b. ¿Qué edad tenías la primera vez que consumiste cigarros electrónicos? 
_____________________________ 
 
c. ¿Con que frecuencia consumes cigarros electrónicos? 
Todos los días o 
casi todos los 
días 
1 








Menos de una 
vez por mes 
 
4 









N. OTRAS DROGAS  




(Fin del Cuestionario) 2 
 
b. ¿Cuál?  
___________________________ 
 
c. ¿Qué edad tenías la primera vez que consumiste esta droga? 
___________________________ 
 
d. ¿Con qué frecuencia consumes esta droga? 
Todos los días o 
casi todos los 
días 
1 








Menos de una 
vez por mes 
 
4 














9.2. Systematic Review: Search Strategies 
9.2.1. ASSIA Applied Social Sciences Index and Abstracts 
Systematic Review: Cannabis Use and Psychosis in Adolescents 




3. Marijuana  
4. Cannabis use 
5. Adolescent 
Adolescent psychiatry 
6. Psychotic symptom* / Psychotic N/5 symptom* 
7. Psychosis 
8.  Prodrom* N/5 symptom* 
9. Vulnerability N/5 psychosis  
10. Early onset N/5 psychosis  
11. First episode N/5 psychosis 
12. Psychotic like N/5 experiences 
 
Defined Search Strategy: Systematic Review  
((“substance abuse”) OR (“drug abuse”) OR (cannabis) OR (skunk) OR (marijuana) OR 
(“cannabis use”)) AND ((adolescent) OR (“adolescent psychiatry”)) AND ((“psychotic 
symptom*”) OR (psychotic N/5 symptom) OR (psychosis) OR (prodrom* N/5 
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symptom*) OR (vulnerability N/5 psychosis) OR (“early onset” N/5 psychosis) OR 
(“first episode” N/5 psychosis) OR (“psychotic like” N/5 experiences)) 
((substance abuse) OR (drug abuse) OR (cannabis) OR (skunk) OR (marijuana) OR 
(cannabis use)) AND ((adolescent) OR (adolescent psychiatry)) AND ((psychotic 
symptom*) OR (psychotic N/5 symptom) OR (psychosis) OR (prodrom* N/5 
symptom*) OR (vulnerability N/5 psychosis) OR (early onset N/5 psychosis) OR (first 
episode N/5 psychosis) OR (psychotic like N/5 experiences)) 
Total: 51 
 
Literature Review: Cannabis Use in Mexico 
1. Substance abuse 
Drug abuse 
2. Addiction  
Drug addiction 
3. Cannabis / Marijuana / Marihuana 
Skunk 
4. Cannabis use 
5. Mexico 
 
Defined Search Strategy: Literature Review Mexico 
((“substance abuse”) OR (“drug abuse”) OR (addiction) OR (“drug addiction”) OR 




((substance abuse) OR (drug abuse) OR (addiction) OR (drug addiction) OR (cannabis) 
OR (marijuana) OR (marihuana) OR (skunk) OR (cannabis use)) AND ((Mexico))  
Total: 176 
 
9.2.2. CINHAL: Cumulative Index to Nursing and Allied Health Literature 
Systematic Review: Cannabis Use and Psychosis in Adolescents 
1. Substance abuse 
2. Cannabis 
3. Marijuana 
4. Cannabis use 
5. Adolescent 
Adolescent psychiatry 
6. Psychotic symptom* 
7. Psychosis 
8. Prodrom* symptom* 
9. Vulnerability for psychosis  
Substance-induced psychoses  
10. Early onset psychosis 
11. First episode psychosis 
12. Psychotic like experiences 
 
Defined Search Strategy: Systematic Review 
((“substance abuse”) OR (cannabis) OR (marijuana) OR (“cannabis use”)) AND 
(adolescent) OR (“adolescent psychiatry”)) AND ((“psychotic symptom*”) OR 
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(psychosis) OR (“prodrom* symptom*”) OR (“vulnerability for psychosis”) OR 
(“substance-induced psychoses”) OR (“early onset psychosis”) OR (“first episode 
psychosis”) OR (“psychotic like experiences”)) 
((substance abuse) OR (cannabis) OR (marijuana) OR (cannabis use)) AND 
(adolescent) OR (adolescent psychiatry)) AND ((psychotic symptom*) OR (psychosis) 
OR (prodrom* symptom*) OR (vulnerability for psychosis) OR (substance-induced 




Literature Review: Cannabis Use in Mexico 
1. Substance abuse  
2. Addiction 
Substance dependence  
3. Cannabis / Marijuana / Marihuana 
4. Cannabis use 
5. Mexico 
 
Defined Search Strategy: Literature Review Mexico 
((“substance abuse”) OR (addiction) OR (“substance dependence”) OR (cannabis) OR 
(marijuana) OR (marihuana) OR (“cannabis use”)) AND ((Mexico)) 
 
((substance abuse) OR (addiction) OR (substance dependence) OR (cannabis) OR 






Systematic Review: Cannabis Use and Psychosis in Adolescents 
1. Substance abuse 










6. Psychotic symptom* / Psychotic near Symptom*  
7. Psychosis 
Substance induced psychoses 
8. Prodrom* symptom* / Prodrom* near Symptom* 
9. Vulnerability for psychosis / Vulnerability near Psychosis  
10. Early onset psychosis / “Early onset” near Psychosis  
11. First episode psychosis / “First episode” near Psychosis  
12. Psychotic like experiences / “Psychotic like” near Experiences 
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Defined Search Strategy: Systematic Review  
((“substance abuse”) OR (“substance related disorders”) OR (cannabis) OR (“marijuana 
abuse”) OR (“marijuana smoking”) OR (marijuana) OR (“cannabis use”) OR (“cannabis 
abuse”)) AND ((adolescent) OR (“adolescent psychiatry”)) AND ((“psychotic 
symptom*”) OR (psychosis) OR (“substance induced psychoses”) OR (“prodrom* 
symptom*”) OR (prodrom* near symptom*) OR (“vulnerability for psychosis”) OR 
(vulnerability near psychosis) OR (“early onset psychosis”) OR (“early onset” near 
psychosis) OR (“first episode psychosis”) OR (“first episode” near psychosis) OR 
(“psychotic like experiences”) OR (“psychotic like” near experiences)) 
 
((substance abuse) OR (substance related disorders) OR (cannabis) OR (marijuana 
abuse) OR (marijuana smoking) OR (marijuana) OR (cannabis use) OR (cannabis 
abuse)) AND ((adolescent) OR (adolescent psychiatry)) AND ((psychotic symptom*) 
OR (psychosis) OR (substance induced psychoses) OR (prodrom* symptom*) OR 
(prodrom* near symptom*) OR (vulnerability for psychosis) OR (vulnerability near 
psychosis) OR (early onset psychosis) OR (early onset near psychosis) OR (first 
episode psychosis) OR (first episode near psychosis) OR (psychotic like experiences) 
OR (psychotic like near experiences)) 
Total: 57  
 
Literature Review: Cannabis Use in Mexico 
1. Substance abuse 
Substance related disorders 
2. Addiction 









Defined Search Strategy: Literature Review Mexico 
((“substance abuse”) OR (“substance related disorders”) OR (addiction) OR (cannabis) 
OR (marijuana) OR (marihuana) OR (“marijuana abuse”) OR (“marijuana smoking”) 
OR (“cannabis use”) OR (“cannabis abuse”)) AND ((Mexico))  
((substance abuse) OR (substance related disorders) OR (addiction) OR (cannabis) OR 
(marijuana) OR (marihuana) OR (marijuana abuse) OR (marijuana smoking) OR 





9.2.4. EMBASE  
9.2.5. Excerpta Medica Database  
Systematic Review: Cannabis Use and Psychosis in Adolescents 







4. Cannabis use 
Tetrahydrocannabinol 
5. Adolescent 
6. Psychotic symptom* / Psychotic ADJ5 Symptom*     
7. Psychosis 
Cannabis-induced psychosis 
8.  Prodrom* symptom* / Prodrom* ADJ5 Symptom* 
9.  Vulnerability for psychosis / Vulnerability ADJ5 Psychosis 
Disease predisposition  
10. Early onset psychosis / Early ADJ5 Psychosis 
11. First episode psychosis / First ADJ5 Psychosis  
12. Psychotic like experiences / Psychotic ADJ5 Experiences 
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Defined Search Strategy: Systematic Review 
((“substance abuse”) OR (“drug abuse”) OR (cannabis) OR (“cannabis addiction”) OR 
(“cannabis-induced psychosis”) OR (“cannabis smoking”) OR (marijuana) OR 
(“cannabis use”) OR (tetrahydrocannabinol)) AND ((adolescent)) AND ((“psychotic 
symptom*”) OR (psychotic ADJ5 symptom*) OR (psychosis) OR (“prodrom* 
symptom*”) OR (prodrom* ADJ5 symptom*) OR (“vulnerability for psychosis”) OR 
(vulnerability ADJ5 psychosis) OR (“disease predisposition”) OR (“early onset 
psychosis”) OR (early ADJ5 psychosis) OR (“first episode psychosis”) OR (first ADJ5 
psychosis) OR (“psychotic like experiences”) OR (psychotic ADJ5 experiences)) 
 
((substance abuse) OR (drug abuse) OR (cannabis) OR (cannabis addiction) OR 
(cannabis-induced psychosis) OR (cannabis smoking) OR (marijuana) OR (cannabis 
use) OR (tetrahydrocannabinol)) AND ((adolescent)) AND ((psychotic symptom*) OR 
(psychotic ADJ5 symptom*) OR (psychosis) OR (prodrom* symptom*) OR (prodrom* 
ADJ5 symptom*) OR (vulnerability for psychosis) OR (vulnerability ADJ5 psychosis) 
OR (disease predisposition) OR (early onset psychosis) OR (early ADJ5 psychosis) OR 
(first episode psychosis) OR (first ADJ5 psychosis) OR (psychotic like experiences) OR 
(psychotic ADJ5 experiences)) 
Total: 1,236 
 
Literature Review: Cannabis Use in Mexico 
1. Substance abuse 
Drug abuse 
2. Addiction 










Defined Search Strategy: Literature Review Mexico 
((“substance abuse”) OR (“drug abuse”) OR (addiction) OR (cannabis) OR 
(marijuana) OR (marihuana) OR (“cannabis addiction”) OR (“cannabis-induced 
psychosis”) OR (“cannabis smoking”) OR (“cannabis use”) OR 
(tetrahydrocannabinol)) AND ((Mexico)) 
 
((substance abuse) OR (drug abuse) OR (addiction) OR (cannabis) OR (marijuana) 
OR (marihuana) OR (cannabis addiction) OR (cannabis-induced psychosis) OR 






9.2.6. IPA: International Pharmaceutical Abstracts 
9.2.7. No Subject Headings 
Systematic Review: Cannabis Use and Psychosis in Adolescents 
1. Substance abuse 
2. Cannabis 
3. Marijuana 
4. Cannabis use 
5. Adolescent 
6. Psychotic symptom* / Psychotic ADJ5 Symptom*     
7. Psychosis 
8. Prodrom* symptom* / Prodrom* ADJ5 Symptom* 
9. Vulnerability for psychosis / Vulnerability ADJ5 Psychosis 
10. Early onset psychosis / Early ADJ5 Psychosis 
11. First episode psychosis / First ADJ5 Psychosis 
12. Psychotic like experiences / Psychotic ADJ5 Experiences  
 
Defined Search Strategy: Systematic Review 
((“substance abuse”) OR (cannabis) OR (marijuana) OR (“cannabis use”)) AND 
((adolescent)) AND ((“psychotic symptom*”) OR (psychotic adj5 symptom*) OR 
(psychosis) OR (“prodrom* symptom*”) OR (prodrom* adj5 symptom*) OR 
(“vulnerability for psychosis”) OR (vulnerability adj5 psychosis) OR (“early onset 
psychosis”) OR (early adj5 psychosis) OR (“first episode psychosis”) OR (first adj5 




((substance abuse) OR (cannabis) OR (marijuana) OR (cannabis use)) AND 
((adolescent)) AND ((psychotic symptom*) OR (psychotic adj5 symptom*) OR 
(psychosis) OR (prodrom* symptom*) OR (prodrom* adj5 symptom*) OR 
(vulnerability for psychosis) OR (vulnerability adj5 psychosis) OR (early onset 
psychosis) OR (early adj5 psychosis) OR (first episode psychosis) OR (first adj5 
psychosis) OR (psychotic like experiences) OR (psychotic adj5 experiences))  
Total: 12 
 
Literature Review: Cannabis Use in Mexico 
1. Substance abuse 
2. Addiction 
3. Cannabis / Marihuana / Marijuana 
4. Cannabis use 
5. Mexico 
 
Defined Search Strategy: Literature Review Mexico 
((“substance abuse”) OR (addiction) OR (cannabis) OR (marijuana) OR (marihuana) 
OR (“cannabis use”)) AND ((Mexico)) 
 
((substance abuse) OR (addiction) OR (cannabis) OR (marijuana) OR (marihuana) OR 






9.2.8. MEDLINE  
Systematic Review: Cannabis Use and Psychosis in Adolescents 
1. Substance abuse 
Substance related disorders 
2. Cannabis 
3. Marijuana 






6. Psychotic symptom* / Psychotic ADJ5 Symptom*     
7. Psychosis 
8. Prodrom* symptom* / Prodrom* ADJ5 Symptom* 
9. Vulnerability for psychosis / Vulnerability ADJ5 Psychosis 
Substance-induced psychoses 
10. Early onset psychosis / Early ADJ5 Psychosis 
11. First episode psychosis / First ADJ5 Psychosis 
12. Psychotic like experiences / Psychotic ADJ5 Experiences 
 
Defined Search Strategy: Systematic Review 
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((“substance abuse”) OR (“substance related disorders”) OR (cannabis) OR (marijuana) 
OR (“cannabis use”) OR (“marijuana abuse”) OR (“marijuana smoking”)) AND 
((adolescent) OR (“adolescent psychiatry”)) AND ((“psychotic symptom*”) OR 
(psychotic adj5 symptom*) OR (psychosis) OR (“prodrom* symptom*”) OR (prodrom* 
adj5 symptom*) OR (“vulnerability for psychosis”) OR (vulnerability adj5 psychosis) 
OR (“substance-induced psychoses”) OR (“early onset psychosis”) OR (early adj5 
psychosis) OR (“first episode psychosis”) OR (first adj5 psychosis) OR (“psychotic like 
experiences”) OR (psychotic adj5 experiences))  
 
((substance abuse) OR (substance related disorders) OR (cannabis) OR (marijuana) OR 
(cannabis use) OR (marijuana abuse) OR (marijuana smoking)) AND ((adolescent) OR 
(adolescent psychiatry)) AND ((psychotic symptom*) OR (psychotic adj5 symptom*) 
OR (psychosis) OR (prodrom* symptom*) OR (prodrom* adj5 symptom*) OR 
(vulnerability for psychosis) OR (vulnerability adj5 psychosis) OR (substance-induced 
psychoses) OR (early onset psychosis) OR (early adj5 psychosis) OR (first episode 
psychosis) OR (first adj5 psychosis) OR (psychotic like experiences) OR (psychotic 
adj5 experiences))  
Total: 498 
 
Literature Review: Cannabis Use in Mexico 
1. Substance abuse 
Substance related disorders 
2. Addiction 
3. Cannabis / Marijuana / Marihuana 







Defined Search Strategy: Literature Review Mexico 
((“substance abuse”) OR (“substance related disorders”) OR (addiction) OR (cannabis) 
OR (marijuana) OR (marihuana) OR (“cannabis use”) OR (“marijuana abuse”) OR 
(cannabinoids)) AND ((Mexico)) 
 
((substance abuse) OR (substance related disorders) OR (addiction) OR (cannabis) OR 
(marijuana) OR (marihuana) OR (cannabis use) OR (marijuana abuse) OR 





9.2.9. PsycINFO  
Systematic Review: Cannabis Use and Psychosis in Adolescents 
1. Substance abuse 
Drug abuse 
2. Cannabis 
3. Marijuana  






6. Psychotic symptom* / Psychotic ADJ5 Symptom*     
7. Psychosis 
8. Prodrom* symptom* / Prodrom* ADJ5 Symptom* 
Prodrome  
9. Vulnerability for psychosis / Vulnerability ADJ5 Psychosis 
10. Early onset psychosis / Early ADJ5 Psychosis 
11. First episode psychosis / First ADJ5 Psychosis 
12. Psychotic like experiences / Psychotic ADJ5 Experiences  
 
Defined Search Strategy: Systematic Review 
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((“substance abuse”) OR (“drug abuse”) OR (cannabis) OR (marijuana) OR (“cannabis 
use”) OR (“marijuana usage”) OR (“drug usage”)) AND ((adolescent) OR (“adolescent 
psychiatry”) OR (“adolescent psychopathology”)) AND ((“psychotic symptom*”) OR 
(psychotic adj5 symptom*) OR (psychosis) OR (“prodrom* symptom*”) OR (prodrom* 
adj5 symptom*) OR (prodrome) OR (“vulnerability for psychosis”) OR (vulnerability 
adj5 psychosis) OR (“early onset psychosis”) OR (early adj5 psychosis) OR (“first 
episode psychosis”) OR (first adj5 psychosis) OR (“psychotic like experiences”) OR 
(psychotic adj5 experiences)) 
 
((substance abuse) OR (drug abuse) OR (cannabis) OR (marijuana) OR (cannabis use) 
OR (marijuana usage) OR (drug usage)) AND ((adolescent) OR (adolescent psychiatry) 
OR (adolescent psychopathology)) AND ((psychotic symptom*) OR (psychotic adj5 
symptom*) OR (psychosis) OR (prodrom* symptom*) OR (prodrom* adj5 symptom*) 
OR (prodrome) OR (vulnerability for psychosis) OR (vulnerability adj5 psychosis) OR 
(early onset psychosis) OR (early adj5 psychosis) OR (first episode psychosis) OR (first 
adj5 psychosis) OR (psychotic like experiences) OR (psychotic adj5 experiences)) 
Total: 554 
 
Literature Review: Cannabis Use in Mexico 
1. Substance abuse 
2. Addiction 
Drug addiction 
3. Cannabis / Marijuana / Marihuana 






Defined Search Strategy: Literature Review Mexico 
((“substance abuse”) OR (addiction) OR (“drug addiction”) OR (cannabis) OR 
(marijuana) OR (marihuana) OR (“cannabis use”) OR (“marijuana usage”)) AND 
((Mexico)) 
 
((substance abuse) OR (addiction) OR (drug addiction) OR (cannabis) OR (marijuana) 






Systematic Review: Cannabis Use and Psychosis in Adolescents 
1. Substance abuse 




3. Marijuana  
4. Cannabis use 
5. Adolescent 
Adolescent psychiatry 
6. Psychotic symptom*  
7. Psychosis 
8. Prodrom* symptom*  
9. Early onset psychosis  
10. First episode psychosis  
11. Psychotic like experiences  
 
Defined Search Strategy: Systematic Review 
((“substance abuse”) OR (“substance related disorders”) OR (cannabis) OR (“marijuana 
abuse”) OR (“marijuana smoking”) OR (marijuana) OR (“cannabis use”)) AND 
((adolescent) OR (“adolescent psychiatry”)) AND ((“psychotic symptom*”) OR 
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(psychosis) OR (prodrom* symptom*) OR (“early onset psychosis”) OR (“first episode 
psychosis”) OR (“psychotic like experiences”)) 
 
((substance abuse) OR (substance related disorders) OR (cannabis) OR (marijuana 
abuse) OR (marijuana smoking) OR (marijuana) OR (cannabis use)) AND ((adolescent) 
OR (adolescent psychiatry)) AND ((psychotic symptom*) OR (psychosis) OR 
(prodrom* symptom*) OR (early onset psychosis) OR (first episode psychosis) OR 
(psychotic like experiences)) 
Total: 1,560 
 
Literature Review: Cannabis Use in Mexico 
1. Substance abuse 
2. Addiction 
3. Cannabis / Marijuana / Marihuana 
Marijuana abuse 
Marijuana smoking 
4. Cannabis use 
5. Mexico 
 
Defined Search Strategy: Literature Review Mexico 
((“substance abuse”) OR (addiction) OR (cannabis) OR (marijuana) OR (marihuana) 





((substance abuse) OR (addiction) OR (cannabis) OR (marijuana) OR (marihuana) OR 
(marijuana abuse) OR (marijuana smoking) OR (cannabis use)) AND ((Mexico)) 
Total: 1,115 
9.2.11. SCOPUS  
Systematic Review: Cannabis Use and Psychosis in Adolescents 
1. Substance abuse 
2. Cannabis 
3. Marijuana  
4. Cannabis use 
5. Adolescent 
6. Psychotic symptom* / Psychotic W/5 Symptom*  
7. Psychosis 
8. Prodrom* symptom* / Prodrom* W/5 Symptom* 
9. Vulnerability for psychosis / Vulnerability W/5 Psychosis 
10. Early onset psychosis / “Early onset” W/5 Psychosis 
11. First episode psychosis / “First episode” W/5 Psychosis 
12. Psychotic like experiences / Psychotic W/5 Experiences  
9.2.12. No Subject Headings 
Defined Search Strategy: Systematic Review 
((“substance abuse”) OR (cannabis) OR (marijuana) OR (“cannabis use”)) AND 
((adolescent)) AND ((“psychotic symptom*”) OR (psychotic W/5 symptom*) OR 
(psychosis) OR (“prodrom* symptom*”) OR (prodrom* W/5 symptom*) OR 
(“vulnerability for psychosis”) OR (vulnerability W/5 psychosis) OR (“early onset 
psychosis”) OR (“early onset” W/5 psychosis) OR (“first episode psychosis”) OR (“first 
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episode” W/5 psychosis) OR (“psychotic like experiences”) OR (“psychotic like” W/5 
experiences)) 
 
((substance abuse) OR (cannabis) OR (marijuana) OR (cannabis use)) AND 
((adolescent)) AND ((psychotic symptom*) OR (psychotic W/5 symptom*) OR 
(psychosis) OR (prodrom* symptom*) OR (prodrom* W/5 symptom*) OR 
(vulnerability for psychosis) OR (vulnerability W/5 psychosis) OR (early onset 
psychosis) OR (early onset W/5 psychosis) OR (first episode psychosis) OR (first 




Literature Review: Cannabis Use in Mexico 
1. Substance abuse 
2. Addiction 
3. Cannabis / Marijuana / Marihuana 
4. Cannabis use  
5. Mexico 
 
Defined Search Strategy: Literature Review Mexico 
((“substance abuse”) OR (addiction) OR (cannabis) OR (marijuana) OR (marihuana) 
OR (“cannabis use”)) AND ((Mexico))  
 
((substance abuse) OR (addiction) OR (cannabis) OR (marijuana) OR (marihuana) OR 





9.2.13. Web of Science 
9.2.14. No Subject Headings  
Systematic Review: Cannabis Use and Psychosis in Adolescents 
1. Substance abuse 
2. Cannabis 
3. Marijuana  
4. Cannabis use 
5. Adolescent 
6. Psychotic symptom* / Psychotic NEAR/5 Symptom  
7. Psychosis 
8. Prodrom* symptom* / Prodrom* NEAR/5 Symptom 
9. Vulnerability for psychosis / Vulnerability NEAR/5 Psychosis 
10. Early onset psychosis / “Early onset” NEAR/5 Psychosis  
11. First episode psychosis / “First episode” NEAR/5 Psychosis  
12. Psychotic like experiences / “Psychotic NEAR/5 Experiences  
 
Defined Search Strategy: Systematic Review 
((“substance abuse”) OR (cannabis) OR (marijuana) OR (“cannabis use”)) AND 
((adolescent)) AND ((“psychotic symptom*”) OR (psychotic NEAR/5 symptom*) OR 
(psychosis) OR (“prodrom* symptom*”) OR (prodrom* NEAR/5 symptom*) OR 
(“vulnerability for psychosis”) OR (vulnerability NEAR/5 psychosis) OR (“early onset 
psychosis”) OR (“early onset” NEAR/5 psychosis) OR (“first episode psychosis”) OR 
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(“first episode” NEAR/5 psychosis) OR (“psychotic like experiences”) OR (“psychotic 
like” NEAR/5 experiences)) 
 
((substance abuse) OR (cannabis) OR (marijuana) OR (cannabis use)) AND 
((adolescent)) AND ((psychotic symptom*) OR (psychotic NEAR/5 symptom*) OR 
(psychosis) OR (prodrom* symptom*) OR (prodrom* NEAR/5 symptom*) OR 
(vulnerability for psychosis) OR (vulnerability NEAR/5 psychosis) OR (early onset 
psychosis) OR (early onset NEAR/5 psychosis) OR (first episode psychosis) OR (first 
episode NEAR/5 psychosis) OR (psychotic like experiences) OR (psychotic like 
NEAR/5 experiences)) 
Total: 1,447 
Literature Review: Cannabis Use in Mexico 
1. Substance abuse 
2. Addiction 
3. Cannabis / Marihuana / Marijuana 
4. Cannabis use  
5. Mexico 
 
Defined Search Strategy: Literature Review Mexico 
((“substance abuse”) OR (addiction) OR (cannabis) OR (marijuana) OR (marihuana) 
OR (“cannabis use”)) AND ((Mexico))  
 
((substance abuse) OR (addiction) OR (cannabis) OR (marijuana) OR (marihuana) OR 




9.3. Systematic Review: Tables 
9.3.1. Table 1. Studies Included in Systematic Review: Logistic Regression Analysis  
 
Author / Country / Study 
Design 
Participants / Cannabis Use 
Assessment / Psychotic-Like 
Experiences Assessment 
Prevalence of 








Cannabis Use in 



















Age range: 11-26 years old 
 
Cannabis Use Assessment 
Controls: Never or once 
 
Cannabis users at age 15: three 
times or more 
 
Cannabis users at age 18: three 





Standardized interview scheduled 
(DSM-IV) 
 

























Association between Cannabis 




Model 1: Cannabis Use Only 
Cannabis Users by 15: 
OR: 4.50 (1.11 to 18.21) 
p = 0.035 
 
Cannabis Users by 18: 
OR: 1.65 (0.65 to 4.18) 
p = 0.293 
 
Model 2: Adds to Model 1 
Controls for Childhood Psychotic 
Symptoms 
 
Weak Psychotic Symptoms at age 
11: 
OR: 4.65 (1.84 to 11.78) 
p = 0.001 
 
Strong Psychotic Symptoms at 
age 11: 
OR: 15.97 (3.38 to 75.47) 
p = 0.001 
 
Cannabis Users by 15: 
OR: 3.12 (0.73 to 13.29) 
p = 0.124 
 
Cannabis Users by 18: 
OR: 1.42 (0.54 to 3.74) 
 
Association between 





Model 1: Cannabis Use Only 
Cannabis Users by 15: 
b = 6.91 
SE = 0.91 
p = 0.001 
 
Cannabis Users by 18: 
b = 1.04 
SE = 0.40 
p = 0.009 
 
Model 2: Adds to Model 1 
Controls for Childhood 
Psychotic Symptoms 
 
Weak Psychotic Symptoms at 
age 11: 
b = 0.68 
SE = 0.53 
p = 0.201 
 
Strong Psychotic Symptoms 
at age 11: 
b = 5.16 
SE = 1.39 
p = 0.001 
 
Cannabis Users by 15: 
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Author / Country / Study 
Design 
Participants / Cannabis Use 
Assessment / Psychotic-Like 
Experiences Assessment 
Prevalence of 




Covariates Analysis Odds Ratio Unstandardized Beta 
p = 0.473 
 
Model 3: Adds to Model 1 
Controls for Other Drug Use 
 
Other drug users at 15 to 18: 
OR: 0.30 (0.05 to 1.62) 
p = 0.160 
 
Cannabis Users by 15: 
OR: 11.38 (1.84 to 70.45) 
p = 0.009 
 
Cannabis Users by 18: 
OR: 1.95 (0.76 to 5.01) 
p = 0.167 
b = 6.56 
SE = 0.91 
p = 0.001 
 
Cannabis Users by 18: 
b = 1.03 
SE = 0.39 
p = 0.009 
 
Model 3: Adds to Model 1 
Controls for Other Drug Use 
Other drug users at 15 to 18: 
b = -0.3 
SE = 0.69 
p = 0.615 
 
Cannabis Users by 15: 
b = 7.2 
SE = 1.07 
p = 0.001 
 
Cannabis Users by 18: 
b = 1.1 
SE = 0.42 





and Psychotic Symptoms 
in Young People 
 














Cannabis Use Assessment 
Composite International 
Diagnostic Interview (CIDI) 
Diagnostic and Statistical Manual 




Items from the Symptom 
Checklist 90 (SCL-90) 
 



















Prior psychotic symptoms and 
mental health 
 









regression model to 
predict the logarithm 
of the psychotic 
symptom count from 
cannabis dependence 
at each age. 
 
Linkages between 
measures of cannabis 
dependence and 
psychotic symptom 
scores were modelled 




Mean Psychotic Symptoms (Past 
Month) by Cannabis Dependence 





No: Mean: 0.78 
Yes: Mean: 2.89 
p < 0.0001 
Rate Ratio (95%) 




No: Mean: 0.87 




Dependence and Psychotic 
Symptoms after Adjustment 
for Confounding Factors 
 
Regression Parameter 
B = 0.570 
SE = 0.189 
p < 0.005 
Rate Ratio (95%) 
1.8 (1.2 – 2.6) 
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Author / Country / Study 
Design 
Participants / Cannabis Use 
Assessment / Psychotic-Like 
Experiences Assessment 
Prevalence of 




Covariates Analysis Odds Ratio Unstandardized Beta 
Affiliation with deviant peers 
 
Adverse life events 
 
Age of leaving the family home 
 
Incidence Rate Ratio 
interpreted as the 
relative increase in the 
rate of psychotic 
symptoms for those 
who were cannabis 
dependent in 
comparison to those 
who were not. 
p < 0.0001 
Rate Ratio (95%) 





Study of Cannabis Use, 
Predisposition for 
Psychosis, and Psychotic 
Symptoms in Young 
People 
 












14 to 24 year olds 
 
Cannabis Use Assessment 
Munich-Composite International 






Diagnostic Interview (M-CIDI) 
 










At 4 year follow up at 













Use of other drugs 
 

















Association Between Any 
Cannabis Use at Baseline and 
Any Psychotic Symptom at 
Follow Up: OR (95%) 
 
Unadjusted 
OR: 1.79 (1.36 – 2.36) 
 
Adjusted (Age, sex, 
socioeconomic status, urbanicity, 
childhood trauma, predisposition 
for psychosis at baseline) 
OR: 1.69 (1.26 – 2.25) 
 
Additional Adjustment (Other 
drug use, tobacco and alcohol) 
OR: 1.67 (1.13 – 2.46) 
 
Additional Adjustment 
(Predisposition for psychosis at 
follow up and depression at 
baseline and follow up) 
OR: 1.53 (1.13 – 2.07) 
 
At Least 2 Psychotic Symptoms 
Adjusted 
OR: 2.23 (1.52 – 3.29) 
 
Associations Between Frequency 
of Cannabis Use at Baseline and 






Author / Country / Study 
Design 
Participants / Cannabis Use 
Assessment / Psychotic-Like 
Experiences Assessment 
Prevalence of 








OR: 1.01 (0.55 – 1.86) 
 
3–4 Times/Month: 
OR: 1.56 (0.91 – 2.68) 
 
1–2 Times/Week: 
OR: 2.28 (1.28 – 4.09) 
 
3-4 Times/Week: 
OR: 3.07 (1.49 – 6.31) 
 
Almost Daily: 
OR: 2.57 (1.52 – 4.34) 
 
Linear Trend: Increase in risk 
with one unit change in cannabis 
frequency 
OR: 1.24 (1.15 – 1.35) 
 
Adjusted (Age, sex, 
socioeconomic status, urbanicity, 
childhood trauma, predisposition 
for psychosis at baseline) 
<1/Month: 
OR: 0.99 (0.53 – 1.84) 
 
3–4 Times/Month: 
OR: 1.50 (0.86 – 2.62) 
 
1–2 Times/Week: 
OR: 1.95 (1.07 – 3.55) 
 
3-4 Times/Week: 
OR: 2.44 (1.16 – 5.13) 
 
Almost Daily: 




Author / Country / Study 
Design 
Participants / Cannabis Use 
Assessment / Psychotic-Like 
Experiences Assessment 
Prevalence of 




Covariates Analysis Odds Ratio Unstandardized Beta 
Linear Trend: Increase in risk 
with one unit change in cannabis 
frequency 





Association of Cannabis 
Use with Prodromal 
Symptoms of Psychosis in 
Adolescence 
 












15 to 16 year olds 
 
























Parental social class based on 
occupation 
 
Regular tobacco use 
 
Use of other drugs 
 








Analysis (Never vs. 
Ever) 
 
Ever tried cannabis more likely to 
report 3 or more symptoms: 
Crude OR 
2.79 (2.24 – 3.46) 
 
Proportion of those with high 
scores increased linearly by 
cannabis use category: 
OR for Linear Trend 
1.42 (1.23 – 1.64) 
 
Logistic Regression 
(never vs ever): 
OR: 2.23 (1.70 – 2.94) 
 
High scores in prodromal 
symptoms increased linearly by 
cannabis use category 
 
 
Test of Analysis of 
Covariance 
 
Ever tried cannabis had 
higher mean number of 
prodromal symptoms: 
3.11 v. 1.88 
t-test = 8.68 
p<0.001 
 
Test of analysis of covariance 




Prodromal Symptoms by 
Cannabis Use 
Mean and SD 
 
Never: 
Mean = 1.88 
SD = 1.94 
 
Once: 
Mean = 2.97 
SD = 2.53 
 
2-4 Times: 
Mean = 3.08 
SD = 2.61 
 
5 Times or More: 
Mean = 3.68 
SD = 2.90 
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Author / Country / Study 
Design 
Participants / Cannabis Use 
Assessment / Psychotic-Like 
Experiences Assessment 
Prevalence of 




Covariates Analysis Odds Ratio Unstandardized Beta 
 
Regular Use: 
Mean = 3.11 




Continued Cannabis Use 
and Risk of Incidence 
and Persistence of 
Psychotic Symptoms: 10 
Year Follow-up Cohort 
Study 
 










Age range: 14 to 24 year olds 
 



















T2 lifetime: 23% 






















Association Between Incident 
Cannabis Use at T2 (3.5 years 
after baseline) and Incident 
Psychotic Experiences at T3 (8.4 
years after baseline) 
OR (95%) 
 
Unadjusted Whole Sample 
OR: 1.8 (1.3 – 2.4) 
p < 0.001 
 
Adjusted Whole Sample 
(Age, sex, socioeconomic status, 
use of other drugs, childhood 
trauma and urban/rural 
environment) 
OR: 1.5 (1.1 – 2.1) 
p = 0.018 
 
Unadjusted After Exclusion 
(Excludes individuals with 
baseline cannabis use and pre-
existing psychotic symptoms) 
OR: 2.1 (1.3 – 3.4) 
p = 0.004 
 
Adjusted After Exclusion 
(Age, sex, socioeconomic status, 
use of other drugs, childhood 
trauma and urban/rural 
environment) 
(Excludes individuals with 
baseline cannabis use and pre-





Author / Country / Study 
Design 
Participants / Cannabis Use 
Assessment / Psychotic-Like 
Experiences Assessment 
Prevalence of 




Covariates Analysis Odds Ratio Unstandardized Beta 
OR: 1.9 (1.1 – 3.1) 
p = 0.021 
 
Association Between Continued 
Use of Cannabis (from baseline 
to T2) and Persistence of 
Psychotic Experiences at T2 and 
T3 OR (95%) 
 
Risk of Persistence of Psychotic 




At Baseline but not at T2 
OR: 2.0 (0.95 – 4.4) 
p = 0.068 
 
At T2 but not at Baseline 
OR: 1.9 (1.1 – 3.2) 
p = 0.022 
 
At Baseline and T2 
OR: 2.6 (1.5 – 4.6) 
p = 0.001 
Risk of Persistence of Psychotic 
Experiences and Cannabis 
Continuation 
Adjusted (Age, sex, 
socioeconomic status, use of 
other drugs baseline and T2, 
childhood trauma, urban/rural 
environment) 
 
At Baseline but not at T2 
OR: 2.1 (0.9 – 4.7) 
p = 0.078 
 
At T2 but not at Baseline 
OR: 1.4 (0.8 – 2.5) 
p = 0.202 
 
At Baseline and T2 
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Author / Country / Study 
Design 
Participants / Cannabis Use 
Assessment / Psychotic-Like 
Experiences Assessment 
Prevalence of 




Covariates Analysis Odds Ratio Unstandardized Beta 
OR: 2.2 (1.2 – 4.2) 





Cannabis Use at a Young 
Age is Associated with 
Psychotic-Experiences 
 











Age range 18 to 25 year olds 
 
Cannabis Use Assessment 





Community Assessment of 















Other drug use 
 




Amount of Euros/Week and 
10% Total CAPE Score: OR 
(95%) 
 
0 to 3 Euros 
OR: 0.96 (0.82 – 1.13) 
 
3 to 9 Euros 
OR: 1.46 (1.21 – 1.76) 
p < 0.05 
 
9 to 25 Euros 
OR: 2.00 (1.68 – 2.38) 
p < 0.05 
 
>25 Euros 
OR: 3.54 (2.94 – 4.26) 
p < 0.05 
 
Amount of Euros/Week and 
10% Positive Dimension Score: 
OR (95%) 
 
0 to 3 Euros 
OR: 0.98 (0.84 – 1.15) 
 
3 to 9 Euros 
OR: 1.72 (1.44 – 2.06) 
p < 0.05 
 
9 to 25 Euros 
OR: 1.96 (1.65 – 2.33) 






Author / Country / Study 
Design 
Participants / Cannabis Use 
Assessment / Psychotic-Like 
Experiences Assessment 
Prevalence of 




Covariates Analysis Odds Ratio Unstandardized Beta 
>25 Euros 
OR: 3.54 (2.94 – 4.26) 
p < 0.05 
 
Initial Age OR for a Top 10%  
Total CAPE Score 
 
>20 years 
OR: 1.18 (0.90 – 1.55) 
 
18-20 years 






OR: 1.16 (1.01 – 1.32) 
p < 0.05 
 
<12 years 
OR: 1.82 (1.23 – 2.70) 
p < 0.05 
 
Initial Age OR for a Top 10%  
Positive Dimension Score 
 
>20 years 
OR: 1.06 (0.76 – 1.48) 
 
18-20 years 






OR: 1.15 (1.01 – 1.31) 
p < 0.05 
 
<12 years 
OR: 3.05 (2.14 – 4.34) 
p < 0.05 
 
304 
Author / Country / Study 
Design 
Participants / Cannabis Use 
Assessment / Psychotic-Like 
Experiences Assessment 
Prevalence of 








Linking Substance Use 
with Symptoms of a 
Subclinical Psychosis in a 
Community Cohort Over 
30 Years 
 













Cannabis Use Assessment 
Structured Psychopathological 
Interview and Rating of the Social 
Consequences of Psychological 



























Family history of mental 
disorders 
 




Use of other drugs 
 
Associations between 
substance use and 
psychotic symptoms 
were evaluated with 
discrete-time hazard 




models for bivariate 
associations which rely 




Initially conducted a 
series of bivariate 
analysis of substance 
use and psychotic 
symptoms for separate 
substance-use 
variables, each was 
adjusted. 
 
In the multivariate 
analysis (models) 
included all such 
variables that shown a 
significant association 
in bivariate analysis. 
 
 
Discrete-Time Hazard Models 
for Bivariate Associations 
between Substance Use and 
“Schizotypal Signs” 
Frequency of Cannabis Use in 
Adolescence OR (95%) 
Casual Use 
OR: 1.80 (1.22 – 2.66) 
p = 0.003 
 
Frequency of Cannabis Use in 
Adolescence OR (95%) 
Regular Use 
OR: 2.29 (1.32 – 3.97) 
p = 0.003 
 
Frequency of Cannabis Use in 
Adulthood OR (95%) 
Casual Use 
OR: 1.47 (0.94 – 2.29) 
 
Frequency of Cannabis Use in 
Adulthood OR (95%) 
Regular Use 
OR: 1.80 (1.00 – 3.22) 
 
Discrete-Time Hazard Models 
for Bivariate Associations 
between Substance Use and 
“Schizophrenia Nuclear 
Symptoms” 
Frequency of Cannabis Use in 
Adolescence OR (95%) 
Casual Use 
OR: 1.13 (0.74 – 1.73) 
 
Frequency of Cannabis Use in 
Adolescence OR (95%) 
Regular Use 






Author / Country / Study 
Design 
Participants / Cannabis Use 
Assessment / Psychotic-Like 
Experiences Assessment 
Prevalence of 




Covariates Analysis Odds Ratio Unstandardized Beta 
Frequency of Cannabis Use in 
Adulthood OR (95%) 
Casual Use 
OR: 1.59 (1.03 – 2.46) 
 
Frequency of Cannabis Use in 
Adulthood OR (95%) 
Regular Use 
OR: 1.77 (0.96 – 3.24) 
 
Discrete-Time Hazard Models 
for Multivariate Associations 
between Substance Use and 
“Schizotypal Signs” 
Frequency of Cannabis Use in 
Adolescence OR (95%) 
Casual Use 
OR: 1.80 (1.24 – 2.59) 
p = 0.002 
 
Frequency of Cannabis Use in 
Adolescence OR (95%) 
Regular Use 
























Cannabis Use Assessment 











































Class Trajectory Model: 
Psychotic-Like Experiences 
(Low, Elevated and Increasing) 
 
Associations Between Cannabis 
Use at Time 1 and Trajectory 
Class 
 
Elevated vs. Low RR (95% CI) 
Cannabis Use Onset Ages 14 and 
16 
RR: 1.66 (0.67-4.15) 
 
Cannabis Use Onset Prior to 14 
RR: 2.54 (1.22-5.23) 
p<0.05 
 


















Author / Country / Study 
Design 
Participants / Cannabis Use 
Assessment / Psychotic-Like 
Experiences Assessment 
Prevalence of 




Covariates Analysis Odds Ratio Unstandardized Beta 
Bullying  
Cannabis Use Frequency Once 
RR: 2.02 (0.92-4.41) 
 
Cannabis Use Frequency >2 
Times 
RR: 2.30 (1.01-5.24) 
p<0.05 
 
Increasing vs. Low RR (95% 
CI) 
 
Cannabis Use Onset Ages 14 and 
16 
RR: 1.99 (1.04-3.82) 
p<0.05 
 
Cannabis Use Onset Prior to 14 
RR: 2.16 (1.20-3.90) 
p<0.05 
 
Cannabis Use Frequency Once 
RR: 1.90 (1.00-3.73) 
p<0.05 
 
Cannabis Use Frequency >2 
Times 
RR: 2.22 (1.25-3.96) 
p<0.01 
 
Effect of Cannabis Use on 
Subsequent Changes in 
Psychotic Experiences in Each 
Trajectory Class 
 
Trajectory Class: Low 
Cannabis Use Onset Ages 14 and 
16 
RR: 0.17 (0.06 – 0.28) 
p < 0.01 
 
Cannabis Use Onset Prior to 14 
RR: 0.11 (0.01 – 0.22) 






Author / Country / Study 
Design 
Participants / Cannabis Use 
Assessment / Psychotic-Like 
Experiences Assessment 
Prevalence of 




Covariates Analysis Odds Ratio Unstandardized Beta 
p < 0.05 
 
Cannabis Use Frequency Once 
RR: 0.10 (0.01 – 0.20) 
p < 0.05 
 
Cannabis Use Frequency >2 
Times 
RR: 0.24 (0.13 – 0.35) 
p < 0.01 
 
Trajectory Class: Elevated 
Cannabis Use Onset Ages 14 and 
16 
RR: 0.16 (-0.79 – 1.11) 
 
Cannabis Use Onset Prior to 14 
RR: 0.19 (-0.63 – 1.00) 
 
Cannabis Use Frequency Once 
RR: 0.01 (-0.80 – 0.82) 
Cannabis Use Frequency >2 
Times 
RR: 0.21 (-0.69 – 1.10) 
 
Trajectory Class: Increasing 
Cannabis Use Onset Ages 14 and 
16 
RR: 0.23 (-0.25 – 0.72) 
 
Cannabis Use Onset Prior to 14 
RR: 0.43 (0.01 – 0.87) 
p < 0.05 
 
Cannabis Use Frequency Once 
RR: 0.04 (-0.50 – 0.58) 
 
Cannabis Use Frequency >2 
Times 




Author / Country / Study 
Design 
Participants / Cannabis Use 
Assessment / Psychotic-Like 
Experiences Assessment 
Prevalence of 








Associations of Cannabis 
and Cigarette Use with 
Psychotic-Experiences at 
Age 18: Findings from 
the AVON Longitudinal 
Study of Parents and 
Children 
 








































Ordinal Logistic Regression of 
Cumulative Cannabis Use at age 
16 and Psychotic Experiences at 
age 18 (95%) 
 
Excluding Psychotic Experiences 
at 12: 
 
Model 1: Psychotic Experiences 
at 18 by categorical cumulative 
cannabis use at 18 
OR: 1.48 (1.018 – 1.86) 
p = 0.001 
 
Model 2: As model 1 with 
additional adjustment for pre-
birth confounders 
OR: 1.53 (1.21 – 1.92) 
p < 0.001 
 
Model 3: As model 2 with 
additional adjustment for 
childhood confounders 
OR: 1.57 (1.23 – 2.00) 
p < 0.001 
 
Model 4a: As model 3 with 
additional adjustment for 
cigarette use 
OR: 1.27 (0.91 – 1.76) 
p = 0.160 
 
Model 4b: As model 3 with 
additional adjustments for 
alcohol use 
OR: 1.57 (1.19 – 2.08) 
p = 0.002 
 
Model 4c: As model 3 with 
additional adjustment for illicit 
drug use (other than cannabis) 





Author / Country / Study 
Design 
Participants / Cannabis Use 
Assessment / Psychotic-Like 
Experiences Assessment 
Prevalence of 




Covariates Analysis Odds Ratio Unstandardized Beta 
p = 0.165 
 
Model 5: As model 3 with 
additional adjustment for 
cigarette, alcohol and other illicit 
drug use 
OR: 1.12 (0.76 – 1.65) 
p = 0.553 
 
Excluding Psychotic Experiences 
at 12 and 16: 
 
Model 1: Psychotic Experiences 
at 18 by categorical cumulative 
cannabis use at 18 
OR: 1.35 (0.98 – 1.86) 
p = 0.070 
 
Model 2: As model 1 with 
additional adjustment for pre-
birth confounders 
OR: 1.40 (1.01 – 1.95) 
p = 0.043 
 
Model 3: As model 2 with 
additional adjustment for 
childhood confounders 
OR: 1.50 (1.07 – 2.10) 
p = 0.019 
 
Model 4a: As model 3 with 
additional adjustment for 
cigarette use 
OR: 1.08 (0.69 – 1.69) 
p = 0.744 
 
Model 4b: As model 3 with 
additional adjustments for 
alcohol use 
OR: 1.62 (1.10 – 2.39) 




Author / Country / Study 
Design 
Participants / Cannabis Use 
Assessment / Psychotic-Like 
Experiences Assessment 
Prevalence of 




Covariates Analysis Odds Ratio Unstandardized Beta 
Model 4c: As model 3 with 
additional adjustment for illicit 
drug use (other than cannabis) 
OR: 1.30 (0.84 – 2.01) 
p = 0.247 
 
Model 5: As model 3 with 
additional adjustment for 
cigarette, alcohol and other illicit 
drug use 
OR: 1.09 (0.65 – 1.82) 







Effects of Adolescent 

















Cannabis Use Assessment 





Youth Self Report: Subclinical 
psychotic symptoms 
 


















regressions used to 
examine the within-
individual association 
between changes in 
weekly marijuana use 
and psychotic 
symptoms between 
ages 13 and 18. 
 
Poisson fixed-effects 
regression model for 
total subclinical 
symptoms and logistic 
fixed-effects regression 





Incidence rate ratios 
are reported for total 
symptoms and odds 




Three models were 
run. 
 
Total Subclinical Psychotic 
Symptoms 
 
Current weekly use without 
covariates: 
1.37 (1.16 – 1.62) 
p<0.001 
 




1.20 (0.97 – 1.48) 
 
_>2 Years: 
1.45 (1.09 – 1.93) 
p<0.05 
 
Test of linear trend without 
covariates: 
1.20 (1.05 – 1.38) 
p<0.01 
 
Current weekly use with 
covariates: 
1.12 (0.93 – 1.35) 
 






Author / Country / Study 
Design 
Participants / Cannabis Use 
Assessment / Psychotic-Like 
Experiences Assessment 
Prevalence of 




Covariates Analysis Odds Ratio Unstandardized Beta 
 
To examine the 




whether changes in 
current and prior 
subclinical psychotic 
symptoms predicted 
changes in weekly 
marijuana use. 
 






Linear trend analysis 
the number of years of 
prior use was treated as 
a continuous predictor 
 
1 Year: 
1.15 (0.91 – 1.46) 
 
_>2 Years: 
1.51 (1.08 – 2.11) 
P<0.05 
 
Test of linear trend with 
covariates: 
1.21 (1.03 – 1.42) 
p<0.05 
 
Effect of Years of Prior Weekly 
Marijuana Use 
 
No Marihuana Use in the Past 
Year 
Incidence Rate Ratio or Odds 
Ratio 
 
Total subclinical psychotic 
symptoms 












1.16 (0.64 – 2.09) 
 
Some Marihuana Use in Past 
Year 





Author / Country / Study 
Design 
Participants / Cannabis Use 
Assessment / Psychotic-Like 
Experiences Assessment 
Prevalence of 




Covariates Analysis Odds Ratio Unstandardized Beta 
Total subclinical psychotic 
symptoms 












1.08 (0.71 – 1.64) 
 
Lifetime Psychotic Disorder 
 
Years of weekly marijuana use: 
Odds Ratio 95% CI 
 
1 – 2 Years: 
0.85 (0.26 – 2.78) 
 
_>3 Years: 
3.63 (1.22 – 10.83) 
P<0.05 
 
Test of linear trend: 

















13 year olds 
 
Cannabis Use Assessment 
Detection of Alcohol and Drug 






























Linear Regression to 
estimate the 
relationship between 
growth in cannabis 
use, growth in 
potential mediators and 
psychotic-like 
 
Multinomial Logistic Regression 
Models of Cannabis Use Growth 
Over 13 – 16 Years Old 
Predicting Youth’s Membership 
in the PLE Trajectory Class Odds 









Author / Country / Study 
Design 
Participants / Cannabis Use 
Assessment / Psychotic-Like 
Experiences Assessment 
Prevalence of 









Adolescent Psychotic Symptom 
Screener 
 




OR: 1.01 (0.33 – 3.03) 
 
Moderate Increasing Vs. Low 
Decreasing 
OR: 0.38 (0.09 – 1.66) 
 
Moderate Increasing Vs. High 
Decreasing 




High Decreasing Vs. Low 
Decreasing 
OR: 1.00 (0.53 – 1.87) 
 
Moderate Increasing Vs. Low 
Decreasing 
OR: 3.26 (1.50 – 7.07) 
p < .01 
 
Moderate Increasing Vs. High 
Decreasing 
OR: 3.28 (1.47 – 7.27) 
p < .01 
 
Model 2: Adjusted for 
Cumulative Cigarette Use 
Cannabis Intercept 
High Decreasing Vs. Low 
Decreasing 
OR: 0.95 (0.28 – 3.17) 
 
Moderate Increasing Vs. Low 
Decreasing 
OR: 0.28 (0.05 – 1.54) 
 
Moderate Increasing Vs. High 
Decreasing 






Author / Country / Study 
Design 
Participants / Cannabis Use 
Assessment / Psychotic-Like 
Experiences Assessment 
Prevalence of 




Covariates Analysis Odds Ratio Unstandardized Beta 
High Decreasing Vs. Low 
Decreasing 
OR: 0.92 (0.48 – 1.73) 
 
Moderate Increasing Vs. Low 
Decreasing 
OR: 2.59 (1.11 – 6.03) 
p < .05 
 
Moderate Increasing Vs. High 
Decreasing 
OR: 2.82 (1.23 – 6.48) 





substance Use and 
Psychosis Spectrum 
Symptoms in a 
Community-Based 
Sample of US Youth 
 













Age range: 14-21 years old 
 
Cannabis Use Assessment: 
Abbreviated and locally 
computerized version of the 
Minnesota Centre for Twin and 
Family Research self-report 
substance use measure 
 
Psychotic-Like Experiences: 
GOASSSESS, a computerized, 
structured interview adapted from 
the Kiddie Schedule for Affective 
Disorders and Schizophrenia 
 

















Reading subtest score 
 
Significant symptoms of mood, 




















Additional adjustment for alcohol 
frequency group, tobacco 
frequency group and past year 
other substance use 
1.01 (.75-1.34) 
 





Additional adjustment for alcohol 
frequency group, tobacco 
frequency group and past year 
other substance use 
1.51 (.97-2.36) 
 





Additional adjustment for early 





Author / Country / Study 
Design 
Participants / Cannabis Use 
Assessment / Psychotic-Like 
Experiences Assessment 
Prevalence of 




Covariates Analysis Odds Ratio Unstandardized Beta 
past year cannabis use and 
lifetime use of other substance 
1.28 (.78-2.11) 
 





Additional adjustment for early 
alcohol use, early tobacco use, 
past year cannabis use and 





Cannabis Use and 
Psychosis: The Impact of 
Polydrug Use 
 











Age range: 24 years old 
 
Cannabis Use Assessment: 
“Have you ever tried…” 
 




Prevalence of Cannabis 
Use 
31.6% Cannabis Only 




































Combined Patterns of 
Tobacco and Cannabis 
Use in Adolescence with 
Psychotic Experiences 
 










Age range: birth cohort, measures 
of cannabis use were collected at 
6 time points between ages 14-19 
 
Cannabis Use Assessment: 
No use of cannabis or cigarettes 
Cigarette only 









Family history of schizophrenia 
or depression 
 
Family history of drug use 
 




Highest parental social class 
 
IQ (8 years old) 
 
Longitudinal Latent 
Class Analysis: to 
identify number of 
latent classes that 
adequately explain the 
relationship between 













Adjusted for sex, maternal 
education, emotional and 
behavioural problems and 









Author / Country / Study 
Design 
Participants / Cannabis Use 
Assessment / Psychotic-Like 
Experiences Assessment 
Prevalence of 




Covariates Analysis Odds Ratio Unstandardized Beta 
Longitudinal Cohort Study Semi-structured psychosis-like 




Childhood trauma or 
experiencing bullying 
 




Late Onset of Cannabis Use (with 





Adjusted for sex, maternal 
education, emotional and 
behavioural problems and 








Use, Baseline Prodromal 
Symptoms and the Risk 
of Psychosis 
 











Age range: data of cannabis use 
collected when participants were 
aged 15-16 years old. 
 
Cannabis Use Assessment: 
Lifetime use and frequency of use 
(never, once, 2-4 times, 5 times or 
more or regularly 
 





















Place of Residence 
 











Ever Cannabis Use 
2.85 (1.73-4.67) 
 








Model 1: PROD-Screen and 




Model 2: PROD-Screen and 
Other Substance Use, Frequent 













Author / Country / Study 
Design 
Participants / Cannabis Use 
Assessment / Psychotic-Like 
Experiences Assessment 
Prevalence of 








Acute Mental Health 
Symptoms in Adolescent 
Marijuana Users 
 











Age range: 14-18 years old 
 
Cannabis Use Assessment: 
Standardized questions about 
symptoms of cannabis use 
disorder based on the modified 
World Mental Health Composite 





“In the past 12 months, how often 
have you felt anxious or paranoid 
during or after using marijuana?” 
 
“In the past 12 months, how often 
have you seen, felt, or heard 
things that were not really there 
(i.e., hallucinations) during or 
after using marijuana?” 
 
 
Prevalence of Cannabis 
Use 
47.9% 











Race / Ethnicity 
Socioeconomic Status 
 






Models adjusted for: 
Age 
Sex 
Race / Ethnicity 
 
Cannabis Use Disorder vs. Non-
Diagnosis and Hallucinations: 
3.76 (1.69-8.34) 
 
Cannabis Use Disorder vs. Non-




Past Year Frequency of Cannabis 





Past Year Frequency of Cannabis 







9.3.2. Table 2. Studies Included in Systematic Review: Linear Regression Analysis 
 
Author / Country / Study 
Design 
Participants / Cannabis Use 
Assessment / Psychotic-Like 
Experiences Assessment 
Prevalence of Cannabis 
Use / Prevalence of 
Psychotic-Like 
Experiences 






Cannabis Use in 



















Age range: 11-26 years old 
 
Cannabis Use Assessment 
Controls: Never or once 
 
Cannabis users at age 15: three 
times or more 
 
Cannabis users at age 18: three 








(Symptoms and Disorder) 
 












Use of other drugs 
 












Cannabis Use in Adolescence 
and Schizophrenia Symptoms 
(Scores 0-58) 
 
Model 1: Cannabis Use Only 
Cannabis Users by 15: 
b = 6.91 
SE = 0.91 
p = 0.001 
 
Cannabis Users by 18: 
b = 1.04 
SE = 0.40 
p = 0.009 
 
Model 2: Adds to Model 1 
Controls for Childhood 
Psychotic Symptoms 
 
Weak Psychotic Symptoms at 
age 11: 
b = 0.68 
SE = 0.53 
p = 0.201 
 
Strong Psychotic Symptoms at 
age 11: 
b = 5.16 
SE = 1.39 
p = 0.001 
 
Cannabis Users by 15: 
b = 6.56 
SE = 0.91 
p = 0.001 
 
Cannabis Users by 18: 
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Author / Country / Study 
Design 
Participants / Cannabis Use 
Assessment / Psychotic-Like 
Experiences Assessment 
Prevalence of Cannabis 
Use / Prevalence of 
Psychotic-Like 
Experiences 
Covariates Analysis Est. Effect Size 
Unstandardized 
Beta 
b = 1.03 
SE = 0.39 
p = 0.009 
 
Model 3: Adds to Model 1 
Controls for Other Drug Use 
Other drug users at 15 to 18: 
b = -0.3 
SE = 0.69 
p = 0.615 
 
Cannabis Users by 15: 
b = 7.2 
SE = 1.07 
p = 0.001 
 
Cannabis Users by 18: 
b = 1.1 
SE = 0.42 





and Psychotic Symptoms 
in Young People 
 














Cannabis Use Assessment 
Composite International 
Diagnostic Interview (CIDI) 
Diagnostic and Statistical 





Items from the Symptom 
Checklist 90 (SCL-90) 
 
(Symptoms not Disorder) 
 
 















Prior psychotic symptoms and 
mental health 
 






Affiliation with deviant peers 
 
Adverse life events 
 




regression model to 
predict the logarithm of 
the psychotic symptom 
count from cannabis 
dependence at each age. 
 
Linkages between 
measures of cannabis 
dependence and 
psychotic symptom 
scores were modelled 




Incidence Rate Ratio 
interpreted as the relative 
increase in the rate of 
psychotic symptoms for 
those who were cannabis 
 
Mean Psychotic Symptoms 
(Past Month) by Cannabis 
Dependence (Past 12 




No: Mean: 0.78 
Yes: Mean: 2.89 
p < 0.0001 
Rate Ratio (95%) 




No: Mean: 0.87 
Yes: Mean: 2.02 
p < 0.0001 
Rate Ratio (95%) 
2.3 (1.7 – 3.2) 
 
Estimated Association Between 
Cannabis Dependence and 
Psychotic Symptoms after 




B = 0.570 
SE = 0.189 
p < 0.005 
Rate Ratio (95%) 
1.8 (1.2 – 2.6) 
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Author / Country / Study 
Design 
Participants / Cannabis Use 
Assessment / Psychotic-Like 
Experiences Assessment 
Prevalence of Cannabis 
Use / Prevalence of 
Psychotic-Like 
Experiences 
Covariates Analysis Est. Effect Size 
Unstandardized 
Beta 
dependent in comparison 





Cannabis Exposure and 
Positive and Negative 
Dimensions of Psychosis 
 










19 year olds 
 
Cannabis Use Assessment 
Cannabis lifetime frequency 
use (never, once, 2-4 times, 5 
times or more) 





Community Assessment of 
Psychic Experiences (CAPE) 
 
Prevalence of Cannabis 
Use 




2 to 4 times: 1.4% 
 
5 times or more: 1.5% 
 




Mean SD Scores: 
 
Paranoia: 0.20 (0.24) 
 
Grandiosity: 0.20 (0.40) 
 
First Rank Symptoms: 0.10 
(0.17) 
 
Hallucinations: 0.02 (0.15) 
 




School grade obtained 
 





expressed as regression 
coefficients of cannabis 
use in multiple regression 
models of continuous 
scores of positive, 
negative and depression 
dimensions. 
 
To examine whether 
effects of cannabis 
increased linearly with 
and without squared 
cannabis life-time 
frequency of use were 







Association Lifetime Frequency 
of Cannabis Use and Psychosis 
 
Hallucinations and =5 times 
use: 
B = 0.27 
p = 0.058 
 
Hallucinations and Systematic 
use: 
B = 1.39 
p = 0.000 
 
Paranoia and =5 times: 
B = 0.64 
p = 0.000 
 
Paranoia Systematic use: 
B = 0.96 
p = 0.000 
 
Paranoia Regression 
Coefficient Linear Trend 
Unadjusted: 
B = 0.23 
p = 0.000 
 
Paranoia Regression 
Coefficient Linear Trend 
Adjusted: 
B = 0.09 
p = 0.003 
 
Grandiosity and =5 times use: 
B = 0.36 
p = 0.010 
 
Grandiosity and Systematic use: 
B = 0.37 
p = 0.037 
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Author / Country / Study 
Design 
Participants / Cannabis Use 
Assessment / Psychotic-Like 
Experiences Assessment 
Prevalence of Cannabis 
Use / Prevalence of 
Psychotic-Like 
Experiences 




First Rank and =5 times use: 
B = 0.50 
p = 0.000 
First Rank and Systematic use: 
B = 0.55 
p = 0.002 
 
First Rank Regression 
Coefficient Linear Trend 
Unadjusted: 
B = 0.17 
p = 0.000 
 
First Rank Regression 
Coefficient Linear Trend 
Adjusted: 
B = 0.06 
p = 0.000 
 
Effect of Cannabis Age First 
Use on Psychosis Dimension 
 





B = 1.16 
p = 0.000 
 
_>16: 
B = 0.15 




B = 0.91 
p = 0.000 
 
>_16: 
B = 0.36 




Author / Country / Study 
Design 
Participants / Cannabis Use 
Assessment / Psychotic-Like 
Experiences Assessment 
Prevalence of Cannabis 
Use / Prevalence of 
Psychotic-Like 
Experiences 





B = 0.86 
p = 0.000 
 
>_16: 
B = 0.27 




B = 0.84 
p = 0.000 
 
>_16: 
B = 0.33 
p = 0.000 
 




B = 0.74 
p = 0.001 
 
_>16: 
B = -0.18 




B = 0.56 
p = 0.10 
 
>_16: 
B = 0.09 




B = 0.74 





Author / Country / Study 
Design 
Participants / Cannabis Use 
Assessment / Psychotic-Like 
Experiences Assessment 
Prevalence of Cannabis 
Use / Prevalence of 
Psychotic-Like 
Experiences 
Covariates Analysis Est. Effect Size 
Unstandardized 
Beta 
B = 0.18 




B = 1.09 
p = 0.000 
 
>_16: 
B = 0.52 




The Associations between 
Early Cannabis Use and 
Psychotic-Like 
















Age range: 13 to 19 year olds 
 
Cannabis Use Assessment 

























Use of other drugs 
 
General Linear Models 
 
Means and SD of 
Psychotic-Like Experiences 
and Cannabis Exposure 
 
Positive Scale Total 




Mean = 31.2 




Mean = 33.8 
SD = 8.3 
 
Rarely Use: 
Mean = 35.8 




Mean = 29.4 






Author / Country / Study 
Design 
Participants / Cannabis Use 
Assessment / Psychotic-Like 
Experiences Assessment 
Prevalence of Cannabis 
Use / Prevalence of 
Psychotic-Like 
Experiences 






Early Exposure to 
Cannabis and Risk for 
Psychosis in Young 
Adolescents in Trinidad 
 












Age range: 12 to 23 year olds 
 
Cannabis Use Assessment 
Questionnaire on past and 




Community Assessment of 
Psychic Experiences 
 

























Cannabis use before 14 years 
old was significantly associated 





b = 0.39 
CI = 0.04 – 0.74 
P = 0.029 
 
Adjusted: 
b = 0.71 
CI = 0.22 – 1.19 
p = 0.004 
 
>14 
b = -0.11  
CI = -0.57, 0.36 




Early Cannabis Use and 
Schizotypal Personality 
Disorder Symptoms from 
Adolescence to Middle 
Adulthood 
 
















Age range: 9-18 years old 
 
 
Cannabis Use Assessment 
Users: At least monthly use 
 
Non-users: Experimented once 
or twice 
 




Children in the Community 
Self Report Schizotypal 
Personality Disorder Scale 
 








Other type of psychopathology 
 











d = 0.53 
p<0.001 
 
Model 1: Effects of Early 
Cannabis Use on Average over 
the Schizotypal Symptoms 
Trajectory Independent of Age, 
Gender and Socioeconomic 
status effects. 
 
Mean Schizotypal Symptoms at 
Trajectory Mean Age 23 
b = -2.8 
SE = .04 
 
Early Cannabis Use 
b = .24 
p<.01 
SE = .08 
 
Model 2: Schizotypal 
Symptoms Added at Mean Age 




Author / Country / Study 
Design 
Participants / Cannabis Use 
Assessment / Psychotic-Like 
Experiences Assessment 
Prevalence of Cannabis 
Use / Prevalence of 
Psychotic-Like 
Experiences 
Covariates Analysis Est. Effect Size 
Unstandardized 
Beta 
Mean Schizotypal Symptoms at 
Trajectory Mean Age 23 
b = -.25 
SE = .04 
 
Early Cannabis Use 
b =.20 
p<.05 
SE = .08 
 
Model 3: Effects of Early 




Mean Schizotypal Symptoms at 
Trajectory Mean Age 23 
b = -.36 
SE = .04 
 
Early Cannabis Use 
b = .23 
p<.01 
SE = .08 
 
Model 4: Cigarettes and Other 
Drug Use Taken into Account 
 
Mean Schizotypal Symptoms at 
Trajectory Mean Age 23 
b = -.27 
SE = .05 
 
Early Cannabis Use 
b = .18 
p<.05 






Author / Country / Study 
Design 
Participants / Cannabis Use 
Assessment / Psychotic-Like 
Experiences Assessment 
Prevalence of Cannabis 
Use / Prevalence of 
Psychotic-Like 
Experiences 






Cannabis Use and 
Subclinical Positive 
Psychotic Experiences in 
Early Adolescence: 
Findings from a Dutch 
Survey 
 













Age range: 12 to 16 year olds 
 
Cannabis Use Assessment 
Frequency of cannabis use 
(never, ever but not past year, 
once or twice during past year, 




Community Assessment of 
Psychic Experiences (CAPE) 
 
















Social support from father, 













Stand. Regression Est. 
 
Unadjusted Model: 
B = 0.138 
p = 0.000 
 
Adjusted Model: 
B = 0.088 
p = 0.000 
 
CU and Age: 
B = 0.081 
p = 0.000 
Cannabis use and 
subclinical positive 
psychotic experiences are 
strongest for youngest 
children. 
 




B = 0.061 
p = 0.000 
 
Experimental Use: 
B = 0.037 
p = 0.018 
 
Regular Use: 
B = 0.048 
p = 0.005 
 
Heavy Use: 
B = 0.065 
p = 0.000 
 


















Author / Country / Study 
Design 
Participants / Cannabis Use 
Assessment / Psychotic-Like 
Experiences Assessment 
Prevalence of Cannabis 
Use / Prevalence of 
Psychotic-Like 
Experiences 
Covariates Analysis Est. Effect Size 
Unstandardized 
Beta 
p = 0.038 
 
Experimental use: 
B = -0.0337 
p = 0.000 
 
Regular Use: 
B = -0.586 
p = 0.000 
 
Heavy Use: 
B = -0.376 




Cannabis Use and 
Vulnerability for 



















Cannabis Use Assessment 
Self-report items regarding 




Youth Self-report subscales 
 












Use of other drugs: 




Path analysis to address 
the temporal order of 
cannabis use and 
psychosis vulnerability 




alcohol and tobacco use). 
 
Cannabis Use at T3 
predicted Psychosis 
Vulnerability at T4 
 










Effects of Adolescent 












Cannabis Use Assessment 





Youth Self Report: Subclinical 
psychotic symptoms 
 
(Symptoms Not Disorder) 
 















used to examine the 
within-individual 
association between 
changes in weekly 
marijuana use and 
psychotic symptoms 
between ages 13 and 18. 
 
Poisson fixed-effects 
regression model for total 






Current weekly use without 
covariates: 
1.37 (1.16 – 1.62) 
p<0.001 
 








Author / Country / Study 
Design 
Participants / Cannabis Use 
Assessment / Psychotic-Like 
Experiences Assessment 
Prevalence of Cannabis 
Use / Prevalence of 
Psychotic-Like 
Experiences 








regression models (for 
binary symptom 
subtypes) were used. 
Logistic 
 
Incidence rate ratios are 
reported for total 
symptoms and odds ratio 




Three models were run. 
 
To examine the 




changes in current and 
prior subclinical 
psychotic symptoms 
predicted changes in 
weekly marijuana use. 
 






Linear trend analysis the 
number of years of prior 




1.45 (1.09 – 1.93) 
p<0.05 
 
Test of linear trend without 
covariates: 
1.20 (1.05 – 1.38) 
p<0.01 
 
Current weekly use with 
covariates: 
1.12 (0.93 – 1.35) 
 




1.15 (0.91 – 1.46) 
 
_>2 Years: 
1.51 (1.08 – 2.11) 
P<0.05 
 
Test of linear trend with 
covariates: 
1.21 (1.03 – 1.42) 
p<0.05 
 
Effect of Years of Prior 
Weekly Marijuana Use 
 
No Marihuana Use in the 
Past Year 
Incidence Rate Ratio or 
Odds Ratio 
 
Total subclinical psychotic 
symptoms 




2.12 (1.16 – 3.89) 
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Author / Country / Study 
Design 
Participants / Cannabis Use 
Assessment / Psychotic-Like 
Experiences Assessment 
Prevalence of Cannabis 
Use / Prevalence of 
Psychotic-Like 
Experiences 










1.16 (0.64 – 2.09) 
 
Some Marihuana Use in 
Past Year 
Incidence Rate Ratio or 
Odds Ratio 
 
Total subclinical psychotic 
symptoms 

















Years of weekly marijuana 
use: Odds Ratio 95% CI 
 
1 – 2 Years: 
0.85 (0.26 – 2.78) 
 
_>3 Years: 
3.63 (1.22 – 10.83) 
P<0.05 
 
Test of linear trend: 
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Author / Country / Study 
Design 
Participants / Cannabis Use 
Assessment / Psychotic-Like 
Experiences Assessment 
Prevalence of Cannabis 
Use / Prevalence of 
Psychotic-Like 
Experiences 
Covariates Analysis Est. Effect Size 
Unstandardized 
Beta 





















13 year olds 
 
Cannabis Use Assessment 
Detection of Alcohol and Drug 




























Multinomial and Binary 
Logistic Regressions 
 
Linear Regression to 
estimate the relationship 
between growth in 
cannabis use, growth in 






Regression Models of 
Cannabis Use Growth Over 
13 – 16 Years Old 
Predicting Youth’s 
Membership in the PLE 
Trajectory Class Odds 




High Decreasing Vs. Low 
Decreasing 
OR: 1.01 (0.33 – 3.03) 
 
Moderate Increasing Vs. 
Low Decreasing 
OR: 0.38 (0.09 – 1.66) 
 
Moderate Increasing Vs. 
High Decreasing 




High Decreasing Vs. Low 
Decreasing 
OR: 1.00 (0.53 – 1.87) 
 
Moderate Increasing Vs. 
Low Decreasing 
OR: 3.26 (1.50 – 7.07) 





Author / Country / Study 
Design 
Participants / Cannabis Use 
Assessment / Psychotic-Like 
Experiences Assessment 
Prevalence of Cannabis 
Use / Prevalence of 
Psychotic-Like 
Experiences 
Covariates Analysis Est. Effect Size 
Unstandardized 
Beta 
Moderate Increasing Vs. 
High Decreasing 
OR: 3.28 (1.47 – 7.27) 
p < .01 
 
Model 2: Adjusted for 
Cumulative Cigarette Use 
Cannabis Intercept 
High Decreasing Vs. Low 
Decreasing 
OR: 0.95 (0.28 – 3.17) 
 
Moderate Increasing Vs. 
Low Decreasing 
OR: 0.28 (0.05 – 1.54) 
 
Moderate Increasing Vs. 
High Decreasing 




High Decreasing Vs. Low 
Decreasing 
OR: 0.92 (0.48 – 1.73) 
 
Moderate Increasing Vs. 
Low Decreasing 
OR: 2.59 (1.11 – 6.03) 
p < .05 
 
Moderate Increasing Vs. 
High Decreasing 
OR: 2.82 (1.23 – 6.48) 




Age Moderates the 
Association between 
Frequent Cannabis Use 







Age range: 14-24 years old 
 
Cannabis Use Assessment 
Lifetime use 








Use of other drugs 
 








Interaction Between Time, 
Age and Frequent Cannabis 
Use 
Wald X2=9.5, p.=009 
 
Significant Interaction 
Between Age and Time 
Frequent Cannabis Users 
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Author / Country / Study 
Design 
Participants / Cannabis Use 
Assessment / Psychotic-Like 
Experiences Assessment 
Prevalence of Cannabis 
Use / Prevalence of 
Psychotic-Like 
Experiences 
Covariates Analysis Est. Effect Size 
Unstandardized 
Beta 







Frequency of use past six 
months 




Adapted version of the short 
form of the Oxford-Liverpool 
Inventory of Feeling and 
Experiences 
Past Month Cannabis Use 






Family history of Psychosis 
 
Age of First Cannabis Use 
 
Age of First Alcohol Use 
 












Among frequent cannabis users, 
younger age was associated 
with increasing levels of 
negative schizotypy over time. 
In contrast, among occasional 
users, younger age was 
associated with decreasing 
levels of negative schizotypy 
over time. 
 
Emerging human research is 
also pointing to negative 
emotionality as particularly 
affected by early onset cannabis 





Age-Varying Effects of 
Cannabis Use Frequency 
and Disorder on 
Symptoms of Psychosis, 
Depression and Anxiety 
in Adolescents and 
Adults 
 















Age range: 12-18 years old 
 
Cannabis Use Assessment 
Past year use (0= never to 
4=more than once a week) 
 


















































Frequent Cannabis Use and 




Cannabis Use Disorder and 




Significant Sex Differences 
between Cannabis Use 
Disorder and Psychotic-
Symptoms 
Interaction was significant 
following age 26 
b=1.12, 95%CI=0.02-2.21 
when females showed stronger 
associations than males 
 
333 
Author / Country / Study 
Design 
Participants / Cannabis Use 
Assessment / Psychotic-Like 
Experiences Assessment 
Prevalence of Cannabis 
Use / Prevalence of 
Psychotic-Like 
Experiences 













9.3.3. Table 3. Studies Included in Systematic Review: Other Analyses 
 








































































Cox Regression Analysis 
Survival time was defined in 
years, as age at onset of 
psychotic symptoms or if 
psychotic symptoms did not 
occur, as the age at the final 
assessment. 
 
Hazard ratios (HR) were 
computed that indicate the 
association between cannabis 




assumption was tested for the 
time-dependent covariate by 






Psychotic Symptoms and 
Life-Time Cannabis Use 
x2 = 22.9 
p < 0.001 
 
k = 0.11 
p < 0.001 
 
Cannabis use and psychotic-
symptoms absent: 1110 
 




Cannabis use present and 
psychotic symptoms absent: 
305 
 




Cannabis Use Predicted 
Psychotic Symptoms 
 
Hazard Ratio (95%) 
2.81 (1.79 – 4.43) 
Risk of future psychotic 
symptoms in cannabis users 
increased almost threefold 
 
 
Minimum Period of 2 
Years Between Cannabis 
Use and Onset of 
Psychotic Symptoms 
 
Hazard Ratio (95%) 








of Other Types of 
Psychopathology 
 






























Cox Regression Analyses: In 
the first set of analyses it was 
determined whether cannabis 
use increased the risk for 
psychotic-symptoms and if this 
risk occurred independently of 
the other types of 
psychopathology 
 
Survival Analyses with 





Assumption was tested for 
the time-dependent 
covariate for each of the 
CBCL syndrome scores by 
testing interactions with 
time (age) 
 
Cannabis use remained a 
significant predictor of 
psychotic symptoms even 
in the presence of other 
putative predictors such as 









































Checklist to Assess 
Further 
Psychopathology 
CBCL syndrome scale scores 
separately as candidate 
predictors 
 
Survival time was defined in 
years as age of onset of 
psychotic symptoms or if these 
did not occur as the age at final 
assessment 
 
Hazard Ratios to indicate the 
association between cannabis 
use and future psychotic 
symptoms 
 
Cannabis use was entered as a 
time dependent covariate 
 
Possible cohort effects were 










Aberrant Salience in a 
Sample of Belgian 
Students 
 


















































Spearman Correlation Test 
 
Multivariate Econometric 
Linear Regression Model to test 
for significance of correlation 








Cannabis users showed 
significant higher ASI 
scores and higher positive 
and negative dimensions 
CAPE scores than non-
users. 
 
Years of cannabis use and 
frequency of use in the last 
30 days showed a small 
positive correlation with 
ASI scores. Weaker positive 
correlations with CAPE 
positive and negative 





ASI and cannabis use is highly 
statistically significant in all 
regressions even after 
controlling for individuals’ 
observables (244) 
 
No. of years use 
1.171, R2=0.07, p<0.01 
No. of years use + controls 
1.270, R2=0.11, p<0.01 
 
No. days use in last 30 
1.264, R2=0.07, p<0.01 
No. days use in last 30 + 
controls 
1.377, R2=0.12, p<0.01 
 
Quantity use in last 30 
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 5.382, R2=0.12, p<0.01 
Quantity use in last 30 + 
controls 
5.581, R2=0.17, p<0.01 
 
CAPE and cannabis use are 
significant in all regressions 
even after controlling 
 
No. of years use 
0.032, R2=0.02, p<0.05 
No. of years use + controls 
0.029, R2=0.09, p<0.1 
 
No. days use in last 30 
0.033, R2=0.02, p<0.01 
No. days use in last 30 + 
controls 
0.027, R2=0.09, p<0.05 
 
Quantity use in last 30 
0.155, R2=0.04, p<0.01 
Quantity use in last 30 + 
controls 
0.149, R2=0.11, p<0.01 
 
CAPE positive and negative 
dimensions, the correlations 
remained highly significant 
after controlling for individual 
characteristics when 
considering the quantity of 




No. of years use 
0.039, R2=0.04, p<0.01 
 
No. of years use + controls 

















Covariates Analysis Est. Effect Size Odds Ratio 
Unstandardized  
Beta 
No. days use in last 30 
0.037, R2=0.03, p<0.01 
No. days use in last 30 + 
controls 
0.023, R2=0.10, p=not sig 
 
Quantity use in last 30 
0.167, R2=0.06, p<0.01 
Quantity use in last 30 + 
controls 





No. days use in last 30 
0.040, R2=0.01, p<0.05 
No. days use in last 30 + 
controls 
0.042, R2=0.05, p<0.1 
 
Quantity use in last 30 
0.186, R2=0.03, p<0.05 
Quantity use in last 30 + 
controls 






Cannabis Use in 
Adolescents from the 
General Population 
 

























































Sobel Test to verify the 







Relationship between PQ-B and 




Frequency and distress 
associated with psychotic-like 
experiences among cannabis 
users increased 
 





























PQ-B as dependent variable, 
Cannabis as fixed factor 
controlling for covariates 
showed absence of statistically 
significant differences between 
groups 
l=0.999, F(1,1580)=0.523, 
p=0.593 
 
